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Many neurodegenerative disorders are characterised by protein misfolding and 
subsequent amyloid fibrillisation and deposition. Amyloid-beta peptide (Aβ) was found 
to be the main constituent of the extracellular amyloid plaques of Alzheimer’s disease 
(AD) in the 1980s. What triggers amyloid formation or inhibits it are of particular interest. 
This thesis focuses on the effect of endogenous proteins and molecules on amyloid 
fibrillisation. 
 
In Chapter 3, I show that at physiological micromolar levels found in the cerebrospinal 
fluid, human serum albumin inhibits the rate of Aβ fibrillisation. Indeed in vitro the 
amount of amyloid fibres generated directly correlates to the proportion of Aβ not 
competitively bound to albumin. Albumin binds cholesterol and fatty acids in vivo, both 
of which have been linked with an increased risk of developing AD. In Chapter 4, I show 
Aβ competes with these molecules for albumin binding, so disrupting albumin’s ability 
to inhibit Aβ fibrillisation. My observations suggest a significant role for albumin 
regulating Aβ fibril growth. 
 
Albumin also binds Cu2+ in vivo with a tight picomolar affinity. Animal models suggest 
disrupted Cu2+ homeostasis potentiate AD phenotype. In Chapter 5, I show that regardless 
of Aβ alloform or fibrillisation stage, the affinity for Cu2+ is in the ~20 picomolar range 
but weaker than albumin. 
 
Circular Dichroism spectroscopy in the visible region (Vis-CD) is a powerful technique 
to study metal-protein interactions. In Chapter 6, I develop a set of empirical rules that 




complex. These rules are used to gain insight into Cu2+-protein complexes in Prion 
disease and Parkinson’s disease. I show the N-terminal amino group of cellular prion 
protein (PrPC) has a tighter affinity for Cu2+ than the individual octa-repeat binding sites 
present within PrPC and show for the first time that Cu2+ loads on to the N-terminal amino 
group before the single octa-repeat binding sites. I determine the affinity of Cu2+ for 
model N-terminal peptides of alpha-synuclein of Parkinson’s disease and show that side-
chain coordination stabilises the complex and increases the affinity for copper compared 
to main-chain coordination only. 
 
This thesis highlights the importance of overlapping interactions with endogenous 
proteins and molecules in the development of neurodegenerative disease. Indeed, the 
amyloid protein binding partners studied here are all co-localised at the synapse thus 
future in vitro studies of neurodegenerative disease should consider the complex nature 
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TSE − Transmissible Spongiform Encephalopathy 
TTR − Transthyretin 
UV − Ultra-Violet 
Vis − Visible 
Vis-CD − Visible Circular Dichroism Spectroscopy 
 



















1.1. ALZHEIMER’S DISEASE (AD) 
Alzheimer’s disease (AD) was first described by Alois Alzheimer at the beginning of the 
20th century (Alzheimer 1907). It is the most common form of dementia, playing a role 
in almost three quarters of all dementia patients. AD is predominantly a stand-alone 
dementia but mixed dementia, a combination of AD with vascular dementia, also 
accounts for 10 % of all dementia cases (Alzheimer's Society 2014).  
 
1.1.1. The Social and Economic Impact of AD 
Dementia is an ever growing burden to the population, particularly in the developed world 
as the average life expectancy is increasing and the proportion of the population over 65 
is expanding. One in three people over the age of 65 will develop dementia (Alzheimer's 
Society 2014) and it is the fourth leading cause of death in women in England and Wales 
after heart disease, stroke and cancer (Office for National Statistics 2011). Currently there 
are approximately 800,000 people in the UK with dementia and this is predicted to double 
over the next 40 years (Alzheimer's Society 2014). The cost of dementia in the UK was 
estimated to be £23 billion last year (Alzheimer's Society 2014) thus research into the 
cause and ultimately cure of AD is extremely important. It is estimated there are 45 
million people with AD worldwide (Alzheimer's Disease International 2009). 
 
1.1.2. Symptoms, Pathology and Diagnosis 
AD, like other dementias, is caused by the loss of neurons and synapses triggering 
memory loss and other cognitive deficits. Neurodegeneration is predominantly within the 
hippocampus and the cerebral cortex, particularly the parietal lobe, temporal lobe, regions 
of the frontal lobe and the cingulate gyrus. These areas play an important role in memory 
formation,  language  and  navigation  thus  neuron  loss  here  leads  to  the  typical  AD 






Figure 1.01. The Location of Neurodegeneration in AD.  
AD causes neurodegeneration throughout the cerebral cortex and hippocampus, 
particularly in areas responsible for memory and language, causing enlargement of the 
ventricles and shrinkage of the grey matter. Modified from alz.org. 
 
  








symptoms of memory loss, disorientation and problems with communication. A 
schematic of the extent of shrinkage in the AD brain compared to that of a normal brain 
can be seen in Figure 1.01. The neurodegeneration in the cortex affecting the memory 
and language areas is particularly apparent, as is the increased ventricle size. The 
diagnosis of AD is defined by the localisation of neurodegeneration and the presence of 
two types of protein accumulation, extracellular amyloid plaques in the cortical 
interstitium and cerebro-vasculature and secondly intracellular neurofibrillary tangles in 
the brain post-mortem (Figure 1.02). 
 
1.2. AMYLOID-BETA PEPTIDE (A) 
The amyloid plaques observed extracellularly in AD brains are mainly comprised of the 
peptide amyloid beta (A) first characterised by Masters et al. in the 1980s (Masters et 
al. 1985).  
 
1.2.1. A Sequence 
A is a short peptide of typically 39-43 amino acid residues in length. The most common 
alloforms are A(1-40) and A(1-42). The sequence of A(1-42) is shown below: 
 
          5  10      15            20           25           30      35             40                  
DAEFR  HDSGY  EVHHQ  KLVFF  AEDVG  SNKGA  IIGLM  VGGVV  IA 
 
Blue denotes the hydrophilic residues, while red denotes the hydrophobic residues. It is 
clear that the N-terminal is mainly hydrophilic and there are two distinct hydrophobic 
regions; the central hydrophobic cluster (residues 17-21) and the C-terminal (residues 29-
42). Many of these hydrophobic residues have large bulky side chains and therefore have 
a high propensity to form beta-sheets.  






Figure 1.02. Neuritic Plaques and Neurofibrillary Tangles are Hallmarks of AD. 
a) A diagram showing the extracellular neuritic plaques and intracellular neurofibrillary 
tangles associated with AD. b) An immunohistochemically stained hippocampal region 
from an AD patient showing the neuritic plaques (NP) and neurofibrillary tangles (NFT). 













1.2.2. Amyloid Precursor Protein 
A is produced from the Amyloid Precursor Protein (APP), an integral transmembrane 
glycoprotein whose expression is concentrated in the neurons. Its function is unknown 
but it has been suggested to play a role in synapse formation and neuronal plasticity 
(Priller et al. 2006, Turner et al. 2003). The gene encoding APP is located on chromosome 
21 in humans (Kang et al. 1987). Three main isoforms exist that are 695, 751 and 770 
residues in length. The principal form in neurons is the 695 isoform, while the other two 
are predominantly expressed elsewhere in the body (Kang et al. 1987, Kitaguchi et al. 
1988, Ponte et al. 1988, Tanzi et al. 1988). APP can be processed through two distinct 
pathways; the amyloidogenic pathway and the non-amyloidogenic pathway, as shown in 
Figure 1.03. 
 
Amyloidogenic Processing Pathway 
The amyloidogenic pathway is the processing pathway which produces A through 
cleavage of APP by a series of secretases (Haass 2004). First, the extracellular domain is 
cleaved by -secretase between residues 671 and 672 of the 770 isoform, which 
corresponds to residues 596 and 597 of the 695 isoform, leaving the C-terminal fragment 
(CTF) anchored in the membrane and releasing the soluble N-terminal fragment 
(sAPP). The CTF is then cleaved by -secretase within the transmembrane domain to 
produce A. -secretase can cleave the CTF at multiple points, which results in the 
variance in the length of A. Once cleaved, the A is released extracellularly or into the 









Figure 1.03. Processing of APP. 
APP either goes through amyloidogenic processing that results in A production or non-

















Non-Amyloidogenic Processing Pathway 
The non-amyloidogenic processing pathway of APP also involves cleavage by a series of 
secretases. The extracellular domain of APP is cleaved by a-secretase between residues 
687 and 688 of the 770 isoform, which corresponds to Lys16 and Leu17 of A. This 
releases the soluble N-terminal fragment sAPPa and the C-terminal fragment (aCTF) 
anchored in the membrane. The aCTF fragment, like the CTF fragment, is cleaved by 
-secretase. In this case, the P3 fragment (A(17-42)) is released extracellularly and the 
APP intracellular domain (AICD) is released into the cytoplasm, see Figure 1.03. 
 
1.2.3. APP Location and Trafficking 
After synthesis APP can be trafficked from the endoplasmic reticulum to the plasma 
membrane or locate to the trans-Golgi network (TGN). Only a small fraction reaches the 
cell surface and is quickly internalised due to its “YENPTY” motif near the C-terminus 
(Haass et al. 2012, Lai et al. 1995, Marquez-Sterling et al. 1997). Once internalised, APP 
is delivered to endosomes, where a fraction is recycled to the cell surface. A fraction of 
internalised APP is also degraded in lysosomes (Haass et al. 1992). Mutations in the 
YENPTY motif inhibit APP internalisation and decrease A production (Perez et al. 
1999). The non-amyloidogenic pathway of APP processing occurs predominantly at the 
cell surface as this is the location of the a-secretase complex (Haass et al. 2012, Sisodia 
1992). The mature -secretase complex is located both at the cell surface and in the 
endosomal system (Dries et al. 2008, Kaether et al. 2006, Nixon 2007, Pasternak et al. 
2004). 
 
The location of A production from APP is dependent on the location of the -secretase 
complex. The -secretase enzyme BACE1 (-site APP cleaving enzyme 1) is enriched in 




lipid rafts in the plasma membrane (Cordy et al. 2003, Riddell et al. 2001) but also 
undergoes internalisation to endosomes (Huse et al. 2000, Pastorino et al. 2002). BACE1 
is an aspartyl protease and thus optimum activity occurs at an acidic pH (~ pH 4.5) 
(Vassar et al. 1999), which is consistent with major activity in endosomes. However, -
secretase cleavage does not occur exclusively in endosomes (Haass et al. 2012). Figure 
1.04 depicts these trafficking pathways of APP in a non-polarised mammalian cell. 
 
In neuronal cells, APP is transported to axons and dendrites in post-Golgi transport 
vesicles after leaving the TGN (Kins et al. 2006). Axonal delivery uses the fast axonal 
transport system (Koo et al. 1990), and surprisingly, travels unidirectionally continuously 
(Kaether et al. 2000). Major secretion sites of A are distal axons and synapses (Lazarov 
et al. 2002, Sheng et al. 2002). It has been suggested that APP transported in the axonal 
vesicles are processed by - and -secretase, producing A in these vesicles (Kamal et al. 
2001). 
 
Regions of the brain where A plaques are most abundant are regions that exhibit the 
highest baseline of metabolic activity, an indicator of high neuronal and synaptic activity 
(Buckner et al. 2005, Gusnard et al. 2001, Raichle et al. 2001). Stimulation of N-methyl-
D-aspartate receptors (NMDARs) inhibits long term potentiation (LTP) and increases 
APP  expression,  promoting  A production  (Lesné et al. 2005).  Increased  A leads to 
long-term depression (LTD) (Kamenetz et al. 2003). APP overexpression and A 
generation also decreases the number of α-amino-3-hydroxy-5-methylisoxazole-4- 
propionic acid receptors (AMPARs) and NMDARs at the cell surface (Hsieh et al. 2006, 
Snyder et al. 2005).  This forms  a negative  feedback loop:  increased neuronal  activity 






Figure 1.04. Intracellular APP Trafficking.  
APP molecules (black bars) mature through the constitutive secretory pathway (1). Once 
APP reaches the cell surface, it is rapidly internalized (2) and subsequently trafficked 
through endocytic and recycling organelles to the TGN or the cell surface (3). Adopted 
from (Haass et al. 2012). 
 
  






Figure 1.05. Negative Feedback of A at the Glutamatergic Synapse.  
Neuronal activity leads to A release at the synapse, which binds to receptors on the post-
synaptic terminal, causing increased APP expression, enhanced LTD, LTP inhibition and 













produces more A which depresses synaptic function thus decreasing neuronal activity 
(Haass et al. 2012). This feedback loop is depicted in Figure 1.05. 
 
1.2.4. Mutations Found in Familial AD 
Familial early-onset AD represents approximately 5 % of all AD cases. Familial AD 
patients have been found to have mutations in APP or within key proteins in the -
secretase complex; presenilin 1 (PS1) or presenilin 2 (PS2). Interestingly, the majority of 
people with Down’s syndrome will develop early-onset AD. Down’s syndrome is the 
result of a trisomy of chromosome 21, which is the location for the gene encoding APP, 
thus the production of APP is dramatically elevated. As many as 25 mutations have been 
identified in APP and over 150 in PS1 of the -secretase complex (Tabaton et al. 2007). 
Mutations in the -secretase complex promote A(1-42) production over A(1-40) 
(Scheuner et al. 1996, Thinakaran et al. 1996). A summary of common mutants of APP 
are shown in Figure 1.06. These mutations can result in increased A production, such as 
the Flemish mutation (A692G), which inhibits a-secretase cleavage, or the Swedish 
mutation (K670N/M671L) which increases production through potentiation of -
secretase cleavage (Hardy 1997). Alternatively, the point mutations can promote A(1-
42) production over A(1-40), such as the Florida (I716V) and London (V717I) mutations 
which alter the site of -secretase cleavage (Hardy 1997). Point mutations in APP that are 
within the sequence of A itself can increase the amyloidogenic properties of A. The 
majority of A point mutations are clustered around residues 21-23 (residues 692-694 in 
full-length APP770) (Murakami et al. 2002). These either result in the loss of a negative 
charge (e.g. the Dutch mutation E22Q), which increases the pI of A closer to 
physiological pH making A less soluble, or the introduction of a glycine, which may 
promote misfolding. Indeed the Arctic mutation (E22G) will have both of these effects. 






Figure 1.06. Common Point mutations of APP Found in Familial AD. 
The point mutations shown either influence APP cleavage by  and  secretases or are 
within the sequence of A itself. Modified from (Van Dam et al. 2006). 
 
  




1.3. A STRUCTURE 
1.3.1. Monomeric A Structure 
Monomeric A is natively unstructured in water but has the ability to transiently form 
both alpha-helical and beta-sheet structures (Zhang et al. 2000). In a membrane 
mimicking environment, using sodium dodecyl sulphate (SDS), A has been shown to 
form a-helices from residues 17-24 and 28-36 (Barrow et al. 1992, Soto et al. 1995). 
Amyloidogenesis requires A to form a -sheet fold. 
 
1.3.2. Fibrillar A Structure 
A forms amyloid fibres that are approximately 10 nm in diameter and of indeterminate 
length, up to microns, and can exhibit periodical twists. Variability in periodicity and the 
number of protofilaments that form a fibre can occur within a single sample (Figure 1.07) 
(Meinhardt et al. 2009), known as fibril polymorphism. Much work has been done to 
elucidate the structure of A fibres, using a variety of techniques. The information 
gleamed from some of these techniques is discussed. 
 
X-Ray Diffraction 
X-ray diffraction data of A(11-25) fibrils over full-length A fibrils has been used to 
examine the internal structure of fibre protofilaments as X-ray diffraction data is less 
detailed with full-length A(Makin et al. 2005). The A monomers form an extended -
strand and associate to form cross- ribbons, where the chains run perpendicular to the 
fibre axis (Sikorski et al. 2003). The fibres form with an intersheet distance of 
approximately 10 Å and an interstrand distance of 4.7 Å (Sikorski et al. 2003), producing 
a characteristic X-ray fibre diffraction pattern, shown in Figure 1.08a,b. 






Figure 1.07. A Fibres have Periodical Twists.  








Solid-State Nuclear Magnetic Resonance 
Solid-state nuclear magnetic resonance (NMR) has proven to be a particularly useful 
technique for the elucidation of amyloid fibre structure. This is because solid-state NMR 
can provide constraints on inter-atomic distances and torsion angles at a site-specific 
level. Indeed, the measure of inter-atomic distance of 13C up to 6 Å is possible, with 
standard error of only 0.1-0.2 Å (Tycko 2000). Tycko and colleagues have created 
structural models of A fibrils (Figure 1.08c,d) predominantly through the use of solid-
state NMR measurements, specifically of 13C-13C dipole-dipole couplings, chemical 
shifts of 13C and 15N and intramolecular correlations of backbone carbonyl group 
orientations, but also in conjunction with transmission electron microscopy (TEM) 
(Antzutkin et al. 2002, Paravastu et al. 2008, Petkova et al. 2002, Tycko 2006). The 
models are consistent with the X-ray diffraction data. A forms two -strands per 
monomer in a -turn- fold, a hair-pin-like structure, such that the central hydrophobic 
core and the hydrophobic C-terminal domain side chains are packed together and 
hydrophobic interactions stabilise the structure. The structure is also stabilised by a salt 
bridge between Asp23 and Lys28. The N-terminus (residues 1-10) is disordered. Solid- 
state NMR can also be used to establish the supramolecular structure. It has been revealed 
that both A(1-40) and A(1-42) fibres contain in-register, parallel -sheets (Antzutkin 
et al. 2002, Balbach et al. 2002, Benzinger et al. 1998). 
 
Electron Paramagnetic Resonance 
The location and contacts of -strand segments within fibres can be elucidated using 
electron paramagnetic resonance (EPR) spectroscopy. This involves introduction of 
cysteine residues with nitroxide spin labels. EPR measurements on both A(1-40) and 
A(1-42)  fibres indicate  the greatest  side-chain  mobility  in the  N-terminal and  central 






Figure 1.08. A Fibril Structure.  
a) A monomers polymerise to form protofibrils with a cross -sheet structure that have 
constant interstrand and intersheet distances. b) The characteristic X-ray diffraction 
pattern observed for amyloid fibrils. c) and d) show possible fibre structures achieved by 










segments of A(Török et al. 2002), consistent with the structurally disordered regions in 
the Tycko model. The EPR supports the in-register, parallel alignment of the peptide 
chain within the cross- motif (Török et al. 2002). 
 
Hydrogen/Deuterium Exchange 
The molecular structure of fibres can also be probed indirectly through the use of 
hydrogen/deuterium (H/D) exchange. Based upon the availability of backbone amide 
protons to exchange, information about the fold of the protein can be inferred; protons on 
the surface will be readily exchanged whereas protons buried from the solvent or involved 
in hydrogen bonds will exchange slowly, if at all. Between 48 and 55 % of backbone 
amide protons have been reported to be highly protected from H/D exchange in A(1-40) 
fibres (Kheterpal et al. 2003). This is consistent with the Tycko model, where 




In vitro fibre formation has shown that there can be many different polymorphisms within 
a single sample formed (Meinhardt et al. 2009, Petkova et al. 2005). However, fibres with 
a specific molecular structure will be dominant depending on the conditions in which the 
fibres are formed. For example, fibres with 2-fold symmetry shown in Figure 1.07c 
dominate in quiescent (no agitation) conditions whereas fibres with 3-fold symmetry 
(Figure 1.07d) dominate with agitation despite the growth conditions being otherwise 
identical in peptide concentration, pH, temperature, ionic strength and buffer composition 
(Paravastu et al. 2008). It has been shown that fibres grown from seeds of a specific 
molecular structure will take or “inherit” the same structure as the seeds irrespective of 
the fibril growth conditions (Paravastu et al. 2008, Petkova et al. 2005). Interestingly, a 




recent study has isolated A fibril fragments from the brains of AD patients and seeded 
in vitro A fibre growth (Lu et al. 2013). The resultant daughter fibres were homogeneous 
in structure demonstrating that the seeds must all have had the same molecular structure. 
It is surprising that the brain-derived A fibres are not polymorphic and suggests that 
differences in fibril structure may correlate with differences in disease development (Lu 
et al. 2013). Clearly this behaviour has many parallels with different prion strains in 
transmissible spongiform encephalopathies. 
 
1.3.3. Oligomeric A Structure 
Oligomeric A has been suggested to be the most toxic form of A, however there are 
many different oligomeric species reported in the literature. Oligomers can either be off-
pathway or on-pathway to fibril formation and many oligomers exist in dynamic 
equilibrium with monomers, other oligomeric assemblies, protofibrils and fibres (Figure 
1.09). These have been studied from both ex vivo and in vitro sources. 
 
A-Derived Diffusible Ligands (ADDLs) 
Aβ-derived diffusible ligands (ADDLs) are a group of Aβ oligomers whose molecular 




A*56 is the only oligomeric species of a definite size (56 kDa) that has been isolated 
so far and was isolated from transgenic mice brains. This soluble oligomer is larger than 
the size range of the ADDLs (Lesné et al. 2006).  







Figure 1.09. Interconversion Between Different Aβ Assemblies. 
Proposed interconversion between naturally and synthetically-derived Aβ assemblies 
based on pathways described in the literature. Reproduced from (Benilova et al. 2012). 
 
  




Low Molecular Weight A Oligomers (LMW A) 
Low molecular weight oligomers (LMW A) encompass dimers and trimers thus are 6- 
12-kDa assemblies. They have no detectable secondary structure (Walsh et al. 1999, 
Walsh et al. 1997). 
 
A Oligomers (A) 
These are high molecular weight Aβ oligomers that measure 2–5 nm in height with atomic 
force microscopy, indicating a size of 10-100 kDa (Dahlgren et al. 2002).  
 
Protofibrils 
Protofibrils are appear to be composed of beaded chains with a beading periodicity of 3-
6 nm (Walsh et al. 1999). They are sometimes described as flexible and curved and have 
a length of less than 200 nm and a diameter of ~ 8 nm (Hartley et al. 1999, Walsh et al. 
1997). Protofibrils have a -sheet structure but a high level of random coil also exists in 
protofibrillar samples (Walsh et al. 1999). 
 
Annular Protofibrils 
Annular protofibrils, unlike the protofibrils described above, are off-pathway to fibre 
formation (Lasagna-Reeves et al. 2011). They form pores with an outer diameter of 7–12 
nm and an inner diameter of 1.5-2.5 nm (Lashuel et al. 2002, Lashuel et al. 2003). They 
are formed of 40-60 A monomers (Lashuel et al. 2002) and contain substantial -sheet 
character (Kayed et al. 2009). It has been proposed that annular protofibrils are formed 









Amylospheroids are perfectly spherical A assemblies that are 10–15-nm in diameter 
(Hoshi et al. 2003, Matsumura et al. 2011). They are composed of 32–150 monomers 
(Noguchi et al. 2009). 
 
1.4. A FIBRILLISATION 
1.4.1. Kinetics of Fibre Formation 
The progress of A monomer to A fibres follows a characteristic growth curve that has 
distinct stages; nucleation, elongation and a plateau phase (Nilsson 2004), as shown in 
Figure 1.10.  
 
The nucleation stage of A fibrillisation is the rate limiting step of fibre formation. During 
this lag phase the native-state A monomers must undergo misfolding, which allows for 
amyloidogenic aggregation. At this stage the monomers must polymerise to form a 
nucleating seed, which is typically a small oligomer of A. The addition of preformed 
seeds to a monomeric A sample will remove the nucleation stage and fibrillisation will 
enter the elongation stage directly. 
 
The elongation phase of fibrillisation is the rapid addition of A monomers to the ends of 
existing fibrils. Fragmentation of amyloid fibres has a profound influence on the rate of 
fibre formation. Fragmentation of fibres generates many nucleating ends so as to 
accelerate fibre fragmentation. Elongation continues until a plateau stage is reached. This 
is the point of maximal fibril formation. 
 






Figure 1.10. Stages of A Fibril Formation.  
A fibril growth follows a characteristic sigmoidal growth curve. During the nucleation 
phase, a seed forms from which protofibrils and fibres can develop during the elongation 
phase. Reproduced from (Kumar et al. 2011).  
 
  




The transition of A monomers to fibres is not a strict linear progression as each step is 
in dynamic equilibrium with its previous and following steps. For example, protofibrils 
can become either mature fibres or disassemble to become oligomers. 
 
1.4.2. Fibril Detection 
There are several different methods used to detect amyloid fibrils. This can be through 
direct visualisation or through characterisation of features specific to amyloid fibres. 
 
Microscopy 
TEM and Atomic Force Microscopy (AFM) are excellent methods for visualising 
amyloid fibres. The resolution of these types of microscopy means that not just fibres can 
be imaged but also protofilaments and oligomeric assemblies as structures on a nanometre 
scale are visible. However, microscopy is a qualitative technique so the differences in the 
number of fibres generated between samples cannot be readily calculated. 
 
Thioflavin T Fluorescence 
Thioflavin T (ThT) is a benzothiazole dye that binds to amyloid fibres with high 
specificity. Upon binding to amyloid fibres, ThT will fluoresce at an emission maximum 
of 490 nm when excited at 440 nm (LeVine 1993). Free ThT will not fluoresce thus the 
progression of fibrillisation in the presence of ThT will produce the characteristic growth 
curve seen in Figure 1.10. This is an effective quantitative method for detecting fibres 
and has therefore been used throughout this thesis to monitor A fibrillisation. The use 









Congo red is a secondary azo dye that binds to amyloid fibres and is often used as an 
amyloid stain in histopathology. Congo red exhibits birefringence upon binding fibres, 
changing from red to yellow/green. This method was popular for detection but has 
recently been shown to stabilise the native protein monomers, disturbing the amyloid 
formation pathway (Frid et al. 2007). 
 
-Sheet Detection 
The switch in secondary structure from a-helical or random coil to -sheet is a hallmark 
of amyloid assembly thus determination of secondary structure using circular dichroism 
(CD) or Fourier-transform infrared (FTIR) spectroscopy is employed in fibre detection. 
However, this is not completely indicative of amyloidogenic fibre formation as other 
types of aggregates (amorphous) may also display -sheet structure. These techniques 
should therefore be utilised concomitantly with other fibre detection techniques. 
 
1.5. THE NATURE AND MECHANISM OF THE TOXIC A SPECIES 
1.5.1. The Toxic A Species 
The nature of the toxic A species is highly debated. The plaques were first thought to be 
the most toxic species but the lack of correlation between the deposition of plaques and 
neuronal loss contradicts this view (Yankner et al. 2008). However, there is still some 
strong evidence for plaques acting as a toxic species from in vivo studies in transgenic 
mice. A study using multiphoton microscopy established a direct causal relationship 
between plaques and neurodegeneration, showing that plaque formation was followed by 
neurodegeneration, not the other way round, (Meyer-Luehmann et al. 2008). Others have 
shown that neuronal loss only occurs in the vicinity of plaques (Urbanc et al. 2002). 




The toxic oligomer hypothesis suggests oligomers are the toxic species of A aggregates 
(Lambert et al. 1998). The multitude of different A oligomers described in the literature 
(see section 1.3.3) complicates this view with different structures being identified as the 
toxic A species in AD. ADDLs were identified as the toxic species by Lambert et al. 
(Lambert et al. 1998), which was subsequently supported by a study showing their 
concentration is increased in AD patients by approximately 70-fold compared to non-
sufferers (Gong et al. 2003). ADDLs have been shown to inhibit long term potentiation 
in hippocampal neurons (Walsh et al. 2002). A*56 was identified as the toxic species 
by its correlation with decreased mouse performance in a Morris water maze test and 
injection of A*56 decreasing the spatial memory of four month old rats (Lesné et al. 
2006). AOs have been identified to be 40 times more toxic than monomeric A and 10 
times more toxic than fibres (Dahlgren et al. 2002). Protofibrils have been identified to 
be toxic in a number of studies (Hartley et al. 1999, Walsh et al. 1999). Amylospheroids 
have also been identified as toxic in a number of studies (Hoshi et al. 2003, Matsumura 
et al. 2011, Noguchi et al. 2009). The toxicity of A oligomers may therefore not be due 
to one particular species but rather various oligomers acting in non-specific ways to cause 
toxicity (Benilova et al. 2012). Identifying the toxic species is hampered by the 
heterogeneity of oligomeric preparations. 
 
1.5.2. The Mechanism of Toxicity 
Not only is the A species responsible for toxicity still not clear, the mechanism by which 
A causes toxicity is also disputed. The proposed mechanisms can be broadly divided 
into three categories; membrane alterations, oxidative stress and modulation of 
postsynaptic receptor activity. 
 





This may include the formation of annular protofibrils in the membrane, which have been 
proposed to cause toxicity either by non-specific leakage or as a Ca2+ channel (Arispe et 
al. 2007, Arispe et al. 1993, Jang et al. 2010). Alternatively membrane alterations can 
occur through contact with the hydrophobic ends of amyloid fibrils. Indeed, work with 
large unilamellar vesicles (LUVs) as a model for cell membranes has shown that the ends 
of amyloid fibrils can distort the shape of vesicles, puncture the vesicles and cause the 
formation of bubbles in the outer membrane (Milanesi et al. 2012). A has also been 
shown to increase the conductance of the lipid bilayer, either through localised structural 
defects or indirect thinning of the membrane (Sokolov et al. 2006). 
 
Oxidative Stress 
Increased levels of oxidative damage are observed in AD brains. Oxidative stress has 
been detected prior to the formation of amyloid plaques (Nunomura et al. 2006). 
Methionine at position 35 of A is found oxidised in A isolated from plaques (Dong et 
al. 2003). It has been suggested that A produces reactive oxygen species through 
Fenton/Haber-Weiss reactions in the presence of transition metals, specifically copper or 
iron (Huang et al. 1999). 
 
Modulation of Postsynaptic Receptor Activity 
Increasing evidence points to A disrupting normal postsynaptic receptor activity. 
NMDAR-dependent toxicity has been reported by a number of studies, as has LTP 
impairment and increased LTD, which are NMDAR-mediated processes (Alberdi et al. 
2010, Chen et al. 2002, Cullen et al. 1996, Decker et al. 2010, Domingues et al. 2007, 
Ferreira et al. 2012, He et al. 2011, Li et al. 2009, Li et al. 2011a, Rammes et al. 2011, 
Rönicke et al. 2011, Shankar et al. 2007, Tackenberg et al. 2013, Texidó et al. 2011, Wu 




et al. 1995, You et al. 2012). The direct interaction between A and NMDARs is 
discussed in section 1.8.1. 
 
It is possible the theories are closely interconnected and the toxicity of A is not due to 
one single mechanism. Indeed, there is evidence for an interconnection between oxidative 
stress and NMDAR activity modulation to cause neurotoxicity (He et al. 2011). 
 
1.6. AMYLOID CASCADE HYPOTHESIS 
The most widely supported theory for the process of AD development is the amyloid 
cascade hypothesis, shown in Figure 1.11 (Hardy et al. 1992). In this hypothesis, 
increased A production and deposition occurs first causing synaptic dysfunction and 
altered kinase/phosphatase activity, which leads to the hyper-phosphorylation of tau. 
Formation of tau neurofibrillary tangles are therefore a product of increased A 
accumulation with this hypothesis and have been thought to play a secondary role in A 
neurotoxicity. However, tau mediates A toxicity (Ittner et al. 2011), exemplified by tau 
deficiency being protective against A-induced cell death in mice models and neuronal 
cultures (Ittner et al. 2010, Rapoport et al. 2002). Evidence suggests that tau 
hyperphosphorylation is not simply a by-product of A accumulation and there may be a 
direct interaction between A and tau (Guo et al. 2006).  
 
The amyloid cascade hypothesis is not infallible with two main issues. Firstly, 
neurodegeneration can present before amyloid plaque deposition and the severity of AD 
does not necessarily correlate with the extent of deposition (Yankner et al. 2008). This 
can be resolved by the evidence that the toxic species of A is a soluble oligomer rather 
than the plaques.  Secondly,  APP and A are expressed ubiquitously in the human body  





Figure 1.11. The Amyloid Cascade Hypothesis.  
Reproduced from (Hardy et al. 2002). 




throughout their lifetime but AD manifests at old-age and only affects specific regions in 
the brain. 
 
1.7. AD RISK FACTORS 
1.7.1. Genetic Risk Factors 
In addition to the genetic mutations that cause familial AD (discussed in section 1.2.4), 
there are genetic variants that increase the risk of developing sporadic AD. A number of 
these have been identified using genome-wide association studies (GWAS). The most 
significant gene identified is the APOE4 allele. This encodes apolipoprotein E, a protein 
that conjugates with cholesterol and other fats to transport them through the blood plasma. 
Those heterozygous for APOE 4 are up to four times more likely to develop AD and 
homozygotes have an eight-fold increased risk (Corder et al. 1993). 
 
Other genes identified using GWAS include ABCA7, BIN1, CD2AP, CLU, CR1, EPHA1, 
MS4, PICALM and SORL1. The majority of genes that have been identified can be divided 
into four distinct categories; cholesterol metabolism, ubiquitination, endocytosis and 
immunity (Lambert et al. 2013).  
 
1.7.2. Environmental Risk Factors 
An increased risk of developing AD is not exclusive to genetic factors but environment 
can also play a role. Like genetic risk factors, some of these risks are unavoidable, 
however, others can be controlled. 
 
Age has the highest impact on AD, more than doubling the risk of development at the age 
of 80 compared to age 65. AD is more prevalent in women than men but the risk 




associated with gender is likely to be due to age as women have a greater average life 
expectancy. 
 
Existing medical conditions can also increase the risk of developing AD. An increased 
risk is associated with cardiovascular disease, diabetes and traumatic brain injury 
(Biessels et al. 2006, Kivipelto et al. 2002, Kivipelto et al. 2001, Roberts et al. 1994). A 
risk associated with the development of cardiovascular disease and AD is high levels of 
serum cholesterol (Kivipelto et al. 2002).  
Finally, diet and general health can also influence the risk of developing AD. It has been 
shown that obesity and a diet high in saturated fat increase the risk, while exercise and 
diets low in saturated fats and higher in omega 3 and 6 fats reduce the risk (Morris et al. 
2003). 
 
1.8. A BINDING PARTNERS 
The interactions A establishes within the body is an important factor for understanding 
the mechanisms behind the development of AD. A has been shown to interact with a 
variety of proteins and metal ions. These have either been found co-localised with A in 
amyloid plaques, are thought to be implicit in cell surface interactions or bind 
extracellular soluble A, as is the case for albumin (Luo et al. 2014, Stanyon et al. 2012) 
 
1.8.1. Proteins 
Proteins with which A interacts can broadly be split into three categories; membrane 
associated proteins and receptors, intracellular or extracellular chaperones, and other 
amyloid proteins. 
 




N-Methyl-D Aspartate Receptors (NMDARs) 
Excessive NMDAR activation has been implicated in the pathophysiology of AD (Snyder 
et al. 2005). NMDARs are activated by A oligomers (Brito-Moreira et al. 2011). 
Oligomeric A binding NMDAR results in synaptic depression through conformational 
changes rather than changes in ion flow through its channel (Kessels et al. 2013). A 
promotes the endocytosis of NMDARs (Snyder et al. 2005). 
 
Prion Protein (PrP) 
The cellular prion protein (PrPC) is a membrane anchored protein that has been identified 
as a cell surface receptor for A. It was identified through a screening that involved over 
200,000 proteins, using an unbiased cDNA library (Laurén et al. 2009). 
 
A does not interact with PrPC in monomeric form and it is not until A misfolds and 
forms oligomers that the interaction occurs. It has been shown that PrPC binds oligomers 
of A of approximately 20 monomers in size (Younan et al. 2013). A nanomolar affinity 
of the oligomers for PrP has been consistently reported (Balducci et al. 2010, Calella et 
al. 2010, Chen et al. 2010, Gunther et al. 2010, Laurén et al. 2009). Binding of A to 
PrPC halts the A fibrillisation pathway such that the A is arrested in oligomeric form 
and does not form fibres (Younan et al. 2013). PrPC is also able to disassemble mature 
fibres into oligomers (Younan et al. 2013). This ability to trap A in oligomeric form 
suggests a mechanism of increased neurotoxicity in vivo. Indeed, an in vivo model has 
shown that PrP is crucial for the neurotoxicity observed in AD. An AD mouse model with 
a PrP knock-out was shown to develop A plaques but no neurotoxicity was exhibited 
(Gimbel et al. 2010). In addition, in normal mice expressing PrPC the interaction between 
A oligomers and PrPC has been shown to inhibit long term potentiation in hippocampal 




slices (Laurén et al. 2009). Interestingly, PrP can mediate excessive NMDAR activity 
when in a copper-loaded state (You et al. 2012).  
 
Clusterin 
A link between developing AD and the protein clusterin has been identified from GWAS 
(Sleegers et al. 2010). Clusterin (also known as Apolipoprotein J) is part of a family of 
extracellular protein-folding chaperones, which have been shown to stabilise proteins and 
prevent their aggregation in vitro (Humphreys et al. 1999, Narayan et al. 2012a, Narayan 
et al. 2012b, Wyatt et al. 2009, Yerbury et al. 2007). Clusterin forms long-lived stable 
complexes with oligomers of A ranging from dimers to 50-mers (Narayan et al. 2012b). 
Clusterin is a predominant A-binding protein in CSF (Ghiso et al. 1993). An estimated 
Kd of the clusterin-A interaction has been calculated to be 4.8 nM (Hammad et al. 1997). 
Clusterin is found co-localised with A in extracellular amyloid deposits (Yerbury et al. 
2007). It has been suggested that clusterin binds to small A oligomers in vivo in order 
to keep the aggregates soluble, prevent their further formation into toxic aggregates, and 
facilitate their uptake and degradation via receptor-mediated endocytosis (Wyatt et al. 
2011). Clusterin interacts with the cell surface receptor megalin, which mediates 
clusterin-A uptake (Hammad et al. 1997). 
 
Cystatin C (CC) 
Cystatin C (CC) is a protein found in all body fluids and tissues. Cystatins are inhibitors 
of cysteine proteinases and CC has a broad spectrum of biological roles (Bobek et al. 
1992). Within the brain CC has been implicated in the repair of the nervous system and 
in the response to neurodegeneration (Levy et al. 2006). There is evidence that neuronal 
cells are protected directly by CC against a variety of toxic insults, including A induced 




toxicity. CC is itself prone to amyloid formation upon formation of domain-swapped 
dimers (Janowski et al. 2001, Staniforth et al. 2001). 
 
CC has been shown to co-localise with A plaque deposits in animal models (Steinhoff 
et al. 2001, Uchida et al. 1997, Wei et al. 1996). CC predominantly co-localises with A 
in the brains of AD patients in senile plaque cores (Maruyama et al. 1990, Vinters et al. 
1990) and amyloid-laden vascular walls (Bobek et al. 1992). 
 
CC binds to soluble A to inhibit A fibrillisation and oligomerisation in a concentration 
dependent manner (Sastre et al. 2004, Selenica et al. 2007). The interaction involves 
residues 101-117 of CC (Juszczyk et al. 2009) and the N-terminal domain of A (residues 
1-17) with a Kd in the low nanomolar range (Sastre et al. 2004). This inhibitory effect has 
been observed in vivo in mice over-expressing both CC and APP (Kaeser et al. 2007, Mi 
et al. 2007). CC concentrations found endogenously do not seem to be sufficient to inhibit 
A deposition in AD. Moreover, reduced levels of CC have been observed in AD patients 
(Hansson et al. 2009). A polymorphism of the CC gene (CST3), which reduces CC 
secretion, has been identified to increase the risk of developing AD (Finckh et al. 2000). 
Additionally, two PS2 mutations associated with AD cause reduced CC secretion and 
alter CC trafficking (Ghidoni et al. 2007). 
 
Serum Amyloid P Component (SAP) 
Serum amyloid P component (SAP) is a member of the pentraxin family of proteins, 
which are characterised by their homo-pentameric disc-like structure. SAP monomers are 
25 kDa in size and rich in anti-parallel -strands (Emsley et al. 1994, Wood et al. 1988). 
SAP is synthesised and catabolised in the liver (Hutchinson et al. 1994) and is present in 




the CSF at concentrations of approximately 8.5 ng/ml (Hawkins et al. 1994). SAP is 
universally found in all amyloid deposits, including AD plaques (Coria et al. 1988, Pepys 
et al. 1982). SAP is found especially in plaques with fibrillar A deposits but not in 
diffuse plaques (Veerhuis et al. 2003). 
 
The interaction of SAP with A is Ca2+-dependent and has a Kd of 6 nM at pH 7.5 
(Hamazaki 1995b). SAP will promote the aggregation of A at physiological CSF 
concentrations (Hamazaki 1995a). The SAP-A interaction depends on the degree of A 
fibril formation. SAP will bind to mature fibres, covering the surface of the fibres, but not 
protofibrils (Nielsen et al. 2000).  
 
SAP inhibits the degradation of amyloid fibrils by proteases. It has been suggested that 
SAP binding to A fibres in vivo masks their fibrillar conformation, inhibiting their 
degradation (Tennent et al. 1995). 
 
Islet Amyloid Polypeptide (IAPP) 
Islet amyloid polypeptide (IAPP) is a 37 residue peptide hormone. It is mainly produced 
and secreted by -cells in the pancreas (Westermark et al. 1987). IAPP shares a high 
degree of sequence identity (25 %) and similarity (50 %) with A (O'Nuallain et al. 2004). 
IAPP is also prone to formation of amyloid fibrils and its deposition in the pancreatic 
islets are a characteristic of type II diabetes. 
 
In vitro studies have shown that early nonfibrillar and nontoxic Aβ and IAPP species bind 
each other with high affinity forming soluble, nonfibrillar, and nontoxic heteroligomers. 
The cytotoxic self-association and amyloidogenesis of both Aβ and IAPP are delayed by 




this interaction (Yan et al. 2007). However, preformed IAPP or A fibrils are able to seed 
A-IAPP oligomers to further aggregate into hetero-fibrillar cytotoxic assemblies (Yan 
et al. 2014). Short peptide sequences of A and IAPP have been identified as ‘hot regions’ 
of the A-IAPP interaction, which are the shortest sequences that are able to cross-interact 
with a high affinity. These sequences are also involved in the self-association of the 
peptides (Andreetto et al. 2010).  
 
There is a positive association between IAPP and A levels in the serum of AD patients 
(Qiu et al. 2014). Injection of IAPP into AD mouse models reduces the amyloid burden 
and A levels in the brain, improving their learning and memory. Injection causes the 
translocation of A from the brain into the CSF and plasma (Zhu et al. 2014). These 
results suggest a protective effect of IAPP in AD. However, IAPP deposition has been 
witnessed in the brain parenchyma and blood vessels of late-onset AD patients without 
clinically apparent diabetes. IAPP deposition co-localised with A deposition was only 
occasional (Jackson et al. 2013) raising the possibility that IAPP can also contribute to 
AD aetiology. 
 
Human Serum Albumin (HSA) 
In the blood plasma 90-95 % of A is directly bound to HSA (Biere et al. 1996, Kuo et 
al. 2000). The interaction between A and HSA is investigated and discussed in detail in 
Chapters 3 and 4. 
 
Transthyretin (TTR) 
Transthyretin (TTR), also known as prealbumin, is a 55 kDa tetrameric protein 
synthesised predominantly in the liver. It is a thyroid hormone carrier and vitamin A 




transporter (Andrea et al. 1980, Monaco 2002, Raz et al. 1969). It is found in the serum 
and CSF at concentrations of 3-7 mM and 0.1-0.36 mM, respectively (Vatassery et al. 
1991). TTR is a major A-binding protein in CSF and decreased CSF TTR concentrations 
have been reported in AD patients (Hansson et al. 2009, Riisøen 1988, Serot et al. 1997). 
A added to CSF is quickly sequestered by TTR into stable complexes (Schwarzman et 
al. 1994). 
 
TTR has been shown to bind A in vitro and inhibit A fibrillisation (Schwarzman et al. 
1994, Schwarzman et al. 2004, Yang et al. 2013). TTR binds to all forms of A; 
monomers, oligomers and fibrils (Buxbaum et al. 2008, Costa et al. 2008, Giunta et al. 
2005, Liu et al. 2006). However, it binds A aggregates better than monomeric A 
(Buxbaum et al. 2008, Du et al. 2010, Liu et al. 2006). There is also preference for A 
alloform, binding A(1-42) better than A(1-40) (Buxbaum et al. 2008). Binding is 
dependent on the quaternary structure of TTR, with TTR monomers binding better than 
tetramers (Du et al. 2010). The stoichiometry and affinity of binding are difficult to 
establish with very different Kds published of 430 mM and 28 nM (Costa et al. 2008, Liu 
et al. 2006). 
 
A-TTR complexes have been isolated from brains of transgenic mouse models of AD 
and human AD brains (Buxbaum et al. 2008, Li et al. 2011b). Crossing the APP23 AD 
mouse model with a mouse over-expressing TTR normalised cognitive function and 
decreased the amount of A deposited normally observed with the APP23 model 
(Buxbaum et al. 2008). Additionally, TTR knock-out APP23 mice develop A deposits 
sooner than APP23 mice (Buxbaum et al. 2008). 
 




Peptides derived from the -binding domain in TTR are also able to bind A and 
inhibits its toxicity (Cho et al. 2014). 
 
Tau 
Phosphorylated tau has been found to interact with monomeric and oligomeric A in 
damaged neurons in both mouse AD models and AD patients (Manczak et al. 2013). The 
levels of A-tau complexes in the CSF are decreased in AD patients compared to other 
types of dementia and non-demented controls (Kristofikova et al. 2014). A binds tau 
with an affinity in the low nanomolar range, which is tighter than the affinity of tau for 
itself (Guo et al. 2006). Formation of the stable A-tau complex enhances 
phosphorylation of tau, which promotes dissociation of the complex (Guo et al. 2006). 
 
A very recent study has shown that amyloidogenic regions of the two peptides, A(25-
35) and tau(273-284), will cross-interact and polymerise to form heteroligomers. The 
incorporation of tau into A(25-35) reduces the propensity of A(25-35) to fibrillise. 
However, this incorporation also promotes the advancement of tau monomers and dimers 
to larger oligomers and aggregates (Do et al. 2014). 
 
1.8.2. Metal Ions 
Some transition metal ions are found concentrated in AD plaques, in particular Cu2+, Zn2+, 
and Fe3+ (Lovell et al. 1998, Miller et al. 2006). These transition metal ions can interact 
with A and affect its fibrillisation. The interaction of A with Cu2+ has been studied 
most extensively and is discussed in detail in Chapter 5. 
 




Zn2+ ions completely inhibit A fibrillisation, even at low concentrations of both A and 
Zn2+ (Chen et al. 2011, Noy et al. 2008, Sarell et al. 2010). Zn2+ can form an inter-
molecular complex with A, cross-linking histidine residues on multiple A molecules 
(Faller et al. 2009, Miller et al. 2010, Minicozzi et al. 2008, Syme et al. 2006), which 
likely inhibits fibrillisation by interfering with the cross- assembly (Viles 2012). A 
loaded with Zn2+ has also been shown to form annular pore-like oligomers (Chen et al. 
2011). 
 
The affinity of Fe3+ for A is relatively weak (Garzon-Rodriguez et al. 1999, Valensin et 
al. 2011) yet iron dysregulation of iron has been shown to exacerbate the AD phenotype 
in fly and mice models (Grossi et al. 2009, Liu et al. 2011, Rival et al. 2009). Fe3+ inhibits 
the rate of A fibrillisation (Chen et al. 2011, Liu et al. 2011), influencing fibre 
morphology such that shorter, more curved fibres are generated. This altered morphology 
may be what influences A toxicity (Liu et al. 2011). 
 
1.9. HUMAN SERUM ALBUMIN 
The HSA-A interaction is of particular interest in this thesis and is investigated in 
Chapters 3 and 4. In this section an overview of the role and structure of HSA is given. 
 
1.9.1. Location and Function 
HSA synthesis takes place in the liver. The gene is located on chromosome 4 and 
undergoes post-translational cleavage in the rough endoplasmic reticulum and Golgi 
vesicles before it is secreted into the blood stream (Putnam 1975). HSA is the most 
abundant protein in the blood plasma at a concentration of ~ 640 mM. It has many 
functions, mainly as a transport protein but it also maintains oncotic pressure and pH in  





Figure 1.12. The Crystal Structure of HSA and Ligand Binding Sites.  
a) The crystal structure of HSA with no ligands bound (1AO6). b-j) The crystal structure 
of HSA with common ligands bound shown as red space fill structures. b) myristic acid 
(1E7G), c) palmitic acid (1E7H), d) stearic acid (1E7I) e) aspirin (2I2Z), f) diazepam 
(2BXF), g) ibuprofen (2BXG), h) warfarin (2BXD), i) heme (1N5U), j) thyroxine 
(1HK4). The four-character code in brackets denotes the assigned code in the RCSB 










the blood plasma. HSA is also the most abundant protein in the CSF but its concentration 
is much reduced compared to the blood plasma at ~ 3 mM (Stevens et al. 1979). 
 
1.9.2. Structure 
Monomeric HSA is 585 residues in length with a molecular mass of approximately 66 
kDa. HSA is a largely alpha helical globular protein with 67 % of the residues forming 
helices. The remainder is mainly formed form extended peptide chains with 10 % forming 
-loops. The crystal structure is shown in Figure 1.12a (Carter et al. 1994). It comprises 
three domains that are in turn divided into two subdomains, which together form a heart-
like shape. It contains 35 cysteines, which form 17 disulphide bridges that stabilise the 
fold. A dimer of HSA can form that is joined by a disulphide bridge between the free thiol 
from Cys34 in each monomer. HSA has many hydrophobic pockets that bind a variety of 
hydrophobic molecules.  
 
1.9.3. Common Ligands 
HSA binds a wide variety of ligands including fatty acids, thyroid hormones, metal ions 
and pharmaceuticals. The crystal structures of many ligands binding to HSA have been 
deposited in the RCSB Protein Data Bank. The majority of these are for different chain 
length fatty acids, such as myristic acid, palmitic acid, and stearic acid (Figure 1.12 b-d) 
(Bhattacharya et al. 2000). However, crystal structures of HSA complexed with common 
pharmaceuticals (Ghuman et al. 2005, Yang et al. 2007), heme (Wardell et al. 2002) and 
the thyroid hormone thyroxine (Petitpas et al. 2003) have also been resolved (Figure 
1.12e-j). It is clear that, with the exception of thyroxine, all of these ligands bind in one 
or more of seven hydrophobic pockets on HSA. 
 




In addition to HSA binding hydrophobic ligands, HSA is also a Cu2+ transport protein. 
The site of Cu2+ binding has been identified to involve the N-terminal residues DAH 
(Patel et al. 1993). The affinity of the Cu2+-albumin is extremely tight with a Kd of 1 pM 
(Rózga et al. 2007). 
 
1.10. AIMS OF THIS THESIS 
Although a great deal of progress has been made since A was first isolated in the 1980s, 
many important details relating to its interaction with endogenous proteins and metal ions 
are missing. The main aims of this thesis are outlined below, but more detailed aims are 
within each of the results chapters, chapters 3 to 6. 
 
I. Compare the fibril formation of A in the presence and absence of HSA at CSF 
concentrations, to establish the influence of HSA on A self-association (Chapter 
3). 
II. Determine the nature of the interaction between A and HSA in terms of the size 
of the A species and location of binding as well as the influence of cholesterol 
and other endogenous albumin binding molecules (Chapter 4). 
III. Determine the affinity of monomeric, oligomeric and fibrillar A to ascertain if 
Aβ has a high enough affinity for Cu2+ to compete with HSA for Cu2+ and be 
physiologically relevant (Chapter 5). 
IV. Develop predictive rules for Cu2+-peptide coordination geometry using visible CD 
and use these to investigate the coordination and affinity of Cu2+ for other amyloid 
peptides, specifically the prion protein and alpha-synuclein (Chapter 6). 
 
 












MATERIALS, METHODS AND 
THEORY 
  




In this chapter I first outline a little of the basic theory behind some of the techniques 
employed in this thesis. This is followed by materials and methods. Methods used in a 
single chapter can be found in the individual chapters. 
 
2.1 THEORY 
2.1.1 Absorbance (UV-Vis) Spectroscopy 
This technique uses the ultraviolet (UV), 180 to 400 nm, and visible (Vis) spectrum, 400 
to 800 nm. The basis of absorbance spectroscopy is that the energy from UV-Vis radiation 
can excite peripheral electrons from a ground state to a higher energy level. The 
wavelength (energy) of light absorbed depends on the energy difference between the two 
electronic orbitals and is therefore a characteristic of the particular molecule. The more 
energy required, the shorter the wavelength at which absorbance will occur. Transition 
metals have electrons in their d-orbitals, the energy difference between d-orbitals is small 
and so typically occur in the visible region. π-orbital transitions found in, for example, 
aromatic rings, such as those in the side chains of the amino acids tryptophan and tyrosine, 
require more energy giving an absorption spectrum close to 280 nm. 
 
UV-Vis spectroscopy is a particularly useful approach to determine the concentration of 
proteins. The absorbance of tryptophan and tyrosine side-chains, along with disulphide 
bonds at 280 nm can be used as concentration monitors of proteins. The Beer-Lambert 
law (eq 2.01) highlights the linear relationship between absorbance and concentration of 
a protein: 
A = ε. c . l                (eq 2.01) 
Rearrangement of this equation to make concentration the product is demonstrated by eq 
2.02: 






ε . l                 (eq 2.02) 
where A is the absorbance, c is the molar concentration of a protein, ε is the extinction 
coefficient of the side chains and l is the pathlength in centimetres (cm). To calculate the 
concentration of a protein in a 1 cm pathlength cuvette using the absorbance at 280 nm, 
the following equation (eq 2.03) would be used to account for the contribution of each 






              (eq 2.03) 
where εx is the extinction coefficient and Nx is the number of the chromophores (Gill et 
al. 1989). Substituting in the extinction coefficients of each of the chromophores at 280 




              (eq 2.04) 
 
When measuring the concentration of proteins, any light scatter present due to aggregates 
in solution must be taken into account to avoid an overestimate of the A280. The effect of 
light scattering is determined at longer wavelengths prior to the onset of the absorption at 
280 nm, specifically over the wavelength range 320-350 nm. The absorption intensity at 
280 nm that is due to light scatter is calculated from equation 2.05: 
Ascatter,280=10
(2.5logA320-1.5logA350)             (eq 2.05) 
 
The equation used for determination of the concentration of a protein in a 1 cm pathlength 




              (eq 2.06) 




Only absorbance measurements between 0.1-1 are used (ideally at 0.8) because it is 
inaccurate to determine concentration outside this range of absorbance values. Quartz 
glass cuvettes are used because quartz does not absorb light in the UV- or the Vis-regions. 
 
For further information on absorbance spectroscopy, Chapters 12 and 13 by Alex Drake 
in “Methods in Molecular Biology” volume 22 are an excellent guide (Drake 1994a, 
Drake 1994b). 
 
2.1.2 Fluorescence Spectroscopy 
Electrons that have been excited to a higher state, as described for absorption 
spectroscopy, emit energy when they return to their ground state. This energy may be 
emitted as heat or occasionally as light radiation. Fluorescence spectroscopy measures 
this light radiation after excitation. The emitted light will have less energy than the 
excitation energy due to energy lost from collisions and heat thus will emit light at a 
longer wavelength, known as the Stokes shift (Figure 2.01). Substances that exhibit 
fluorescence typically have delocalised electrons, in the form of conjugated double bonds 
and are referred to as fluorophores. 
 
Despite the intensity of a fluorescence signal potentially being proportional to the 
concentration of the fluorophore, assuming there is no self-absorption or quenching, 
values obtained from fluorescence spectroscopy cannot be compared between machines. 
This is because the amount of fluorescence detected from a system is not consistent with 
instrumentation. Fluorescence units are therefore described as arbitrary fluorescence units 
(AFU). 






Figure 2.01. State Diagram of Fluorescence.  
Electrons are excited to a high energy state at one wavelength and emit fluorescence at a 
lower energy wavelength due to energy lost through heat and collisions. Adapted from 
(Wei et al. 2012). 
 
  




For further information on the theory of fluorescence, refer to “Principles of Fluorescence 
Spectroscopy” (Lakowicz 1999) and Chapter 15 of “Methods in Molecular Biology” 
volume 22 (Varley 1994) 
 
Two different types of instrumentation have been used in this thesis to detect 
fluorescence; single-cell spectrophotometers and multi-well fluorescence readers. 
 
Single Cell Fluorescence 
A fluorescence spectrophotometer uses a xenon lamp to produce a light beam, which is 
converged on to the entrance slit of the excitation monochromator through two lenses. 
After monochromation the excitation beam is converged on to the sample cell. The 
emitted fluorescence is detected at 90o to the excitation beam through the emission slit, 
which is then directed to the computer resulting in a fluorescence spectrum (see Figure 
2.02a). 
 
The advantage of using a single-cell spectrophotometer is that the monochromator allows 
any excitation wavelength to be used and an emission spectrum sweeping a large range 
of wavelengths to be collected. 
 
Multi-Well Fluorescence 
A multi-well spectrometer can hold multi-well plates that allow for many fluorescence 
experiments to be run concomitantly under identical conditions (e.g. temperature or 
agitation). Rather than containing a monochromator like the single-cell 
spectrophotometer, the excitation and emission wavelengths are controlled by filters in a 
multi-well fluorescence reader. The fluorescence detected is therefore at a wavelength 
specific to the emission filter used,  not a spectrum.  An outline of the set-up of a  multi- 









Figure 2.02. Schematics of Typical Fluorescence Reader Systems.  
The typical set up of a) a single-cell fluorescence spectrometer, and b) a multi-well 















well plate fluorescence reader is shown in Figure 2.02b. The multi-well fluorescence 
reader used throughout this thesis (BMG Fluostar Galaxy) allows for orbital shaking of 
the multi-well plate in addition to temperature control. The fluorescence emission can be 
detected from above or below the plate. 
 
Two types of fluorophore exist; intrinsic fluorophores and extrinsic fluorophores. 
Intrinsic fluorophores include the side chains of aromatic amino acids, such as tyrosine 
and tryptophan. Extrinsic fluorescence requires the addition of a fluorescent probe to a 
sample, such as Thioflavin T (ThT) in the case of amyloid fibre detection.  
 
ThT Fluorescence 
ThT fluorescence was used in this thesis to study Aβ fibre formation. ThT is a fluorescent 
dye that interacts with amyloids (Sunde et al. 1997). The structure of ThT is shown in 
Figure 2.03. It has a Kd of ~ 1 µM for Aβ amyloids and the interaction is not affected by 
salts, such as NaCl (LeVine 1993). ThT will only fluoresce once bound to amyloid fibrils. 
Fluorescence is observed at ~ 490 nm when excited at 440 nm. The stoichiometric ratio 
used in this thesis is 1:2 Aβ:ThT.  
 
Intrinsic Tyrosine Fluorescence 
Intrinsic tyrosine fluorescence was used in establishing the affinity of Aβ for Cu2. Aβ 
contains a tyrosine at position 10, which when excited at 280 nm will emit fluorescence 
at ~ 310 nm. The intrinsic tyrosine fluorescence of Aβ can be quenched by binding of 
Cu2+ close to the fluorophore. The tyrosine fluorescence will return when the Cu2+ is no 
longer bound to Aβ, which can be achieved through the use of a competing ligand with a 
known affinity for Cu2+. 







Figure 2.03. The Structure of Thioflavin T.  




2.1.3 Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy is a form of absorption spectroscopy that uses 
circularly polarised light. Circularly polarised light can rotate clockwise (right) and anti-
clockwise (left). The difference in absorption (∆A) between the left (AL) and right (AR) 
circularly polarised light by a chromophore results in a CD spectrum. A difference 
between the absorption depends on the chirality of the chromophore thus a non-chiral 
molecule will absorb left and right circularly polarised light to the same extent, resulting 
in no CD signal. A diagram of the main features of a CD instrument is shown in Figure 
2.04. 
 
The difference in absorption can be related to the molar extinction coefficient using the 




                 (eq 2.07) 
where ∆ε is the difference in molar extinction coefficient, or molar ellipticity, ∆A is the 
difference in absorbance, c is the molar concentration and l is the pathlength of the sample 
in centimetres.  
 
The relationship between the direct CD measurements, θ  (mdeg) and ∆A is shown in 
equation 2.08. 
θ=∆A . 33,000                (eq 2.08) 
 
Therefore, the direct CD measurements can be converted to molar ellipticity (∆ε) with 




                (eq 2.09) 





Figure 2.04. Schematic of the Basic Components of a CD Spectrometer.  





















Visible CD (Vis-CD) utilises wavelengths 300 to 800 nm of the light spectrum. Therefore, 
like visible absorbance spectroscopy, it is useful for observing d-d transitions of metal 
ions. As Vis-CD requires a chiral chromophore, the metal ion typically forms a complex 
with a ligand to be chirally active. There are three particular effects which contribute to 
the activity of a metal–ligand complex, these are: 
• The configurational effect. This occurs when the distribution of donor atoms 
coordinating the metal ion are asymmetrical. 
 
• The conformational effect. This is due to ring puckering and is less applicable to 
complexes with planar coordination geometry of Cu2+ and Ni2+ complexes studied in 
this thesis. 
 
• The vicinal effect. This effect is observed when a chiral carbon atom is in the 
backbone of a ring between two chelated donor atoms, typically main chain amides. 
This effect is the main determinant of optical activity in metal-peptide complexes 
studied in this thesis. 
 
These effects mean that in addition to free metal ions, metal ions bound to non-chiral 
molecules, such as glycine, also have no optical activity and are CD silent. This was 
exploited in calculating an affinity for peptide-Cu2+ complexes in Chapter 6. 
 
For more information on the theory of circular dichroism (CD), refer to Chapter 16 of 
“Methods in Molecular Biology”, Volume 22 (Drake 1994c) and Chapter 10 of 
“Biophysical Tools for Biologists”, Volume 1 (Martin et al. 2008). 
 




2.1.4 Electron Paramagnetic Resonance 
Electron paramagnetic resonance (EPR), also known as electron spin resonance, studies 
the resonant transitions between energy levels of electron magnetic dipole moments. 
Every electron has a magnetic dipole moment, which can either align parallel (low energy 
state) or anti-parallel (high energy state) to an applied external magnetic field. The 
magnetic field is scanned such that the energy of the applied electromagnetic radiation 
matches the gap between these low and high energy states, thus allowing the electrons to 
move between their two states. The EPR spectrum is converted from the net absorption 
of energy that occurs due to more electrons being in the low energy state.  
 
The spin, which is the intrinsic angular momentum of an electron, is another vector of 
EPR. All elementary particles of a given kind have the same unitless spin quantum 
number. For example, the copper nucleus has a spin of 3/2 and an electron has a spin of 
1/2. Only species which contain unpaired electrons, such as Cu2+ which has one unpaired 
electron in its outer shell, have the spin necessary to interact with the applied 
electromagnetic field. 
 
A simple energy level diagram for an electron with spin 1/2 is shown in Figure 2.05. The 
energy level separation can be changed by varying the applied magnetic field, B. 
Resonant absorption occurs if the frequency is adjusted so that ΔE = hv. The separation 
between the low energy state and the high energy state is ΔE  = gµBBz. Therefore, this can 
be written as equation 2.10. The two states are described by the g-factor (g), the Bohr 
Magneton (µB) and the strength of the experimental magnetic field (Bz) in gauss. 
 
ΔE  =hv = gµBBz               (eq 2.10) 
 






Figure 2.05. Energy Level Diagram for an Electron with Spin 1/2. 
An unpaired electron moves between the two energy levels by either emitting or 
absorbing electromagnetic radiation (-1/2 gµBBz and +1/2 gµBBz, respectively) such that 
hv=∆E. The 2 states are described by the g-factor (g), the Bohr Magneton (µB) and the 













Experimentally, it is easier to vary the magnetic field by small increments than vary the 
frequency of the radiation. The position of the line in an EPR spectrum is indicated by 
the value of the magnetic field at which the sample has absorbed energy. g-factors are 
used to denote line position instead of field or frequency due to differences in EPR 
spectrometers and experimental conditions.  
 
The g-factor 
The g-factor (g) is a dimensionless quantity, which can be used to identify the electronic 
structure of the paramagnetic centre. Comparisons between the g-factor for an electron in 
an experimental system (calculated using equation 2.10) and the g-factor for a free 
electron in a vacuum (ge = 2.002319) can be used to obtain information on the nature of 
the atomic or molecular orbital containing the unpaired electron. This is particularly 
relevant for studies with transition metal ions, such as in this thesis, where the g-factors 
can be drastically affected by interactions between the electron spin and orbitals. 
 
The only cause of the deviations of the g-factors from 2.002319 are the magnetic 
interactions involving the orbital angular momentum of the unpaired electron, which 
depends on its chemical environment. There are two interactions that involve the orbital 
angular momentum; its interaction with the external magnetic field and spin-orbit 
coupling. The spin-orbit coupling results from the nucleus “orbiting” around the electron 
(from the electron’s point of view), which generates a magnetic field at the electron due 
to the motion of the positive charge.  
 
The orbital motion of the electron is quenched when the electron is orbiting close to nuclei 
because of the electrostatic effect between the negatively charged electron and the nuclei. 
The orbital motion of the electron will be affected differently depending on whether the 




electrostatic effect is equal along all the axes. Some examples of potential molecular 
geometries for peptide-Cu2+ complexes and the resulting EPR spectra are shown in Figure 
2.06. Octahedral geometry is isotropic for all rotations (Figure 2.06a), whereas tetrahedral 
geometry is anisotropic for all rotations (Figure 2.06c). Axial square-planar geometry has 
linear rotational symmetry thus anisotropy is observable except when the applied 
magnetic field is in the plane perpendicular to the axis of symmetry (Figure 2.06b). Cu2+-
EPR is usually of the axial type (Figure 2.06b). Two components of the EPR spectrum 
shown are the gII (the parallel g factor) and g⊥ (the perpendicular g-factor), which are the 
g-factors appropriate to the magnitudes of the applied magnetic field when it is parallel 
or perpendicular to the system’s symmetry axis, respectively. Figure 2.06b shows a major 
absorption at g⊥ (high field) and a lesser absorption at gII (low field).  
 
Hyperfine Splitting 
After unpaired electrons are placed in a magnetic field, the number of energy levels are 
increased from one to two (E = + ½ gµBBz and E = - ½ gµBBz), as shown in Figure 2.05. 
This increase in the number of energy levels through exposing the electrons to a magnetic 
field is called splitting. Further splitting in energy levels, known as hyperfine splitting, 
arises from the interactions between the electrons and the nucleus. The magnetic moment 
of the nucleus is restricted to a few particular orientations relative to the external magnetic 
field. For example, the copper nucleus has a spin of 3/2, and thus has nuclear spin 
orientations of +3/2, +1/2, -1/2 and -3/2. The nuclear magnetic moment’s orientation 
affects the magnetic energy of the electron meaning absorption lines are obtained over a 
range of magnetic field values from what would otherwise be the one resonance 
absorption line. The EPR spectrum therefore consists of a number of bands rather than 
just one (see Figure 2.07). As well as the anisotropy in g there may be an anisotropy in 
the  hyperfine splittings (A) as well.  Typically for Cu2+-EPR,  the hyperfine splitting A⊥ 






Figure 2.06. Typical EPR Spectra for Different Cu2+ Coordination Geometries. 
The typical EPR spectra observed for Cu2+-peptide complexes with a) octahedral, b) 
square-planar, and c) tetrahedral coordination geometries. Adapted from (Sarell 2010). 
 
  






Figure 2.07. Hyperfine Splitting of the Cu2+ Electron 
Four transitions are allowed from the ground state to the excited state based on the 
orientation of the nuclear angular momentum vector (MI) shown by the purple arrows, 
which results in four splittings. If the magnetic field is kept constant, the smaller the 


















(the hyperfine splitting at g⊥) is poorly resolved, while the AII (the hyperfine splitting at 
gII) is much larger, with the four features at gII resolved. 
 
An idealised Cu2+-peptide EPR spectrum is shown in Figure 2.08 with its two component 
parts arising from the axial coordination of Cu2+, meaning anisotropy of the g-factor is 
exhibited, resulting in parallel (low field) and perpendicular (high field) components. The 
hyperfine splitting (A) results in four splittings within both components of the spectra. 
The g value is reported as the centre of the multiplet and A is measured as the field 
between splittings. 
 
Using EPR to Identify Coordination Ligands 
An influential paper by Peisach and Blumberg describes how EPR spectra of Cu2+ 
tetragonal complexes can be used to infer the identity of the ligands in the equatorial plane 
(Peisach et al. 1974). Using different classes of model compounds, they studied the 
relationship between the AII and gII values and produced a guide that can be used to 
suggest binding ligands in the complex, see Figure 2.09. The AII values are obtained in 
gauss (∆H) from the EPR spectrum but are converted to millikaysers (mK) for the 
Peisach-Blumberg plot using equation 2.11: 
A = 0.046686*g*∆H              (Eq 2.11) 
where g is the free electron g-factor (2.002319). 
 
For more information on the theory of EPR, please refer to “Electron Paramagnetic 
Resonance: Elementary Theory and Practical Applications” (Weil et al. 2007). 
  






Figure 2.08. A Model EPR Spectrum for Cu2+-Peptide Complexes 
 Cu2+ shows a square-planar geometry in the Cu2+-peptide complex, giving g-parallel (gII) 
and g-perpendicular (g⊥) bands. There is clearly resolved hyperfine splitting of these 
bands (AII and A ⊥) due to the orientation of the copper nucleus, which has spin of 3/2. 













Figure 2.09. Peisach-Blumberg Plot 
The Peisach-Blumberg plot can be used to predict the coordinating ligands (Nitrogen, 
Oxygen, Sulphur) of a Cu2+-peptide complex with square-planar geometry from the 
relationship between the AII and gII obtained from an EPR spectrum. Adapted from 








































The Principles of Affinity 
Any reaction or binding event can be thought of as an equilibrium between the reactants 
and products. In the case of a protein (P) binding to a ligand (L) in a one to one ratio to 
form a protein-ligand complex (PL) then: 
P+L PL               (eq 2.11) 
The association constant (Ka) for this binding event is given by the ratio of the products 





PL              (eq 2.12) 
The reverse reaction, where the metal dissociates from the ligand, is inversely 
proportional to the Ka. The dissociation constant (Kd) is given by equation 2.13 and has 
units in Molar concentrations. 
Kd=
PL
PL                (eq 2.13) 
The smaller the dissociation constant, and accordingly the bigger the association constant, 
the higher the affinity between the two components of the complex. The dissociation 
constant, Kd, is useful as it indicates at what concentration of ligand half of the protein’s 
binding site will be occupied by the ligand. For example, for a complex with a Kd of 1 
nM, at a ligand concentration of 1 nM, half of the available protein binding sites will be 
occupied. If the concentration of ligand is sub-nanomolar, then only a small amount of 
the ligand will be bound to the protein, even if the ligand is in excess relative to the 
protein. Alternatively, ligand concentrations much greater than 1 nM, will result in ligand 
occupying all available protein binding sites. 
 
 





Figure 2.10. Ligand Binding Curves. 
a) Shows a typical binding curve with saturation of the binding site (θ) on the y axis and 
free ligand concentration ([Lfree]) on the x axis. The Kd is calculated at 50 % binding site 


















































































































Effect of pH and Temperature 
Stability constants can either be expressed as the ‘absolute’ affinity, a value which is pH-
independent or the ‘apparent affinity’, a value which is pH-dependent. In this thesis the 
experimentally measured affinity of Cu2+-peptide complexes is the apparent affinity. It is 
more useful to know the affinity at a particular pH, e.g. at physiological pH 7.4, as the 
affinity of Cu2+ for a peptide can be strongly influenced by pH. This is because H+ ions 
can compete with Cu2+ ions for binding sites. Thus the affinity can be much tighter in 
alkaline conditions compared to acidic conditions. 
 
The affinity of a peptide for a ligand is strongly influenced by its surroundings. Affinity 
is temperature dependent; the Kd increases with increasing temperature for exothermic 
reactions but decreases for endothermic reactions. 
 
Methods of Calculating Affinity 
There are multiple different ways the affinity of a complex can be determined, with any 
technique that can quantitatively measure the levels of products or reactants present 
potentially able to measure the affinity. In this thesis spectroscopic techniques, 
specifically Vis-CD, intrinsic tyrosine fluorescence and EPR, are employed. 
 
A common method of presenting affinity data is as a binding curve. Binding curves are 
graphs of ligand concentration on the x axis against the saturation of the binding site (θ) 
on the y axis (see Figure 2.10a). The shape of the binding curve gives information of the 
strength of binding between the peptide and ligand, examples shown in Figure 2.10b. The 
dissociation constant Kd can be calculated when θ = 0.5, i.e. half the ligand is bound and 
half is not. However, if the binding curve exhibits tight binding, it can only be determined 
that the Kd is stronger than the concentrations of peptide and ligand used. For tight 




binding, all of the added ligand binds to the peptide, as it is titrated in, and no detectable 
free ligand remains in solution. 
 
In this thesis, the equipment used to measure affinity requires micromolar concentrations 
of peptide and Cu2+ ions, which results in tight binding curves. The Kd therefore cannot 
be calculated directly. Consequently, competitive chelators with a known affinity for Cu2+ 
ions were used to generate an observed equilibrium between free Cu2+, chelator-bound 
Cu2+ and peptide-bound Cu2+. 
 
Affinity Calculations 
The absolute affinities (Abs Ka) of Cu
2+ chelators commonly used in determining the 
affinity of Cu2+-peptide complexes, glycine and nitrilotriacetic acid (NTA), are quoted at 
25-30 °C at ionic strengths between 0.01 to 0.5 in “Data for Biochemical Research” 
(Dawson 1986). From this, the apparent stability constants (App Ka) at pH 7.4 can be 
calculated using equations 2.14 and 2.15. The Abs Ka, App Ka and App Kd for Cu
2+(Gly)2, 
and Cu2+(NTA) are shown in Table 2.01. 
 
log α=pKa - pH               (eq 2.14) 
log App Ka=logAbsKa- log α              (eq 2.15) 
 





Log App Ka at 
pH 7.4 
App Ka at pH 
7.4 (M-1) 
App Kd at pH 
7.4 (M) 
NTA 13.1 10.7 5.0 * 1010 1.99 * 10-11 
Glycine 
Ka1 8.1 5.87 7.4 * 10
5 
1.35 * 10-6 
Ka2 7.1 4.87 7.4 * 10
4 
1.35 * 10-5 
 




For example, the pKa of NTA is 9.8 and the absolute affinity of NTA for Cu
2+ is 13.1 
(Dawson 1986) so using equations 2.14 and 2.15, the apparent affinity at pH 7.4 can be 
calculated:  
 
log α= 9.8-7.4 = 2.4 
log App Ka at pH 7.4 = 13.1 – 2.4 = 10.7 
 
This gives an apparent affinity at pH 7.4 of 5.0 * 1010 M-1 or a dissociation constant of 
19.9 pM.  
 
Calculating the Affinity of Cu2+ for Peptides 
At equilibrium, where the concentrations of Cu2+ bound to the peptide and Cu2+ bound to 
the competing chelator are evenly distributed, the Kd is equal to the concentration of free 









             (eq 2.16) 
 
Where, [Cu2+bound to peptide] is equal to half the Cu
2+ concentration, AppKa is the apparent 
Ka of the competing chelator and [Competitorfree] = [Competitortotal]-[Cu
2+
bound to peptide]. 
Alternatively, the Kd can also be calculated from the observed Kd in the presence of the 
competing ligand by using equation 2.17 (Wells et al. 2006). 
Kd=ObsKd.
AppKd
Competitorfree              (eq 2.17) 
 
Where, ObsKd is the observed Kd and is equal to [Cu
2+
bound to peptide] and the AppKd is the 
apparent Kd of the competing chelator. 




Worked Example for Calculating Cu2+ Affinity for Aβ Using NTA as a Competing 
Chelator 
Below is a worked example of calculating the affinity of Aβ(1-42) for Cu2+ using NTA 
as a competing Cu2+ chelator. The experimental specifics are taken from one of the 
fluorescence experiments in Chapter 5 (Figure 5.02a): 
 
[Aβ total] = 10 * 10-6 M 
[Cu2+ total] = 4 * 10-6 M 
[Cu2+ bound to Aβ] = 2 * 10
-6 M 
Apparent Ka at pH 7.4 for NTA = 5.0 * 10
10 M-1 
Apparent Kd at pH 7.4 for NTA = 2.0 * 10
-11 M 
[NTAtotal] = 6 * 10
-6 M 
[NTAfree] = 6 * 10
-6 – 2 *10-6 = 4 * 10-6 M 
 









Kd = 9.99995 * 10
-12 M = 10 pM 
 







Kd = (2 * 10
-6)(5 * 10-6) 
Kd = 10 * 10
-12 M = 10 pM 
 




Calculating the Affinity of Cu2+-Peptide Complexes using Glycine as a Competing 
Chelator 
Calculating the affinity of Cu2+-peptide complexes using glycine, as I have in Chapter 6, 
is more complicated than using NTA. This is because glycine can form either a Cu(Gly) 
or Cu(Gly)2 complex, thus their affinity is given by Ka1 and Ka2 (Dawson 1986), see Table 
2.01. The equation used to calculate the Kd is similar to equation 2.16 but takes into 





           (eq 2.18) 
 
If the Cu2+-peptide complex has an affinity much tighter than the Cu(Gly) complex (at 
least three orders of magnitude), it can be assumed that all Cu2+ not bound to peptide 
forms a Cu(Gly)2 complex. However, if the affinity of the Cu
2+-peptide complex is similar 
to glycine then the distribution of Cu2+ between the two complexes must be calculated to 
determine the concentration of free glycine. 
 
It is known that: 
[Glyfree] = [Glytotal] – [Cu(Gly)] – 2[Cu(Gly)2]           (eq 2.19) 
where, [Cu(Gly)] and [Cu(Gly)2] are the concentrations of Cu
2+ in the respective glycine 
complexes. 
 




Gly =AppKa2Glyfree              (eq 2.20) 
 





Glytotal] – [Cu(Gly)] – 2[Cu(Gly)2]          (eq 2.21) 




It is known that the concentration of Cu2+ bound to glycine is equal to the concentration 
of Cu2+ bound to peptide at equilibrium, thus equation 2.22 can be substituted into 
equation 2.21 and simplified to give equation 2.23. 
[Cu(Gly)2] = [Cu
2+
bound to peptide] – [Cu(Gly)]            (eq 2.22) 
 
[Cu2+bound to peptide]-[Cu(Gly)] = AppKa2[Glytotal][Cu(Gly)] + AppKa2[Cu(Gly)]
2 –  
2AppKa2[Cu
2+
bound to peptide][Cu(Gly)]        (eq 2.23) 
 
When all known values are substituted into equation 2.23, the resulting equation will be 
in the form ax2 +bx + c = 0, where x is [Cu(Gly)]. [Cu(Gly)] can therefore be calculated 
using the quadratic formula (eq 2.24). Of course, a quadratic equation shows two 
solutions for x but as [Cu(Gly)] is constrained by [Cu2+total], only the value for x that is 




                (eq 2.24) 
 
Once the value of [Cu(Gly)] is known, equation 2.22 can be used to calculate the value 
of [Cu(Gly)2]. From this, equation 2.19 can be used to determine [Glyfree]. Finally, once 
[Glyfree] has been calculated, the Kd can be determined using equation 2.18. 
 
Worked Example for Calculating Cu2+ Affinity for PrPC using Glycine as a Competing 
Chelator  
Below is a worked example of calculating the affinity of the first three N-terminal 
residues of PrPC (KKR) for Cu2+ using glycine as a competing Cu2+ chelator. The 
experimental specifics are taken from one of the Vis-CD experiments in Chapter 6B 
(Figure 6B.02a): 




[PrPtotal] = 200 * 10
-6 M 
[Cu2+total] = 200 * 10
-6 M 
[Cu2+ bound to PrP] = 100 * 10
-6 M 
[Glytotal] = 267 * 10
-6 M 
Apparent Ka1 at pH 7.4 for Gly = 7.4 * 10
5 M-1 
Apparent Ka2 at pH 7.4 for Gly = 7.4 * 10
4 M-1 
 
First [Cu(Gly)] (x) is calculated from equation 2.23 followed by equation 2.24: 
 
100*10-6 – x = (7.4*104 * 267*10-6*x) + 7.4*104x2 – (2 * 7.4*104 * 100*10-6 * x) 






x = 1.42589 * 10-5 M 
 
[Cu(Gly)2] is then calculated using equation 2.22: 
[Cu(Gly)2] = 100*10
-6 – 1.42589*10-5 = 8.57411 * 10-5 M 
 
[Glyfree] can then be calculated using equation 2.19: 
[Glyfree] = 267*10

















Kd = 2.3798 * 10
-7 M = 240 nM 
 
In the original paper published (Stanyon et al. 2014), the concentration of the free glycine 
at θ = 0.5 calculated did not take into account the distribution of Cu2+ between the two 
binding modes of glycine. This caused an over-estimation of the Kd calculated, for 
example in the case illustrated above, 61 nM rather than 240 nM was obtained. This over-
estimation of affinities does not affect the conclusions within the paper. 
 
For an excellent review on calculating affinity see Xiao et al. (Xiao et al. 2010). 
 
2.1.6 Aβ Solubilisation 
There are several different methods currently used for the solubilisation of Aβ. Organic 
cosolvents, usually hexafluoroisopropanol (HFIP) or trifluoroethanol (TFE) (Chen et al. 
2001, Zagorski et al. 1992) are common in the literature. The use of chaotropic agents 
such as dimethylsulfoxide (DMSO) (Stine et al. 2003) and organic acids such as 
trifluoroacetic acid (TFA) (Zagorski et al. 1999) are also used. Alternatively basic 
conditions, such as using dilute sodium hydroxide (NaOH) to obtain a pH of ~10.5 have 
also been shown to effectively solubilise Aβ (Fezoui et al. 2000) and is used extensively. 
 
A problem with using organic solvents such as HFIP is that they influence fibrillogenesis 
and cytotoxicity and might not be fully removed. This adds to the variability that is 
already a major problem in fibril growth studies (Shen et al. 1995). Residual presence of 
these organic solvents from data collected in vitro presents the problem of whether the 




results are physiologically relevant. Using dilute sodium hydroxide for solubilisation 
avoids these problems.  
 
An additional advantage of using high pH solubilisation conditions is that it avoids Aβ 
being near its isoelectric point. Aβ synthetically produced using Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry contains bound trifluoroacetate, which will create 
an acidic environment when Aβ is solubilised. When Aβ is subsequently added to buffer 
at a neutral pH the solution passes through the isoelectric point of Aβ (pH 5.3), where the 
potential for Aβ aggregation and precipitation is maximised. This can result in highly 
variable kinetic behaviour and fibril morphologies (Wood et al. 1996). The use of basic 
conditions to solubilise Aβ avoids the transition from low pH via its pI to physiological 
pH, preventing the problems associated with Aβ being at its pI (Fezoui et al. 2000, 
Teplow 2006). 
 
The NaOH method has been shown to be as effective as three other commonly used 
methods; the HFIP method, the DMSO/water/Tris method, and the NaCl/PO4 method 
(Hortschansky et al. 2005, Lashuel et al. 2003). Furthermore, NaOH pretreatment has 
been shown to result in fewer aggregates and diminish variability (Fezoui et al. 2000). 
Because of this, dilute NaOH was used to solubilise lyophilised Aβ in the studies in this 
thesis, although these other solubilisation methods were explored. 
  






The chemicals used in this thesis are listed in Table 2.02 with details of the supplier, 
purity and molecular weight. 
 













Sodium Hydroxide (NaOH) 
BDH 
Biochemical 
40.00 ≥ 99 % 
Copper (II) Chloride Dihydrate 
(CuCl2 · 2H2O) 
Sigma - Aldrich 170.48 ≥ 99.99 % 
Nickel (II) Chloride Hexahydrate 
(NiCl2 · 6H2O) 
BDH 
Biochemical  
237.69 ≥ 98 % 
Sodium Chloride (NaCl) Sigma - Aldrich 58.44 ≥ 98 % 
N-ethylmorpholine (EM) Sigma - Aldrich 115.20 ~ 99 % 
2-[4-(hydroxyethyl)piperazin-1-
yl] ethanesulfonic Acid (HEPES) 
Sigma - Aldrich 238.30 ≥ 99.5 % 
Potassium Phosphate Monobasic 
(KH2PO4) 1 M solution 
Sigma - Aldrich - - 
Potassium Phosphate Dibasic 
(K2HPO4) 1 M solution 
Sigma - Aldrich - - 





Nitrilotriacetic acid (NTA) Sigma - Aldrich 191.1 ≥ 99 % 
Phosphotungstic acid (PTA) Sigma - Aldrich 2880.05 
Microscopy 
grade 
Cholesterol Sigma - Aldrich 386.66 ≥ 99 % 
Palmitic Acid Sigma - Aldrich 256.42 ≥ 99 % 
Dimethylsulfoxide (DMSO) Sigma - Aldrich 78.13 ≥ 99.9 % 
 
 




2.2.2 Peptides and Proteins 
Amyloid-Beta 
All Aβ peptides were purchased commercially from Zinsser Analytic and Cambridge 
Research Biochemicals and supplied as lyophilised powder. Aβ peptides were 
synthesised using solid-phase Fmoc chemistry. After removal from the resin and de-
protection, the peptides were purified using reverse-phase HPLC and characterised using 
mass-spectrometry. The sequence of Aβ peptides used throughout this thesis were based 
on the human sequence of Aβ. Aβ(1-40) and Aβ(1-42) were designed with the native 
amino and carboxyl groups at the N-terminus and C-terminus, respectively. The truncated 
Aβ(1-16) was utilised for some studies as it is missing the residues responsible for 
fibrillisation but still contain the Cu2+ binding residues. This is not a native sequence thus 
the C-terminus was amidated to mimic the continuation of the peptide sequence. The 

















Human Serum Albumin 
Human serum albumin used throughout this thesis was essentially fatty acid and globulin 
free and was purchased from Sigma-Aldrich as a lyophilised powder. 
 
2.2.3 Equipment And Software 
The details of all instruments used to collect data in this thesis are given in their respective 
individual method sections. The software used to process the data presented is this thesis 
is listed below in Table 2.03. 
 
Table 2.03. The Software Used in this Thesis to Present Data. 
Software Manufacturer Version 
Pro-Data Suite Applied PhotoPhysics 4.2.0 
KaleidaGraph Synergy Software  4.01 
Chimera University of California, San Francisco 1.9 
 
2.3 METHODS 
2.3.1 General Methods 
pH and Buffers 
Ultra-high quality water (10-18 Ω-1cm-1 resistivity) was used throughout. Typically 
experiments were carried out at pH 7.4, unless otherwise specified, to recreate 
physiological conditions. The pH was adjusted to within 0.05 pH units of the desired pH 
using small aliquots of 10-100 mM NaOH or HCl when needed. The pH was measured 
using a Thermo Electron Orion 3 Star pH benchtop meter with an electrode with a 3 mm 
stem diameter to allow the pH of samples to be read whilst in 1 cm path length quartz 
cuvettes. Buffers used included HEPES, EM and Phosphate Buffer, a mixture of mono- 
and dibasic potassium phosphate. 





Lyophilised full length Aβ(1-40) or Aβ(1-42) was solubilised at 0.7 mg/mL in dilute 
NaOH in water at pH ~10.5 and gently rocked at 5 °C for 48 – 72 hours. Prior to use, the 
solubilised Aβ was centrifuged at 16,100 x g at 5 oC for 5 minutes. 
 
Determining Protein Concentration 
For proteins containing tryptophan and tyrosine residues, the concentration was 
determined from UV-Vis absorption at 280 nm using equation 2.06. UV-Vis absorption 
spectra were obtained with a Hitachi U-3010 double beam spectrophotometer, using a 1 
cm path length quartz cuvette (Hellma). 
 
2.3.2 Aβ Fibrillisation 
Thioflavin T Fluorescence 
The kinetics of amyloid formation was monitored by the binding of ThT. The ThT 
measurements were conducted on a BMG Galaxy Fluostar 96 well plate fluorescence 
reader. Readings were obtained using an excitation wavelength of 440 nm and emission 
wavelength of 490 nm. Readings were taken every 30 minutes for approximately 400 
hours with the well plates being subjected to 30 seconds of orbital shaking prior to each 
measurement. 10 µM Aβ was incubated with 20 µM ThT at 30 oC in 160 mM NaCl. 30 
mM HEPES buffer was used throughout to maintain pH at 7.4. 
 
Curve Fitting 
As discussed in Chapter 1, Aβ fibrillisation follows a characteristic growth curve. The 
data obtained from ThT fluorescence over time can be fitted to the growth curve using 
equation 2.24 (Uversky et al. 2001). 






+ mix+ (yf+ mfx)
1+ e−(x−x0) τ⁄               (eq 2.24) 
 
where, Y is the ThT fluorescence intensity, x is the time, x0 is the time at half height of 
fluorescence (t50) and τ is a time constant. The initial and final fluorescence are given by 
the straight lines yi + mix and yf + mfx, respectively. 
 
A number of empirical parameters relating to the kinetics of fibrillisation can be extracted 
from this curve. In addition to the t50, the time taken for nucleation or lag time (tlag), and 
the apparent rate of elongation (kapp) can also be determined from equations 2.25 and 
2.26, respectively. 
 
tlag = x0-2τ                (eq 2.25) 
kapp = 1/τ                (eq 2.26) 
 
Kinetic Parameter Statistical Analysis 
Kinetic parameters have been extracted from typically 6 or more raw traces and the mean 
values and standard errors calculated. Analysis of variance (ANOVA) was used to 
compare the kinetic parameters extracted from curve fitting under different conditions, 
such as in the presence of different concentrations of HSA (Chapter 3). One-way ANOVA 
with Tukey-HSD post-hoc tests were used to reveal significant differences at α = 0.05. 
 
2.3.3 Visible Circular Dichroism 
Typically, Visible CD spectra were recorded at 25° C on an Applied Photophysics 
Chirascan instrument between 260 and 800 nm, with sampling points every 2 nm, using 
a 1 cm pathlength quartz cell (Hellma). Typically, three scans were recorded and 
averaged, the baseline spectrum (three scans averaged) subtracted from each spectrum 




followed by smoothing using a window of 6 nm. The molar ellipticity, ∆ε (M-1cm-1), 
spectra were obtained through conversion of the direct CD measurements, (θ, in 
millidegrees), using equation 2.09. 
 
Small aliquots of fresh aqueous solutions were used to add metal ions (Cu2+ as 
CuCl2.2H2O, Ni
2+ as NiCl2.6H2O) and glycine for titrations. Titrations carried out at pH 
7.4 were in the presence of 20 mM ethylmorpholine buffer whereas titrations carried out 
at pH 9.5 were in the absence of buffers. The pH was measured before and after acquiring 
each spectrum. 
 
2.3.4 Electron Paramagnetic Resonance (EPR) 
EPR spectra were recorded at 10 K on a Bruker E580 X-band EPR spectrometer equipped 
with a super high Q continuous wave cavity and Oxford Instruments ESR900 continuous 
flow LHe cryostat. Spectra were obtained at an X-band microwave frequency of 9.38 
GHz, using a microwave power of 0.5 mW across a sweep width of 2000 G, centred at 
3000 G with a modulation amplitude of 10 G and modulation frequency of 100 KHz. 
Typically, two scans were recorded and averaged then baseline spectrum subtracted. 
Samples were loaded into an EPR quartz tube with an outside diameter of 4 mm and 
inside diameter of 3 mm (Wilmad Lab Glass). Samples were run in 50 mM temperature-
independent pH (TIP) buffer composed of 60 % HEPES and 40 % phosphate buffer 
(Sieracki et al. 2008). TIP buffer was at pH 7.5, unless stated otherwise. 
 
 











HUMAN SERUM ALBUMIN CAN 
REGULATE AMYLOID-BETA 









3.1.  ABSTRACT 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by extracellular 
accumulation of amyloid-beta peptide (A) in the brain interstitium. Human serum 
albumin (HSA) binds 95 % of A in blood plasma and is thought to inhibit plaque 
formation in peripheral tissue. However, albumin’s role in binding A in the 
cerebrospinal fluid (CSF) has been largely overlooked. Here I investigate the effect of 
HSA on both A(1-40) and A(1-42) fibril growth. I show that at micromolar CSF levels, 
HSA inhibits the kinetics of A fibrillisation, significantly increasing the lag-time and 
decreasing the total amount of fibrils produced. Furthermore, I show that the amount of 
amyloid fibres generated directly correlates to the proportion of A not competitively 
bound to albumin. My observations suggest a significant role for HSA regulating A fibril 
growth in the brain interstitium.  
 
The work presented in this chapter forms the basis of work published in J Biol Chem 2012 
(Stanyon et al. 2012). 
 
  





Interestingly, unlike systemic amyloid related diseases, although A is found in the blood 
plasma at 0.1 – 0.5 nM concentrations (Seubert et al. 1992), similar to A levels found in 
the cerebrospinal fluid (CSF) (Lame et al. 2011), A amyloid deposits are largely found 
in the interstitium within the brain. Human serum albumin (HSA) binds 90-95 % of the 
A found in blood plasma (Biere et al. 1996, Kuo et al. 2000). HSA is the most abundant 
protein in blood serum, at a concentration of ~640 M (Carter et al. 1994), but has a 
markedly reduced concentration in the CSF of typically 3 M (Stevens et al. 1979). This 
may explain why A plaques are only observed in the extracellular space of the brain and 
not the peripheral tissue. 
 
The affinity of monomeric A for HSA has been determined and a dissociation constant 
(Kd) of 5-10 M, for both A(1-40) and A(1-42), based upon a 1:1 stoichiometry has 
been consistently reported by a number of groups (Bohrmann et al. 1999, Kuo et al. 2000, 
Rózga et al. 2007). Indeed, with 640 M concentration of albumin in blood plasma, a Kd 
of only 30 M would be sufficiently tight to bind more than 95 % of physiological A. 

The level of HSA in the CSF (3 M) and a micromolar affinity (Kd = 5-10 M) for A 
suggests that although the majority of A is bound to HSA in the blood, the capacity of 
albumin to bind A in the brain interstitium will be quite sensitive to changes in HSA 
levels. Therefore, variations in the capacity of HSA to bind A, through decreased HSA 
concentration or competition for the A binding site, could play a role in the build-up of 
toxic A oligomers and fibres within the brain. 
 




There is some debate over whether HSA binds to A monomers or oligomers. Milojevic 
et al have performed a series of experiments that have produced results consistent with 
HSA binding to oligomers but not monomers or fibrils (Milojevic et al. 2007, Milojevic 
et al. 2011, Milojevic et al. 2009). Similarly it has been suggested that HSA traps A in 
an oligomeric form (Reyes Barcelo et al. 2009). Others have suggested HSA binds 
monomers of A (Kuo et al. 2000, Rózga et al. 2007). A study using immobilised A 
polymers and biotin labelling indicates HSA can inhibit soluble A addition to 
immobilized A seeds, suggesting A polymerisation inhibition (Bohrmann et al. 1999). 
 
As HSA interacts with A I was interested in how HSA might affect the kinetics of fibril 
formation; fibre nucleation and elongation. Although it is has been suggested albumin 
inhibits fibre formation (Bohrmann et al. 1999, Reyes Barcelo et al. 2009), I know of no 
direct study of the kinetics of amyloid formation in the presence of CSF levels of albumin. 
Here I study inhibition of A-fibril growth in detail. 
3.3. AIM 
To understand fibre formation and kinetics in vivo I monitor fibril growth rates using 
physiologically relevant (1-10 M) and substoichiometric concentrations of HSA to 
determine the concentration dependent inhibition of A fibril formation. 
 
3.4.  EXPERIMENTAL 
3.4.1. ThT Fluorescence 
Fibre growth was followed using ThT fluorescence, as described in Chapter 2. 
 
 




3.4.2. Transmission Electron Microscopy (TEM) 
Glow-discharged carbon-coated 300-mesh copper grids (SPI supplies, PA, USA), were 
prepared using the droplet method, where 5 μl aliquots of samples from the fibre growth 
assay were adsorbed for 1 minute followed by 5 μl of 2% (w/v) of phosphotungstic acid 
adjusted to pH 7.4, to negatively stain the sample. Images were recorded on a JEOL 
JEM-1230 electron microscope (Tokyo, Japan) operated at 80 kV. 
 
3.4.3. Affinity Calculations 
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             (eq 3.01) 
 
This can be rewritten as: 
Kd = 
([Total HSA]-[Bound HSA])([Total A]-[Bound A])
[Bound HSA-A]
          (eq 3.02) 
 
As the bound concentration is unknown, this becomes x: 
Kd = 
([Total HSA]-x) ([Total A]-x)
x
             (eq 3.04) 
 
When the appropriate values are submitted within the above equation, a quadratic 
equation is produced. Therefore, x is solved using the following quadratic formula (eq 
2.23). 




Example Worked Calculation 
 
For total A concentration of 10 M and total HSA concentration of 10 M: 
 
5 M = 




5x = x2 – 20x + 100 
 
x2 – 25x + 100 = 0 
 
x = 




x = 5, x= 20. 
 
However, as the concentration bound must be lower than the total concentration,  





5 M × 100
10 M
= 50 % 
 
3.5. RESULTS 
3.5.1. HSA inhibits the kinetics of A(1-40) fibre formation 
The kinetics of A fibril formation were monitored using Thioflavin T (ThT), a dye that 
fluoresces upon binding to amyloid fibrils. The rate of fibre formation of A(1-40) was 
monitored over time in the presence and absence of increasing concentrations of HSA, 
using a 96 well-plate fluorescence reader. A characteristic fibrillisation growth curve is 
obtained, which has a lag-phase and growth-phase, due to nucleation and fibril elongation 
respectively. 




In Figure 3.01 I show the fibrillisation growth curves obtained from 10 M A(1-40) in 
the presence of 0, 3, 5 and 10 M HSA. Typically 6 individual traces were obtained at 
each albumin concentration and key kinetic parameters, including the t50, tlag and kapp, 
extracted through fitting the characteristic sigmoidal growth curves (Uversky et al. 2001). 
For comparison, the average t50 of A fibrillisation in the absence of albumin is depicted 
as a dashed line on each trace. It is clear from Figure 3.01 that fibril growth is delayed by 
all three substoichiometric concentrations of HSA as the elongation phase of the growth 
curves are all past the average t50 for A(1-40) alone.  
 
There was some variation in the fibril growth kinetics and so essentially the identical 
experiment was repeated on three other separate occasions, an example of which is shown 
in Figure 3.02. The fibril growth kinetics from these four separate experiments, for A(1-
40) fibrillisation in the presence of increasing concentrations of HSA were averaged 
together to generate large n numbers (n = 24), and the standard errors calculated, as shown 
in Figure 3.03. Variation in the kinetic parameters for fibril growth recorded on separate 
days was comparable to variation for individual fibre growth experiments. One way 
ANOVA with Tukey-HSD post-hoc tests was performed on this data; HSA increases the 
t50 of A(1-40) fibril growth but this was only significant (P < 0.05) at half a molar 
equivalent of HSA (5 M) and higher. Analysis of the tlag and kapp indicates HSA prolongs 
the lag-phase of A fibril formation with as little as 1 M HSA but has no significant 
effect on the rate of elongation of fibres (kapp) once nucleation has taken place. This means 
the effect on the t50s is exclusively due to the inhibition of fibre nucleation, measured as 
the lag-time (tlag). It is clear that substoichiometric amounts of HSA at concentrations 
found in the CSF increase the lag time of A(1-40) fibre formation. 
 






Figure 3.01. Aβ(1-40) Fibril Growth in the Presence of Albumin.  
Fibrillisation of 10 μM Aβ(1-40) was monitored using ThT fluorescence. Concentrations 
of albumin found in the CSF inhibit fibre formation. Here individual traces of a) Aβ alone, 
and Aβ in the presence of b) 3 μM, c) 5 μM, and d) 10 μM HSA are shown. The mean t50 

















































































































No HSA 3 M HSA
5 M HSA 10 M HSA






Figure 3.02. Aβ(1-40) Fibril growth in the Presence of HSA. (One of 4 Repeat 
Experiments)  
Fibrillisation of 10 μM Aβ(1-40) in 30 mM HEPES and 160 mM NaCl at pH 7.4 at 30 °C 
was monitored using ThT fluorescence. Here individual traces of a) Aβ alone, and Aβ in 
the presence of b) 3 μM, c) 5 μM, and d) 10 μM HSA are shown. The average t50 for Aβ 
alone is shown on traces a-d as a dashed line. This is a repeat of the experiment shown in 
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Figure 3.03. Kinetic Parameters for Aβ(1-40) Fibril Growth Experiments in the 
Presence of Increasing HSA. 
The mean a) t50, b) tlag, and c) kapp values pooled from 4 separate experiments are shown, 
with their standard errors (n =24). Significant differences are shown by connecting lines 
at  = 0.05. These have been calculated using one-way ANOVA, with Tukey HSD post-


















































































































































3.5.2. HSA reduces the total number of fibres generated 
There is also a reduction in the total amount of fibres generated as indicated by the 
maximal fluorescence signal produced after more than 400 hours. From Figure 3.01 it is 
clear that the ThT fluorescence signal for 10 M HSA present is approximately half the 
intensity relative to A(1-40) in the absence of HSA. The mean maximum fluorescence 
intensities and the associated standard errors from the four repeat experiments of A(1-
40) fibrillisation were also calculated and are shown in Figure 3.04a. The trend that can 
be observed from this is that the maximum fluorescence intensity, or total amount of 
fibres generated, decreases as the concentration of HSA present increases. This closely 
agrees with what is known about the Kd of HSA for A. With a Kd of 5 M and an 
equimolar mixture of A and HSA (at 10 M) then 50 % of the A molecules will bind 
to HSA (see example calculation in Section 3.4.3.). Interestingly, at this level of HSA 
there is exactly a 50 % reduction in total fibres generated for A(1-40). Using the known 
dissociation constant between A and HSA (Kd = 5 M), it is possible to calculate the 
amount of free and bound A for any concentration of A and HSA by solving simple 
quadratic equations derived from the equation for the dissociation constant, see Section 
3.4.3 and Table 3.01. 
 
Table 3.01. The Proportion of 10 M ABound to HSA Based on a Kd of 5 M 
Total HSA (M) A Bound to HSA (M) A Free (M) A Free (%) 
10 5.00 5.00 50.0 
5 2.93 7.07 70.7 
3 1.86 8.14 81.4 
1 0.65 9.35 93.5 
 






Figure 3.04. Competitive Effects of Albumin on Total A Fibrils Generated.  
a) The average maximum fluorescence values pooled from 4 separate experiments of 
A(1-40) with increasing concentrations of albumin are shown, with their standard errors. 
Significant differences from A alone are shown by connecting lines at  = 0.05. b) The 
correlation between fraction of fibres generated and the calculated fraction of A free to 
form fibres (not bound to increasing concentrations of HSA). Based upon a Kd of 5 M. 
There is a strong correlation (R = 0.998) between the percentage of fibres generated and 






































































































Figure 3.05. TEM of A(1-40) Fibril Growth in a) the Absence and b) the Presence 
of Albumin.  
A forms many long, twisted fibres alone but very few are formed with HSA present. 
The scale bar is 100 nm. 10 M A(1-40) in the presence and absence of 10 M HSA in 
30 mM HEPES and 10 mM NaCl at pH 7.4 was incubated for 400 hours at 30 oC with 
intermittent agitation. Samples are negatively stained with phosphotungstic acid.  
  
a) b)




The strong correlation between the total amount of fibres generated and the predicted 
amount of available A (not bound to HSA) is striking, as shown in Figure 3.04b. In 
particular the linear regression gives an R value of 0.998 and gradient of 1.0. 
 
To confirm that albumin has indeed inhibited fibre formation a second detection method 
was used. A(1-40) was incubated with 10 M HSA for 400 hours as before (Figure 3.01) 
and TEM images obtained. In the absence of albumin typical fibre morphology is 
observed with numerous fibres generated (Figure 3.05a). In the presence of albumin 
almost no fibres or oligomers could be observed after searching many squares per grid 
(Figure 3.05b). 
 
3.5.3. Albumin has the same effect on A(1-42) 
Next I wanted to investigate the effect of albumin on A(1-42), the more amyloidogenic 
A peptide found in plaques. A(1-42) shows similar fibril growth kinetics to A(1-40), 
as shown in Figure 3.06, with all traces in the presence of 5 and 10 M HSA showing 
delays in fibre formation relative to A alone. One-way ANOVA with Tukey-HSD post-
hoc tests showed that HSA significantly (P < 0.05) increased the lag phase and t50 of 
A(1-42) fibril growth at concentrations over 5 M (Figure 3.07). Once again it can be 
observed that the maximal ThT fluorescence intensity for the fibril growth is reduced in 
the presence of albumin, indicating that as well as increasing the time required for fibrils 
to form, the total concentration of fibres formed is also reduced. 
  






Figure 3.06. Aβ(1-42) Fibril Growth in the Presence of HSA.  
Fibrillisation of 10 μM Aβ(1-42) was monitored using ThT fluorescence. Here individual 
traces of a) Aβ alone, and Aβ in the presence of b) 5 μM, and c) 10 μM HSA are shown. 
The average t50 for Aβ alone is shown on traces a-c as a dashed line. d) The average t50 
values for each concentration of HSA with their standard errors. Significant differences 
from A alone are shown by connecting lines at  = 0.05. Physiologically relevant 











































































































































Figure 3.07. Kinetic Parameters for Mean Fibril Growth of A(1-42) in the Presence 
of Varying Concentrations of HSA.  
Fibrillisation of 10 M A(1-42) in 30 mM HEPES and 160 mM NaCl at pH 7.4 at 30 
°C was monitored using ThT fluorescence. Here the a) t50, b) tlag, and c) kapp, with their 
standard errors are shown. Significant differences between A alone and albumin 
















































































































































Perhaps because levels of albumin are so much lower in the CSF than the blood plasma a 
role for HSA interacting with extracellular A in the brain interstitium has largely been 
overlooked. However, 3 M concentration of albumin still represents the major protein 
component of the CSF. Furthermore, even though the affinity of A for HSA is quite 
modest (Kd = 5 M), it is clear ~ 40 % of A within the CSF will be bound to HSA. My 
results show that at physiological levels of albumin the rate at which fibre formation is 
nucleated for both A(1-40) and A(1-42) is significantly inhibited. Moreover the total 
concentration of fibre generated is reduced by HSA, this suggests that HSA binds to A 
molecules and traps them in a non-fibrillar form so they are not available to form fibres.  
 
In the presence of physiological micromolar levels of albumin, some but not all A is 
trapped in a non-fibrillar form of A. Indeed, the total concentration of fibres generated 
with increasing levels of HSA (Figure 3.04) shows a remarkably close agreement with 
the amount of free and albumin bound A that would be expected for a Kd of 5 M. The 
predicted percentage of free A based on HSA’s affinity for A is shown in Figure 3.04b. 
HSA can bind to A in a non-fibrillar form as the final amount of fibres produced is 
reduced by the presence of HSA. My data strongly supports HSA interacting with 
monomeric A to form a 1:1 complex with a Kd of 5 M. Although binding oligomers of 
A cannot be ruled out, they must be small, less than five A monomers, as none are 
observed by TEM. It is notable that a gradient of 1.0 in Figure 3.04b (R=0.998) implies a 
Kd very close to 5 M. Albumin binding to the monomeric A effectively reduces the 
concentration of free A available to form fibres. The lag-phase in fibril growth is 
strongly affected by the A concentration, which would explain the reduction in lag-times 
observed. It seems unlikely that the fibre growth inhibition is due to HSA interacting with 




A fibres as the fibre elongation growth rates are not reduced once a nucleating seed has 
formed. This suggests that HSA has a role in preventing the formation of nucleating seeds 
but once they are formed, it has less effect in monomer addition to the ends of growing 
fibres. 
 
There have been a number of protein binding partners of A indicated, in particular, the 
cellular prion protein (Laurén et al. 2009) but also serum amyloid P (SAP) (Likó et al. 
2007), islet amyloid polypeptide (IAPP) (Andreetto et al. 2010) and transthyretin 
(Buxbaum et al. 2008). The composition of plaques from the brain supports the idea that 
HSA interacts with a non-fibrillar / monomeric form of A as HSA is not found within 
plaques, in contrast to SAP (Coria et al. 1988). 
 
HSA is known for its ability to bind many hydrophobic molecules, in particular a number 
of pharmaceuticals, including warfarin and diazepam, as well as endogenous fatty acids 
(Carter et al. 1994). A crystal structure of HSA with fatty acids bound has indicated the 
location of hydrophobic pockets formed within HSA (Curry et al. 1998), which may be 
where part of the hydrophobic C-terminal residues of A could bind to HSA. It has been 
suggested that there are pharmaceutical and endogenous hydrophobic molecules that 
could compete with A binding to HSA (Bohrmann et al. 1999). Albumin is also 
responsible for the transport of the labile pool of Cu2+ ions in blood plasma (Patel et al. 
1993). Of note, the A-Cu2+ interaction and its role in AD have received significant 
interest (Sarell et al. 2010, Viles 2012, You et al. 2012) and Cu2+ may be transferred from 
Ato HSA (Perrone et al. 2010), meaning albumin could have two mechanisms by which 
it inhibits fibre formation. 




The concentration of HSA that will delay the fibrillisation of A is of interest, in 
particular, the level where HSA has a significant effect on A fibre formation in vitro as 
it is strikingly similar to the extracellular albumin levels found in vivo. HSA is found at a 
concentration of ~ 3 M in the cerebrospinal fluid and brain interstitium (Licastro et al. 
1993). Although HSA is at substantially lower levels than in blood plasma, 3 M still 
represents a major constituent of the CSF and the brain interstitium. With a 1 nM 
concentration of Ain the CSF and a 5 M Kd for albumin, it can be assumed that 37 % 
of A will be bound to albumin in the CSF. Considerable variation in CSF levels of 
albumin (1-5 M) have been reported (Christenson et al. 1983). A reduction to 1 M 
levels of albumin will lead to 83 % of the A remaining free in solution. Thus a decrease 
in the concentration of HSA could cause an increase in the amount of amyloid fibrils 
produced and as such lead to the build-up of amyloid plaques. It may therefore be possible 
that a small change in HSA in the CSF and interstitium may represent a significant risk 
factor in AD. However, both elevated and reduced levels of albumin have been reported 
in AD patients (Elovaara et al. 1986, Elovaara et al. 1987). It has been noted that A 
plaques are only ever observed in the brain and not the peripheral tissue, probably because 
HSA concentrations are of a much higher magnitude (640 M) in the blood plasma 
(Licastro et al. 1993). Interestingly serum albumin levels, in vivo, decrease with age, 
which is also a known risk factor in AD (Klonoff-Cohen et al. 1992). Furthermore levels 
of albumin are often reduced in association with inflammation also linked with AD. 
 
In conclusion, although the affinity of A for HSA is not thought to be remarkable (Kd = 
5 M), it follows that with levels of albumin in the CSF and brain interstitium of 3 M, 
40 % of A in the CSF will be bound to albumin. I show that this A bound to albumin 
is trapped in a non-fibrillar form thus reducing the amount of A available to form fibres. 




Furthermore, based on my fibre growth studies small variations in albumin in CSF are 
therefore likely to regulate the amount of extracellular fibril formation in the CSF and 
brain interstitium. Currently HSA is showing promise in phase II clinical trial, using an 
albumin plasma exchange schedule to reduce levels of A in blood plasma (Boada et al. 
2009). A reduction of the A pool in plasma will, in turn, reduce A levels in the CSF as 










AND THE COMPETITIVE 
EFFECTS OF CHOLESTEROL 
AND FATTY ACIDS 
  




In Chapter 3, I have shown that albumin is capable of inhibiting A fibrillisation from 
monomeric A at physiological concentrations. However, albumin’s effect on mature 
fibres has yet to be elucidated. Here I show, in contrast to its effect on A monomers, that 
albumin will not disassemble mature A fibres over a month timescale. This work in 
combination with size exclusion chromatography and mass spectrometry indicates 
albumin binds monomeric or a small oligomer of A to inhibit fibre formation. Albumin 
binds a variety of endogenous hydrophobic molecules in vivo, including cholesterol and 
fatty acids. High fat diet and cholesterol levels have both been linked with an increased 
risk of AD. Here I show A competes with both of these hydrophobic molecules for HSA 
binding, negating the inhibitory effect of HSA on A fibrillisation kinetics. My 
observations suggest a role for HSA in the associated risk of high cholesterol and fat for 
AD development. My work indicates the use of albumin plasma exchange could be a 
powerful tool to treat AD through clearance of A-HSA complexes, but also replacement 
of HSA bound to cholesterol and fatty acids with HSA free to bind A may be beneficial. 
  




The kinetics of Afibril growth in the presence of HSA show that micromolar levels of 
albumin inhibits A fibre formation during nucleation (Chapter 3 and (Stanyon et al. 
2012)) but the effect of HSA on the later stages of fibrillisation and fibril disassembly are 
yet to be elucidated. The effect of albumin on these stages is important for understanding 
the mechanism through which albumin exchange as a treatment for AD, which is showing 
promise in phase II clinical trial, is effective (Boada et al. 2009). If albumin only has an 
effect on A fibrillisation in the early stages, the treatment would only be effective in 
reducing A burden in the early stages of AD development prior to A plaque deposition. 
 
Despite HSA being known to bind A in vivo (Biere et al. 1996), it is not yet confirmed 
where A binds or the stoichiometry of the complex formed. There is disagreement as to 
whether HSA binds oligomers (Milojevic et al. 2014, Milojevic et al. 2007, Milojevic et 
al. 2011, Milojevic et al. 2009, Reyes Barcelo et al. 2009) or monomers (Kuo et al. 2000, 
Rózga et al. 2007). It is important to determine the size and stoichiometry of the HSA-
A complex to understand the role of HSA in the progression of AD. Current perspectives 
on A neurotoxicity implicate diffusible soluble pre-fibrillar oligomers as the major cause 
rather than mature A fibres (Brouillette et al. 2012, Cleary et al. 2004, Dahlgren et al. 
2002, Kim et al. 2003, Walsh et al. 2002). Therefore, if HSA arrests A fibrillisation as 
highly toxic soluble oligomers, elevated albumin levels would increase the rate of 
neurodegeneration. However, if HSA binds A monomers, increased albumin would 
decrease A neurotoxicity. 
 
Albumin is the most abundant protein in the blood plasma at approximately 640 M 
(Carter et al. 1994) and is capable of transporting many different hydrophobic molecules, 
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including cholesterol (Peng et al. 2008, Teir et al. 2012) and fatty acids (Ashbrook et al. 
1975, Bhattacharya et al. 2000, Saifer et al. 1961, Spector 1975). Interestingly, 
cholesterol and a high fat diet are known to increase the risk of developing AD when at 
elevated concentrations in the blood plasma (Kalmijn et al. 1997, Kivipelto et al. 2002, 
Laitinen et al. 2006, Morris et al. 2003, Solomon et al. 2007, Whitmer et al. 2005). These 
endogenous hydrophobic molecules are likely to influence A-HSA interactions in vivo. 
Through using these as competing ligands during fibril growth, it is possible to gain 
insight into whether disruption of the A-HSA interaction could be a mechanism for the 
associated increased risk of developing AD and provide information on the locus of A 
binding. A more detailed background of albumin structure and function can be found in 
Chapter 1. 
 
4.2.1 The Link Between Cholesterol and AD. 
High total serum cholesterol at midlife is a risk factor for the development of dementia 
and AD (Kivipelto et al. 2002, Solomon et al. 2007, Whitmer et al. 2005). Furthermore, 
GWAS point to cholesterol metabolism as a key risk factor (Jones et al. 2010, Wollmer 
2010). High total serum cholesterol is classed as a concentration higher or equal to 6.5 
mM, or 240 mg/ dL (Kivipelto et al. 2001, Notkola et al. 1998). The total serum 
cholesterol is found in two forms; esterified and non-esterified. The majority (~75 %) is 
transported in the esterified form, particularly as low density lipoproteins (LDLs) bound 
to apolipoproteins such as ApoE (Demeester et al. 2000). The non-esterified, or free, 
cholesterol therefore comprises ~ 25 % of the total cholesterol. In the cerebrospinal fluid 
this shifts such that the percentage of free cholesterol increases to 30 % (Demeester et al. 
2000). The central nervous system (CNS) contains 25 % of the total body cholesterol 
content despite the CNS being only 2 % of the body weight (Dietschy et al. 2004) thus 
this 5 % shift between esterified and free-cholesterol represents a significant amount of 
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cholesterol. CNS cholesterol levels are normally unaffected by serum levels of cholesterol 
as the blood brain barrier (BBB) is not permeable to cholesterol (Chobanian et al. 1962). 
However, an increased flux of cholesterol across the CNS can be observed in aging and 
early AD (Lütjohann et al. 1996). Cholesterol accumulation is observed in association 
with plaques in AD (Mori et al. 2001). Studies in rabbits and mice have shown that higher 
brain accumulation of A plaques occurs when cholesterol levels are elevated and 
increase AD pathology (Hooijmans et al. 2009, Refolo et al. 2000, Sparks et al. 1994, 
Zatta et al. 2002).  
 
There are many different proposed mechanisms by which cholesterol increases AD risk. 
One hypothesis is that cholesterol influences the composition of the membrane in 
neurons, perturbing membrane fluidity and signal transduction thus promoting neuronal 
degeneration (Mattson 2004). Another popular hypothesis is that the cholesterol 
concentration increases in lipid rafts, promoting APP cleavage into Aβ, as both APP and 
-secretase are associated with lipid rafts (Cordy et al. 2006, Ehehalt et al. 2003, Hicks et 
al. 2012, Vetrivel et al. 2010). However, these hypotheses do not account for why high 
serum cholesterol at mid-life increases the risk of developing AD as there is no 
equilibrium between serum cholesterol and brain cholesterol. 
 
Cholesterol can bind to albumin, the most abundant protein in blood plasma and 
cerebrospinal fluid, in “Sudlow site I”. Cholesterol has a relatively weak affinity for HSA 
(25 M) (Peng et al. 2008) but this is still tight enough for binding to occur in vivo due 
to the high concentrations of albumin and cholesterol available in the plasma. Indeed, it 
has been shown that 24 % of all non-esterified cholesterol is bound to albumin in the rat 
serum (Deliconstantinos et al. 1986). It is therefore likely that a significant proportion of 
cholesterol is bound to albumin in human blood plasma also. 
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4.2.2 The Role of Fatty Acids in AD 
High intake of fat, particularly saturated fats has been associated with an increased risk 
of dementia (Kalmijn et al. 1997, Laitinen et al. 2006, Morris et al. 2003). Indeed, a study 
in APP transgenic mice has shown a high fat diet increases cognitive impairment and that 
diet control is capable of ameliorating the memory deficits and A deposition induced by 
the high fat diet (Maesako et al. 2012a, Maesako et al. 2012b). Palmitic acid (PA) and 
oleic acid are the predominant forms of non-esterified fatty acids in human plasma, 
comprising nearly 50 % in fasting humans (Dole 1956). Palmitic acid is therefore one of 
the most physiologically important saturated fatty acids. No direct link has been 
established between increased PA levels and AD. However, traumatic brain injury, which 
is also an independent risk factor for developing AD, is characterised by increased levels 
of saturated fatty acids in the brain; palmitic acid levels increase three-fold to ~ 180 M 
(Lipton 1999).  
 
Fatty acids have been shown to bind HSA in vivo. Under normal physiological conditions, 
HSA carries 0.1-2 moles of fatty acids per mole of albumin (Fredrickson et al. 1958). A 
crystal structure of HSA with PA bound shows that there are 7 distinct hydrophobic 
pockets that PA will bind (Figure 4.01) (Bhattacharya et al. 2000). It is possible that these 
hydrophobic pockets could also act as biding sites for Aand that PA may therefore 
compete with A for binding to HSA thus prevent inhibition of A fibril growth. 
 
4.3 AIMS 
I aim to investigate the effect of HSA on pre-formed mature A fibres and characterise 
the stoichiometry of the A-HSA complex. Finally, I will ascertain whether cholesterol 
and palmitic acid loaded HSA negates the inhibitory effect of albumin on A fibrillisation 
kinetics. 





Figure 4.01. The Crystal Structure of HSA Complexed with Palmitic Acid. 
The structure of HSA is represented as ribbons in grey. The 7 bound palmitic acid 
molecules are shown in a space-filling representation in blue. The structure was created 
from PDB code 1E7H (Bhattacharya et al, 2000) using UCSF Chimera. 
 
  




4.4.1 Albumin Preparation 
Cholesterol-Loaded Albumin 
Cholesterol was solubilised in dimethyl sulfoxide (DMSO) such that when diluted in 
aqueous buffer to the desired cholesterol concentration, the final DMSO concentration 
would be 2 % (v/v). Each HSA monomer binds one cholesterol molecule (Peng et al. 
2008), thus an equimolar concentration of cholesterol and HSA was used throughout. The 
cholesterol and HSA, which had been solubilised as described in Chapter 2, was incubated 
together at room temperature to allow complex formation for a minimum of 30 minutes 
prior to use. 
 
Palmitic Acid-Loaded Albumin 
Palmitic acid was solubilised in DMSO. HSA can bind up to 7 palmitic acid molecules 
(Bhattacharya et al. 2000) thus essentially fatty acid free HSA was loaded with 7 mole 
equivalents of palmitic acid. Stocks of palmitic acid mixed with HSA, which had been 
diluted with water to contain 6 % DMSO, were incubated for 2.5 hours at room 
temperature to allow binding to occur. Excess palmitic acid was removed through 5 
concentration/dilution cycles, using a 10,000 Da molecular weight cut-off centrifugal 
concentrator (Vivaspin, Sartorius) and diluting the complex with 6 % DMSO. Final 
concentrations of palmitic acid-loaded HSA used were diluted such that the samples 
contained 2 % DMSO. 
 
4.4.2 A Fibre Growth and Disassembly 
Multi-Well Fluorescence, ThT Binding and Fibre Formation Kinetics 
Fibre growth was monitored using ThT fluorescence as described in Chapter 2. 
 




Fibre growth and disassembly was followed using ThT Fluorescence. 10 M A(1-40) 
was incubated with 20 M ThT in 160 mM NaCl and 30 mM HEPES, at pH 7.4. Samples 
contained 0.002 % (w/v) sodium azide to prevent microbial growth. The ThT 
measurements were conducted on a temperature-controlled Hitachi F-2500 fluorescence 
spectrophotometer at 30 C. An excitation wavelength of 440 nm was used and data were 
collected between 460 nm and 650 nm. Samples were placed in a 1 cm quartz cuvette 
(Hellma) and three readings were averaged at each time point. Readings were taken every 
day for up to 50 days with samples being subjected to constant shaking at 30 C between 
readings. The samples were kept in the dark to reduce possible degradation of the 
fluorophore and microbial growth. 
 
4.4.3 Size-Exclusion Chromatography 
The Tricorn Superdex 200 10/300 analytical gel-filtration chromatography column (GE 
Healthcare) was used on an automated AKTA FPLC system (GE Healthcare), at a flow 
rate of 0.5 ml/min at 4 C. The column was equilibrated with 1.5 column volumes of 
buffer (160 mM NaCl and 30 mM HEPES, at pH 7.4). A 0.5 ml injection volume was 
used to load the protein sample onto the column. The approximate molecular weights of 
species observed was estimated using the standards bovine serum albumin, lysozyme, 
dextran blue and acetone. The column is capable of separating proteins below 600 kDa. 





                (eq 4.01) 
 
Where, Ve is the elution volume, V0 is the void volume, and Vt is the total volume of the 
column. The Kav of the standards can be plotted against the log of their molecular weights 
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to obtain a linear relationship between the two that can be used to approximate the 
molecular weights of the samples. 
 
4.4.4 Mass-Spectrometry (MS) 
Samples 
Samples were either diluted into 30% acetonitrile/0.1% (v/v) formic acid or 10 mM 
ammonium bicarbonate at pH 7.3 for denaturing or native-like conditions, respectively. 
Prior to use, albumin was subjected to a minimum of four desalting steps into 10 mM 
ammonium bicarbonate pH 7.3 using a BioMax Ultrafree-0.5 PBCC Centrifugal Filter 
Unit with a 10 kDa molecular weight cut-off. Native-like samples were incubated for 20 
hours at 30 oC, shaking at 250 rpm. 
 
Instrumental Details: 
MS experiments were performed on a Synapt HDMS System (Waters Corporation, 
Milford, MA, USA). Samples were introduced into the source region of the instrument 
by direct, static infusion nano-ESI by means of gold-coated fused silica nanospray 
needles (Waters Corporation, Milford, MA, USA). The instrument was operated in ESI 
positive mode with a capillary voltage of typically 1.2 kV, cone voltage of 100 V, 
extraction voltage of 3 V, trap and transfer collision energy of 12 V, trap DC bias of 4V 
and a source temperature of 80 °C for all experiments. The time of flight mass analyser 
was tuned in V-mode to give an operating resolution of 7,000 (Full Width Half 
Maximum) and was calibrated using 1 mg/mL sodium iodide in 50% aqueous propan-2-
ol. A mass acquisition range of 500-7500 m/z was used. Optimised native-like conditions 
were achieved at an indicated pressure of 0.3 mbar backing pressure in the source region. 
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Tandem MS (MS/MS) data were collected from precursor m/z 4718 (15+ charge state 
plus A) using the maximum precursor window, approximately 250 atomic mass units 
(amu). Collision energy was increased until fragment ions were apparent in the m/z region 
500-1600 then held at a constant 45 V. 
 
Data Processing: 
MassLynx™ (v4.1) software (Waters Corporation, Milford, MA, USA) was used to 
acquire data and perform subsequent processing. Mass spectra were recorded at an 
acquisition rate of one spectrum per 2.4 sec with an interscan delay of 100 ms. Spectra 
obtained were deconvoluted onto a true mass scale with MaxEnt, a maximum entropy 
modelling program available within MassLynx™ (v4.1) software. ESI-MS data were 
smoothed, subtracted and centred. 
 
4.5 RESULTS 
4.5.1 Albumin Perturbs the Kinetics and Thermodynamic Equilibrium of A 
Fibre Formation 
It is clear from the data in Chapter 3 that HSA slows the formation of A fibres and 
reduces the total number of fibres generated. However, as some assays showed a 
suggestion of a slight increase of fluorescence over the plateau phase once fibres had 
formed, I wanted to establish whether A will continue forming fibres in the presence of 
albumin, just at a very much slower rate, until the total number of fibres generated equals 
that of A in the absence of HSA. To investigate this further, I have followed A40) 
fibre growth over an extended period of time in both the presence and absence of one 
mole equivalent (10 M) of HSA. It is clear from Figure 4.02 that HSA will almost 
completely inhibit A fibre formation even over a fifty day period. In the absence of 
albumin,  A  forms  fibres  in  less  than  24 hours,  whereas  fibre  formation  reaches  a 





Figure 4.02. HSA Almost Completely Inhibits A Fibre Formation Over Fifty Days. 
10 M A(1-40) fibril growth in the absence and presence of 10 M HSA measured over 
an extended period, detected using ThT fluorescence. A(1-40) was incubated in 160 mM 
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maximum after 10 days in the presence of HSA. The total number of fibres generated in 
the presence of albumin, as indicated by the maximum ThT fluorescence, only reaches ~ 
10 % of that of A alone, even after 50 days. It is clear from Figure 4.02 that there is no 
evidence of a gradual increase in fibre content even after 50 days of incubation. 
 
4.5.2 Albumin Does Not Perturb Preformed Mature A Fibres 
Next, I performed the reverse experiment, here HSA was added to preformed mature 
fibres. The addition of HSA to preformed A fibres also has no effect on the ThT 
signal consistent with the fibre formation not being reversed (Figure 4.03), even over a 
period of one month. 
 
There is a slight drop in ThT fluorescence over this time period (~15 %), which is not 
significant and is likely to be due to degradation of the fluorophore rather than the fibres. 
This variation in fluorophore intensity is often observed, for example, in Figure 4.02 for 
A in the absence of albumin. 
 
4.5.3 The Stoichiometry of the A-HSA Complex 
In order to gain more insight into the mechanism by which albumin is able to inhibit A 
fibrillisation, I have probed the stoichiometry of the complex formed using a variety of 
techniques. My fibrillisation studies and TEM (Chapter 3) are suggestive of one A 
monomer binding an albumin monomer but there is much conjecture in the literature over 
whether monomers or oligomers bind albumin.  
 




Figure 4.03. HSA Does Not Cause Disassembly of Mature A Fibres Over 28 Days.  
The state of 10 M A fibres in 30 mM HEPES and 160 mM NaCl at pH 7.4 in the 
presence of 20 M HSA was monitored using ThT fluorescence over 4 weeks. a) The 
ThT fluorescence spectra of A fibres in the presence of HSA. b) The ThT fluorescence 
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Size exclusion chromatography (SEC) can be used to estimate the molecular weight of 
the albumin-A complex. The size-exclusion chromatograph of albumin, Aand 
albumin and A incubated together is shown in Figure 4.04. Monomeric A(1-40) has a 
molecular weight of ~4 kDa but elutes at a volume which corresponds to ~26 kDa. This 
is because the masses are calculated assuming the molecules have a small axial ratio (i.e. 
globular rather than rod-like or unstructured in shape). Natively unstructured A therefore 
always elutes at a volume like that of a larger molecule, approximately five times larger 
than the real mass (Talmard et al. 2007). Converting the elution peaks of albumin alone 
gives a molecular weight of ~69 kDa for the monomer and ~113 kDa for the dimer, as 
expected. The molecular weight of the dimer is not exactly double that of the monomer, 
highlighting the imprecision of SEC as a method for determining molecular weight. In 
comparison to HSA alone, the shift observed in the elution peaks of albumin and A 
incubated together is slight but is indicative of a larger complex, with molecular weights 
of ~82 kDa and ~137 kDa, respectively. There are no extra elution peaks for larger 
complexes, thus HSA binding a large oligomer can be ruled out. This suggests an A 
monomer or small oligomer (≤ 5 monomers) binds to one HSA monomer, when albumin 
is in both monomeric and dimeric form. However, there is much overlap of the retention 
volume and the decrease in elution time for the HSA-A mixture may not be significant. 
It is clear a large A-HSA complex with multiple A monomers bound does not elute 
from the column. 
 





Figure 4.04. Size Exclusion Chromatography of Aβ(1-40) and HSA. 
Size exclusion chromatography was performed on 500 L samples of 3 M HSA, 
producing peaks at ~113 and ~69 kDa (red); fresh 10 M Aβ(1-40), producing peaks at 
~26 kDa (blue); and 3 M HSA and 10 M Aβ(1-40) incubated together, producing peaks 
at ~137, ~82 and 27 kDa (green). Samples were in 30 mM HEPES and 160 mM NaCl at 
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Mass Spectrometry (MS) 
Next I wanted to probe the A-HSA complex via mass spectrometry (MS). Monomeric 
A when run under denaturing and native-like conditions on a mass spectrometer gives 
identical spectra (Figure 4.05) due to A having no secondary structure. Three distinct 
m/z peaks are visible that are the +3, +4 and +5 charge states. These give A a mass of 
4330, as would be expected from the sequence, with an additional proton for each 
sequential charge state. 
 
Human serum albumin is a globular protein so the denaturing conditions can give a much 
more accurate m/z spectrum than native conditions, which can be deconvoluted to obtain 
a mass of albumin (Figure 4.06). Even under denaturing conditions, a range of masses is 
evident as the sample is heterogeneous and contains albumin with Na+ bound as well as 
the cysteinylated form (at Cys34) in addition to the unmodified form. The native-like 
albumin has very broad peaks so it is not possible to deconvolute the data using MaxEnt 
(Figure 4.07). There are five distinct peaks for the +14 to +18 charge states. The 
calculated average mass is slightly higher when run in the native state at approximately 
66,780 Da. This value is calculated from the centre of the Gaussian peak for each charge 
state as shown in Figure 4.07b. This method does not account for the relative abundance 
of multiple naturally occurring isotopes, 13C in particular. The molecular mass based on 
the sequence alone, accounting for the relative isotope abundance should be 66,438 Da, 
as identified by MaxEnt from Figure 4.06.  
 
When A40) and albumin are incubated together over-night, the native spectrum is 
very similar to that of albumin alone except for appearance of unbound A charge states 
in the lower m/z range and the broadening of the peaks denoting the HSA +14-+18 charge  





Figure 4.05. Mass Spectrum of Aβ(1-40) Under Denaturing Conditions. 
a) Mass spectrum of 20 M A in 30 % acetonitrile (v/v) and 1 % formic acid (v/v). The 



















Figure 4.06. Mass Spectrum of HSA Under Denaturing Conditions. 
a) Deconvolution of the mass spectrum of 10 M HSA in 30 % acetonitrile (v/v) and 1 
% formic acid (v/v) to obtain the most abundant species. Insert shows the mass spectrum 
that has been deconvoluted. b) Table showing the breakdown of the species to which the 
masses from a) correspond. 
 
  
Mass (Da) Change from 66438 HSA species
66438 0 Unmodified
66465 27 Unmodified + Na 
66490 52 Unmodified + 2 Na
66509 71 Unmodified + 3 Na
66529 91 Unmodified + 4 Na
66556 118 Cysteinylated
66580 142 Cysteinylated + Na
66603 165 Unmodified + 1 Glucose
b)
a)





Figure 4.07. Mass Spectrum of HSA Under Native Conditions. 
a) Mass spectrum of 5 M HSA in 10 mM Ammonium bicarbonate at pH 7.3. The 
dominant peaks represent the +14 to +18 charge states that correspond to the masses 
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states (Figure 4.08). This shift from the expected Gaussian distribution could represent 
the overlap of two peaks derived from albumin alone at one charge state and one 
A40) monomer bound to a single HSA monomer at a sequentially higher charge 
state. In order to test this, tandem MS was performed. Tandem MS can be used to select 
ions with a particular m/z value. It is then subjected to mild fragmentation and the 
resulting mass spectrum recorded. Here tandem MS selecting for 4718 m/z was employed, 
as this is the m/z value expected for one A monomer bound to one HSA at the 15+ charge 
state, with a window of 250 amu. The fragmented mass spectrum of this selected ion is 
shown in Figure 4.09. The spectrum suggests no evidence of the A monomer present at 
4718 m/z. 
 
I hypothesised the broadening of the MS spectra observed for HSA incubated with 
Awas due to the high salt content, I therefore looked at the effect of salt. Figure 4.10a 
shows the effect of not desalting albumin on the mass spectrum. The peaks become much 
broader, similar to the peak broadening observed with incubation with A. It was not 
possible to desalt the A prior to incubating with HSA; therefore it is feasible that HSA 
MS peaks are broadened by the high concentrations of salt acquired from A. Figure 
4.10b compares the spectrum of HSA incubated with 2 mole equivalents of A(1-40) 
with and without desalting after incubation. It is evident that the peak width shrinks after 
desalting.  
 
It is clear that even under the mild ionising conditions used here; the A-HSA complex 
has disassociated upon ionisation and is not detected. 
 





Figure 4.08 Mass Spectrum of HSA Incubated with A(1-40) Under Native 
Conditions. 
a) Mass spectrum of 10 M HSA alone, b) with one mole equivalent, and c) with 2 mole 
equivalents of A(1-40) in 10 mM Ammonium bicarbonate at pH 7.3 after overnight 
incubation. Blue spectra in b) and c) are the spectrum of HSA alone shown in a) for 
comparison. Insets show full spectrum between 500 and 7000 m/z, showing the unbound 









Figure 4.09. Tandem MS of HSA and A(1-40) 
a) Tandem MS of 10 M HSA + 10 M A(1-40) in 10 mM Ammonium bicarbonate at 
pH 7.3 after overnight incubation selected for m/z 4718 with a window of  ~ 250 amu. b) 
The results from MS of HSA and A incubated together (as shown in Figure 4.08b) in 
the range A charge states are normally observed (above) compared with the results of 










Figure 4.10. The Presence of Salt Broadens the Albumin Peaks in Mass 
Spectrometry 
a) Mass spectrum of 10 M HSA in 10 mM Ammonium bicarbonate at pH 7.3 with and 
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4.5.4 Cholesterol-Loaded HSA Negates Albumin’s Inhibition Of A Fibrillisation 
Cholesterol is a known risk factor for developing AD and also binds HSA. Therefore, I 
have studied the effect of cholesterol-loaded HSA on A fibrillisation kinetics to 
determine if cholesterol may influence the risk of developing AD by blocking albumin 
from inhibiting A fibre formation. Figure 4.11 shows the ThT binding curves obtained 
for A in the presence of HSA, cholesterol-loaded HSA and cholesterol alone. It is 
evident that 20 M albumin will completely inhibit fibrillisation of A(1-40). However, 
albumin loaded with an equimolar concentration of cholesterol does not fully inhibit fibre 
growth. Fibrillisation is partially recovered such that the tlag is six times longer and the 
total number of fibres generated is dropped by one third. It is likely that some albumin 
may not have any cholesterol bound, and would therefore be able to bind A, which 
would account for the percentage drop in A that forms fibres compared to A alone. The 
control of cholesterol alone has no effect on the total number of A fibres generated but 
has slowed the lag time of fibre growth a little. This means that the recovery of fibre 
growth cannot be due to cholesterol increasing the rate of fibrillisation alone and must 
therefore be due to cholesterol being bound to albumin, preventing A from binding to 
albumin. Cholesterol is not soluble in water and was therefore solubilised in DMSO prior 
to loading in into albumin. To ensure that any effect observed on fibrillisation in the 
presence of cholesterol was due to the cholesterol rather than the low levels of DMSO, 
A fibril growth in the presence of 2 % DMSO was also studied as a control. Figure 4.11e 
demonstrates that the lag time, rate of fibrillisation and total number of fibres generated 
is unaffected by 2 % (v/v) DMSO. 
 




Figure 4.11. Aβ(1-40) Fibril Growth in the Presence of HSA and Cholesterol 
Fibrillisation of 10 μM Aβ(1-40) monitored using ThT fluorescence. Here individual 
traces of a) Aβ alone, and Aβ in the presence of b) 2 % DMSO, c) 20 μM HSA, d) 20 μM 
HSA and 20 M cholesterol, and e) 20 M cholesterol are shown. f) The mean t50 values 
obtained are shown with standard error. Significant differences from A alone are shown 
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The average kinetic parameters of fibril growth were obtained for the growth curves 
shown in Figure 4.11 as well as further fibre growth experiments in the presence of 10 
M cholesterol-loaded and cholesterol-free HSA. At 10 M albumin, the same pattern is 
evident as with 20 M HSA shown by the average kinetic parameters in Figure 4.12. 
There is inhibition of A fibril growth by HSA but to a lesser extent when the albumin is 
loaded with cholesterol. Cholesterol has little effect on A fibrillisation by itself. 
 
The concentration of HSA in the CSF is 3 M so I next studied the effect of this 
physiological concentration on A40) fibrillisation (Figure 4.13). This lower 
concentration of HSA will not completely inhibit fibril formation but the increase in the 
nucleation time (tlag) and decrease in the rate of elongation (kapp) is still significantly 
different compared to A fibre growth on its own. The cholesterol-loaded HSA also 
significantly inhibits fibre growth in terms of nucleation rate and elongation rate 
compared to A fibrillisation but the rate of elongation is increased in comparison to A 
fibre growth in the presence of cholesterol-free HSA. This indicates that cholesterol 
bound to HSA can negate its inhibitory action on A40) fibre formation at 
concentrations found in the CSF. It is clear, based on experiments with 3, 10 and 20 M 
albumin that cholesterol bound to albumin will compete with the A-albumin interaction. 
 
4.5.5 Albumin Will Not Inhibit A Fibrillisation when Complexed with Palmitic 
Acid 
The effect albumin has on A40) fibrillisation when loaded with 7 mole equivalents 
of palmitic acid (PA) is shown in Figure 4.14. Albumin will completely inhibit fibre 
formation at 10 M when it is essentially fatty acid free but when the HSA is loaded with 





Figure 4.12. Kinetics of Aβ(1-40) Fibril Growth in the Presence of HSA and 
Cholesterol 
Fibrillisation of 10 μM Aβ(1-40) monitored using ThT fluorescence. Here the mean a) 
t50, b) tlag, c) kapp, and d) maximum fluorescence values obtained are shown with standard 

































































































































































































































































































































































































































































































Figure 4.13. Aβ(1-40) Fibril Growth in the Presence of Physiological Concentrations 
of HSA and Cholesterol 
a) Average traces of 10 μM Aβ(1-40) fibrillisation in the presence of 3 M, cholesterol, 
cholesterol-loaded and cholesterol-free HSA monitored using ThT fluorescence. b-d) The 
mean kinetic parameters obtained from the fibril growth in a) under each condition: b) 














































































































































































































































































Figure 4.14. Aβ(1-40) Fibril Growth in the Presence of Palmitic Acid Loaded-HSA 
Fibrillisation of 10 μM Aβ(1-40) monitored using ThT fluorescence. Here individual 
traces of Aβ growth in the presence of a) 10 M palmitic acid-loaded and fatty acid-free 
HSA, b) 20  palmitic acid-loaded and fatty acid-free HSA, and c) in the presence of 2 
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PA, the A fibre growth has the same rate as fibrillisation in the absence of albumin. This 
can also be seen for fibre growth in the presence of 20 M HSA. The PA is insoluble in 
water so PA was solubilised with DMSO in order to load it into the albumin and diluted 
such that only 2 % DMSO remained. It is evident in Figure 4.14c that DMSO has no 
effect on the fibrillisation of A. 
 
A repeat of this experiment gave similar results, Figure 4.15. The A(1-40) fibre 
formation is completely inhibited by 20 M fatty acid-free albumin but the PA-loaded 
albumin completely ameliorates this inhibition such that the rate of fibrillisation returns 
to that of A(1-40) in the absence of HSA. In addition to the rate of fibril growth being 
similar, the total number of fibres generated is also equal for the A(1-40) grown in the 
presence of PA-loaded HSA and A(1-40) grown without albumin. The extent of 
inhibition for 10 M fatty acid-free HSA is not complete but the total number of fibres 
generated is reduced by approximately 50 % as well as the tlag being significantly 
increased. However, this is not true for PA-loaded HSA at 10 M; as observed for 20 M 
HSA, the rate and extent of A(1-40) fibrillisation is strikingly similar to that of A fibre 




4.6.1 Albumin May Not Reverse Fibre Formation 
As I show in Chapter 3, albumin will bind A, preventing A self-association into fibres. 
It is likely in the presence of A monomer, the A-HSA complex forms relatively fast. 
The formation of A fibres and the A-HSA complex can therefore be thought of as the 
following equilibrium: 





Figure 4.15. Aβ(1-40) fibril growth in the presence of palmitic acid loaded-HSA 
(Repeat) 
Fibrillisation of 10 μM Aβ(1-40) monitored using ThT fluorescence. Here individual 
traces of Aβ growth in the presence of a) 20 M fatty acid-free HSA, b) 20 M palmitic 
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A binding to HSA will also dissociate and if A has a weaker affinity for albumin than 
A self-association in fibres, it could be expected that the extent of fibre formation would 
eventually equal that of fibre growth in the absence of HSA as the A dissociates from 
HSA and self-associates with the existing A fibres. However, as shown in Figure 4.02, 
A(1-40) fibre growth is almost completely inhibited by one mole equivalent of HSA 
even after a 50 day duration, with no sign of the total number of fibres generated 
increasing over time.  
 
The affinity of A monomer for A fibres has previously been calculated to be in the 1 
M range (O'Nuallain et al. 2005). This is only marginally tighter than the reported 
affinity of A for HSA (5 M) (Rózga et al. 2007) thus the concentration of albumin and 
fibres available for A monomer binding becomes extremely important. Fibres only form 
through A monomer self-association therefore the number of fibres cannot equal the 
number of A monomers in the system. In this experiment, an equimolar concentration 
of HSA and A(1-40) monomer was used thus the number of albumin molecules was 
greater than the number of fibres. Despite the tighter affinity for A fibres, the A 
monomer is therefore more likely to bind albumin due to the number of molecules 
available to bind compared to fibres making A fibre elongation kinetically unfavourable. 
 
A fibres are in dynamic equilibrium with A monomers and oligomers so it could be 
expected that the presence of albumin complexed with A would push the equilibrium 
such that over time fibres disassemble if A bound to HSA does indeed represent the 
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more thermodynamically favourable state and thus returning the equilibrium to its 
preferred state. However, when HSA is added to preformed fibres, there is no evidence 
of fibril disassembly observed (Figure 4.03), even of a period of 28 days. 
 
It is clear that there are conflicting observations in Figures 4.02 and 4.03 suggesting that 
at least one of the reactions must not have reached true thermodynamic equilibrium, even 
after more than four weeks at room temperature. It is clear that one of the reactions is 
kinetically trapped. It could be albumin that traps A as a monomer or that A becomes 
trapped as a fibre once formed. Fibre formation could be kinetically trapped because the 
rate of association is slow, which is evident by the time taken for fibre growth to occur; 
it takes days for fibres to form. Alternatively once fibres are formed, dissociation is 
kinetically slow. It remains a possibility that at true equilibrium fibres may be favoured 
over the A-HSA complex, but albumin is able to trap A as a monomer. Crucially, the 
kinetics of fibre formation are what determines whether AD develops so it is clear that 
albumin has a profound influence on fibre formation. 
 
Overall, albumin has little effect on A fibrillisation beyond the nucleation and elongation 
stage and is therefore likely to bind A only when A is in its monomeric state or is a 
small oligomer. The use of albumin exchange as a treatment for Alzheimer’s disease, is 
showing promise in phase II clinical trial (Boada et al. 2009). My studies suggest it is 
therefore likely to be effective at reducing A burden through removal of fresh A 
monomer and would be less effective at reversing plaque formation. Thus this treatment 
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4.6.2 The Stoichiometry of the A-HSA Complex 
There is debate over the stoichiometry of A binding HSA. The calculated Kd of 5 M, 
which corresponds well with the extent of inhibition of A fibrillisation by HSA observed 
in Chapter 3, is based upon a one to one stoichiometry (Rózga et al. 2007). This is also 
supported by Kuo et al (Kuo et al. 2000). Milojevic et al have performed a series of 
experiments that are consistent with HSA binding A oligomers but not monomers or 
fibres (Milojevic et al. 2014, Milojevic et al. 2007, Milojevic et al. 2011, Milojevic et al. 
2009). Albumin has also been shown to trap A as soluble oligomers (Reyes Barcelo et 
al. 2009). 
 
There are a number of hydrophobic pockets in HSA that are sufficiently large for a 
hydrophobic side-chain to insert and these could be sites for A binding to HSA. Melacini 
and colleagues have used saturation transfer NMR and the effect of individual domains 
of HSA on A fibrillisation in an attempt to characterise the albumin binding site 
(Algamal et al. 2013, Milojevic et al. 2011). They show that each of albumin’s three 
domains are able to inhibit A fibrillisation (Milojevic et al. 2011). Further investigation 
of A fibre growth in the presence of domain 3 of HSA shows that each separate 
subdomain is also capable of inhibiting fibrillisation (Algamal et al. 2013). A 22 residue 
fragment of HSA from domain 3B, HSA(494-515), was tested for its ability to inhibit A 
fibrillisation as it has a high of degree of sequence similarity to the central hydrophobic 
core of AThis fragment is also capable of inhibiting A fibre formation, demonstrating 
hydrophobic interactions between A and HSA are key to inhibiting A fibrillogenesis 
(Algamal et al. 2013). 
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Studying the stoichiometry using SEC indicated no complex larger than HSA bound to ~ 
5 A monomers forms (Figure 4.04) thus HSA binding a large A oligomer can be ruled 
out. However, the resolution is not sufficient to determine whether HSA binds 1 A 
monomer, a small oligomer, or indeed several monomers at different sites. 
 
There was no evidence of A binding HSA using native-like MS. Of course, this does not 
mean an A-HSA complex should be ruled out. Native-like MS utilises a weaker vacuum 
than traditional MS but it is still much stronger than atmospheric pressure thus the non-
covalent A-HSA interaction may not be strong enough to survive the vacuum it is 
subjected to when running the sample on MS. Another possibility is that the A-HSA 
interaction may require the presence of salt, thus it cannot be observed with native-like 
MS. 
 
Overall, the evidence from SEC in combination with the effect of HSA on A 
fibrillisation shown in Chapter 3 and Figures 4.02 and 4.03, is suggestive of HSA binding 
monomeric A, however, a small oligomer of less than 5 A monomers cannot be ruled 
out. This supports the use of albumin exchange for reducing A burden in AD such as 
that showing promise in phase II clinical trial (Boada et al. 2009). A reduction of the Aβ 
pool in plasma through albumin exchange can reduce Aβ levels in the CSF only because 
soluble Aβ is in a dynamic equilibrium between the two and is able to cross the blood-
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4.6.3 Ligands that Complex with Albumin Negate its Inhibitory Action on A 
Fibrillisation 
Both cholesterol and palmitic acid are hydrophobic ligands that bind in hydrophobic 
pockets on albumin. When albumin is complexed with either of these ligands, the extent 
of inhibition on A fibrillisation is reduced. From this I can determine that residues 
involved in binding cholesterol and palmitic acid must also affect A binding. A binding 
could be inhibited directly, through cholesterol and palmitic acid binding the same 
residues in albumin, or indirectly, through conformational changes that occur upon 
cholesterol and palmitic acid binding. It has been shown that the -helical content of 
albumin reduces upon cholesterol binding, increasing the -sheet content (Teir et al. 
2012). Algamal et al. have demonstrated that myristic acid (MA), another fatty acid that 
has been shown to bind albumin, also reduces the inhibitory effect of albumin on A fibre 
formation. Mutants of albumin subdomains that disrupt myristic acid binding still inhibit 
A fibrillisation, indicating that A binding is normally restricted through conformational 
changes in albumin rather than direct competition with MA (Algamal et al. 2013). It may 
also be the case for PA as the HSA-PA complex has been shown to be very similar to the 
HSA-MA complex. 
 
Irrespective of the mechanism by which A competes with cholesterol and palmitic acid 
for binding HSA, it can be assumed that an increase in levels of albumin complexed with 
either of these ligands would result in a decrease in the levels of A-albumin. Indeed, a 
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Biological Significance of the HSA-Cholesterol and HSA-PA Interaction 
High serum cholesterol at mid-life has been identified as an independent risk factor for 
developing AD (Kivipelto et al. 2002, Kivipelto et al. 2001, Notkola et al. 1998, Whitmer 
et al. 2005) yet there is much debate over the mechanism by which it increases risk. 
Cholesterol levels in the brain are unaffected by serum levels as brain cholesterol is 
synthesised in the brain and does not cross the blood-brain barrier (Chobanian et al. 
1962). It is therefore surprising that elevated serum levels of cholesterol is associated with 
a higher risk of AD. The observation that cholesterol will impede binding of A to 
albumin could account for this. Indeed, as total cholesterol increases, the proportion of 
free-cholesterol also increases (Leonard et al. 1965), meaning there is more cholesterol 
available for binding HSA. 
 
Palmitic acid is one of the most physiologically important fatty acids, comprising nearly 
25 % of non-esterified fatty acids in human plasma. In addition it also accounts for nearly 
one quarter of all fatty acids found bound to albumin in vivo (Saifer et al. 1961). 
Therefore, the observation that palmitic acid bound to albumin will negate the inhibition 
of A fibrillisation that is caused by fatty acid-free albumin becomes physiologically 
relevant. The ability to bind albumin is not exclusive to palmitic acid; the binding sites of 
several other fatty acids have also been identified through crystallisation, all of which 
share common binding modes (Bhattacharya et al. 2000). It could be assumed that other 
fatty acids could therefore also negate the effect of HSA on A fibrillisation, indeed 
myristic acid has been shown to have this effect too (Algamal et al. 2013). A high dietary 
intake of fats, particularly saturated fats has previously been identified to increase the risk 
of developing AD (Kalmijn et al. 1997, Laitinen et al. 2006, Morris et al. 2003). This 
study provides a possible mechanism through which fats could influence AD 
development. 
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A number of hydrophobic pharmaceuticals have been shown to bind to HSA (Ghuman et 
al. 2005). This raises the possibility that sustained use of, for example the anti-coagulant 
warfarin, might influence A-HSA binding. 
 
4.7 CONCLUSIONS 
Overall, this study shows that albumin is effective at inhibiting A fibre growth when it 
is not restricted by the presence of hydrophobic molecules such as cholesterol and fatty 
acids. The clearance of A from the CSF might therefore be enhanced by reduction of 
plasma levels of cholesterol and fatty acids, for example, through regulation of diet and 
exercise. Indeed both exercise and regulation of diet have been shown to be effective at 
ameliorating memory deficits and A deposition caused by a high fat diet in APP 
transgenic mice (Maesako et al. 2012b). The use of therapeutic albumin in mild to 
moderate cases of AD (Boada et al. 2009) could therefore also be effective through 
clearance of both HSA that already has A bound and HSA that is blocked by cholesterol 
and fatty acids. 
 
With albumin’s profound effect on A fibre formation, it is perhaps surprising that as yet 
a clear correlation between albumin levels and AD pathology has not been identified. AD 
is a multi-factorial disease and thus a reduction of HSA in the CSF may be masked by 
other effects. If albumin levels in the CSF do not link to the extent of fibre formation, this 
may suggest that the majority load of fibres are in vesicle granules trafficked along the 
axon before they are released at the synapse. 
 












COMPARISON OF Cu2+ AFFINITY 








5.1.  ABSTRACT 
Cu2+ bound to A is concentrated in plaques of Alzheimer’s disease (AD) patients. 
Furthermore, for a number of animal models of AD, disruption of Cu2+ homeostasis 
heightens the disease/phenotypes. However, a role for Cu2+ in AD remains controversial, 
a concern expressed is the affinity of Cu2+ for A with Kds reported ranging from 
micromolar to attomolar. In this chapter, I determine the affinity of Cu2+ for A in 
monomeric, fibrillar, and in the case of A(1-42) in an oligomeric form. Using two 
detection methods and competitive ligands, I show all alloforms have similar Kds in the 
10-20 pM range. This Kd is close to the affinity of albumin (1 pM), the most abundant 
protein in the blood plasma and CSF, which acts as a Cu2+ transport protein. I show that 
despite this close affinity, A cannot sequester Cu2+ ions from albumin in a one to one 









The role of copper on Alzheimer’s disease has received increased interest recently. The 
levels of copper ions in the brain of AD patients are significantly elevated compared to 
control and have been found to be particularly concentrated within the plaques of AD 
patients (Dong et al. 2003, Lovell et al. 1998, Miller et al. 2006). Studies in both cell 
lines and animal models have shown that Cu2+ increases the cytotoxicity of A 
(Sanokawa-Akakura et al. 2010, Sarell et al. 2010, Sparks et al. 2003). Specifically, an 
AD model in Drosophila melanogaster has been exacerbated by impaired copper 
homeostasis (Sanokawa-Akakura et al. 2010), while rabbits fed copper in combination 
with a high cholesterol diet develop learning deficits and amyloid plaques (Sparks et al. 
2003). The study of cytotoxicity of A in cell lines demonstrates that the stoichiometry 
of Cu2+ ions to A is important as sub-stoichiometric levels of Cu2+ enhance toxicity while 
supra-stoichiometric levels become protective (Sarell et al. 2010). 
 
Interestingly, Cu2+ can bind to A and influence the fibrillisation pathway. Supra-
stoichiometric levels of Cu2+ have been shown to induce amorphous aggregation of both 
A(1-40) and A(1-42). Recent work within the group has shown that, surprisingly, at 
sub-stoichiometric concentrations the effect of Cu2+ on A(1-40) and A(1-42) 
fibrillisation is markedly different (Matheou et al. 2014). A(1-40) fibrillisation is 
accelerated significantly, indeed Sarell et al show Cu2+ consistently halves the time taken 
for A(1-40) fibres to form (Sarell et al. 2010). The morphology of the A(1-40) fibres 
formed in the presence of Cu2+ is consistent with fibres formed in the absence of Cu2+ 
(Sarell et al. 2010). However, in the presence of sub-stoichiometric concentrations of 
Cu2+, the kinetics of A(1-42) fibrillisation are inhibited; the lag-time and t50 are 
increased while the kapp is reduced (Matheou et al. 2014). In addition, the total number of 




fibres generated is also reduced. TEM reveals that fibre formation is inhibited in 
preference for the formation of oligomeric species (Figure 5.01) (Matheou et al. 2014). 
 
The stoichiometry of Cu2+ binding to both A monomer and fibres is one to one. A-Cu2+ 
forms a tetragonal complex which involves the imidazole rings of His6, His13 and His14 
as well as the N-terminal amino group and carboxylate side chains (Antzutkin 2004, 
Damante et al. 2008, Dorlet et al. 2009, Drew et al. 2009, Hou et al. 2006, Karr et al. 
2008, Minicozzi et al. 2008, Sarell et al. 2009, Shin et al. 2008, Streltsov et al. 2008, 
Syme et al. 2004). The exact positioning of the coordinating nitrogen and oxygen ligands 
between the equatorial and axial planes is dynamic, with pH particularly affecting the 
distribution of complexes formed (Dorlet et al. 2009, Drew et al. 2009, Sarell et al. 2009, 
Shin et al. 2008). The coordination geometry of the complex is shown in Figure 5.02. 
 
The coordination geometry of Cu2+ bound to some A fibrillisation states may be 
different to that found in monomer. The Cu2+ coordinating ligands fall just on the edge of 
the β-pleated core region of Aβ fibres, which occurs between residues 14 to 40. It has 
been indicated that the fibrillar structure can accommodate Cu2+ coordination in Aβ(1-
40) from solid-state NMR and pulsed EPR of the Cu2+ complex (Gunderson et al. 2012, 
Parthasarathy et al. 2011). However it may be that in oligomers or some fibre 
morphologies the Cu(II) coordination geometry may be different from that found in the 
monomer,  conceivably a cross-linked inter-molecular coordination may occur (Hane et 
al. 2013). 
 
In addition to the coordination geometry of the Cu2+-A complex, there have been many 
studies on the affinity of Cu2+ for A. The affinity of A for Cu2+ is an important factor 
in understanding the role of Cu2+ in AD in vivo and has often been disputed due to some  






Figure 5.01. Aβ(1-42) Self-Association With and Without Cu2+. 
a) TEM image of Aβ(1-42) fibres formed in the absence of Cu2+. b) TEM images of Aβ(1-
42) oligomers and protofibrils formed with 0.4 molar equivalents of Cu2+. Scale bar, 200 
nm. Adapted from (Matheou et al. 2014). In the presence of substoichiometric Cu2+, 












Figure 5.02. The Coordination Geometry of the Aβ-Cu2+ Complex. 
The coordination geometry of Cu2+ binding A at a) pH 5-8  and b) above pH 9. There is 
a switch between the equatorial and axial planes for the N-terminal nitrogen and side-








affinities reported being too weak to be physiologically relevant. Previously published 
affinities (summarised in Table 5.01) vary considerably, with Kds reported in the 
micromolar, nanomolar, picomolar and attomolar ranges (Atwood et al. 2000, Danielsson 
et al. 2007, Garzon-Rodriguez et al. 1999, Guilloreau et al. 2006, Hatcher et al. 2008, 
Hong et al. 2008, Hong et al. 2010, Hou et al. 2006, Jiang et al. 2012, Karr et al. 2005, 
Ma et al. 2006, Maiti et al. 2008, Raman et al. 2005, Rózga et al. 2009, Sarell et al. 2009, 
Syme et al. 2004, Tõugu et al. 2008). The disparity between these values could be 
attributed to the very different conditions from which the Kds have been obtained. 
However, metal affinity measurements are also often plagued by common pitfalls in 
measurements and calculations, as reviewed by Xiao et al (Xiao et al. 2010). For example, 
the effect of pH dependence, the solubility of the metal ion and competing ligand, 
competing buffers, or multiple binding modes of competing ligands are sometimes not 
considered or incorrectly understood. For a more complete review of A-Cu2+ affinities 
specifically and discussion of the effect of competing buffers and multiple ligand binding 
modes, see Faller 2009 (Faller et al. 2009). 
 
Something approaching a consensus for the affinity of A for Cu2+ is emerging, with 
recent affinities reported to be closer to 50-500 pM (Hatcher et al. 2008, Hong et al. 2010, 
Sarell et al. 2009). These are focused primarily on monomeric A and shorter fragments. 
There are few studies that compare the affinity of A of different morphologies, 
particularly fibrillar and oligomeric assemblies. 
 
A recent study by Jiang et al. used A(1-16) (Y10W) as a competitive ligand for Cu2+ 
binding A(1-42) monomers and aggregates. They suggested that both A(1-42) 
aggregates formed in the presence of one mole equivalent of Cu2+ and A(1-42) fibres 




formed in the absence of Cu2+ have an elevated affinity for copper compared to A(1-42) 
monomers. This elevated binding strength is sufficient to sequester copper ions from 
human serum albumin when the A aggregates are 5-fold more concentrated than the 
albumin (Jiang et al. 2012). 
 
5.3. AIMS 
A recent study suggests that the affinity for A(1-42) in an aggregated state is tighter than 
monomeric A(1-42) (Jiang et al. 2012). This was surprising as previous studies have 
indicated no significant differences in affinity between fibre and monomer (Sarell et al. 
2009). Recent unpublished studies in the Viles lab indicate that Cu2+ causes A(1-42) to 
form oligomers almost exclusively at substoichiometric concentrations but only fibres 
with A(1-40) (Matheou et al. 2014). We hypothesised this might be the reason for the 
difference in affinities reported in the two papers. In this chapter I aim to compare the 
affinities of different A peptides, A(1-16), A(1-40) and A(1-42), and aggregation 
states, monomers, oligomers, and fibres, for Cu2+ ions. I also aim to determine whether 













 pH Buffer Method Reference 
A(1-16) 1 M 7.4 10 mM PBS Direct Tyr fl. Maiti et al. 2008 
A(1-16) 0.4 M 7.4 10 mM PBS Competitive Tyr fl. Maiti et al. 2008 
A(1-16) 0.3 nM 7.4 20 mM PIPES ITC Hong et al. 2010 
A(1-16) 0.1 M 7.8 Water Competitive Tyr fl. Ma et al. 2006 
A(1-16) 0.7 nM 7.2 20 mM 
HEPES 
ITC Hong et al. 2008 
A(1-16) 47 M 7.4 100 mM Tris Direct Tyr fl. Karr et al. 2005 
A(1-16) 0.3 nM 7.4 20 mM 
HEPES 
ITC Hatcher et al. 2008 
A(1-16) 0.3 nM 7.4 20 mM PIPES ITC Hatcher et al. 2008 
A(1-16) 0.1 M 7.4 50 mM 
HEPES 
ITC/Direct and 
Competitive Tyr fl. 
Guilloreau et al. 2006 
A(1-28) 23 M 7.4 20 mM ACES ITC Sacco et al. 2012 
A(1-28) 70 nM 7.4 50 mM 
HEPES 
ITC Guilloreau et al. 2006 
A(1-28) 50-100 pM 7.8 Water CD and Competitive 
Tyr fl. 
Syme et al. 2004 
A(1-28) 40 pM 7.4 Water CD Sarell et al. 2009 
A(1-28) 28 M 7.5 100 mM Tris Direct Tyr fl. Karr et al. 2005 
A(1-28) 2.5 M 7.2 10 mM 
HEPES 
Competitive Tyr fl. Danielsson et al. 2007 
A(1-40) 0.9 M 7.4 50 mM 
HEPES 
Direct Tyr fl. Tougu et al. 2008 
A(1-40) 0.5 M 7.4 50 mM 
HEPES 
Competitive Tyr fl. Tougu et al. 2008 
A(1-40) 1.6 M 7.4 10 mM Tris Direct Tyr fl. Garzon-Rodriguez et al. 
1999 
A(1-40) ~0.5 nM 7.4 20 mM PIPES ITC Hong et al. 2010 
A(1-40) 11 M 7.5 100 mM Tris Direct Tyr fl. Karr et al. 2005 
A(1-40) 1.6 M 7.3 5 mM 
Phospate 
buffer 
NMR Hou et al. 2006 
A(1-40) 8 M 7.4 50 mM PBS Direct Tyr fl. Raman et al. 2005 
A(1-40) 0.4 nM 7.4 20 mM 
HEPES 
ITC Hatcher et al. 2008 
A(1-40) 1.1 nM 7.2 20 mM PIPES ITC Hatcher et al. 2008 
A(1-40) 50 pM 7.4 20 mM Tris CMCA Atwood et al. 2000 
A(1-40) 57 nM 7.4 50 mM 
HEPES 
Tyr fl. Rozga et al. 2010 
A(1-42) 0.7 M 7.4 10 mM PBS Direct Tyr fl. Maiti et al. 2008 
A(1-42) 2 M 7.4 10 mM Tris Direct Tyr fl. Garzon-Rodriguez et al. 
1999 
A(1-42) 7 aM 7.4 20 mM Tris CMCA Atwood et al. 2000 
A(1-42) 0.76 M 7.4 20 mM 
HEPES 
Direct Tyr fl. Tougu et al. 2008 
A(1-42) 36-62 pM 7.4 Water Competitive Tyr fl. Sarell et al. 2009 
A(1-42) fibres 50-69 pM 7.4 Water Competitive Tyr fl. Sarell et al. 2009 
A(1-42) fibres ~4 pM 7.4 10 mM 
HEPES 
Competitive Tyr fl. Jiang et al. 2012 
A(1-42) 
aggregates 
~1 pM 7.4 10 mM 
HEPES 
Competitive Tyr fl. Jiang et al. 2012 
  




5.4.  EXPERIMENTAL 
5.4.1. Sample Preparation 
A Monomers 
A(1-40) and A(1-42) was solubilised as described in Chapter 2. A(1-16) was 
solubilised directly into UHQ water. All preparations were centrifuged for 10 minutes at 




A(1-40) and A(1-42) fibres were grown as described in Chapter 2 in multi-well plates, 
followed by ThT fluorescence. Fibre samples used in this chapter are ThT-free but grew 
alongside fibres generated in the presence of ThT in otherwise identical conditions. 
Unless otherwise specified, the fibres were grown in 30 mM HEPES at pH 7.4 and 160 
mM NaCl at 30 oC with shaking for 30 seconds every 30 minutes. 
 
A Oligomers 
A(1-42) oligomers were produced in the same manner as the A(1-42) fibres, however, 
they were grown in the presence of substoichiometric concentrations of Cu2+ ions, added 
in the form of CuCl2. Unless otherwise specified, fibres were grown in the presence of 
0.4 mole equivalents of Cu2+. Once again, oligomeric A samples were grown in the 









DAH and Albumin 
Albumin was solubilised and the concentration determined as described in Chapter 2. 
DAH peptide, the first 3 residues of human serum albumin, was purchased from Imperial 
College as a lyophilised powder. It was synthesised using Fmoc chemistry with a free N-
terminal amino group and an amidated C-terminus to mimic the continuation of the 
albumin sequence. It was solubilised in UHQ water. The concentration cannot be 
calculated using absorbance at 280 nm as it does not contain any aromatic residues. The 
lyophilised peptide had approximately 20 % water content but the exact concentration 
was determined from saturation of Cu2+ binding, as it is known to bind with 1:1 
stoichiometry (Sadler et al. 1994), followed using visible CD. 
 
5.4.2. Fluorescence 
The intrinsic tyrosine fluorescence of A was studied. Data were collected between 300 
and 450 nm on a Hitachi F-2500 fluorescence spectrophotometer using an excitation 
wavelength of 280 nm at 25 OC. Samples were placed in a 1 cm quartz cuvette (Hellma). 
 
5.4.3. Affinity Measurements 
The competing ligand NTA was used to determine the affinity of Afor Cu2+. There is a 
linear relationship between the extent of the tyrosine fluorescence that is quenched and 
the amount of Cu2+ bound to A(Sarell et al. 2009). Therefore the return of fluorescence 
upon NTA binding the Cu2+ can be used to calculate the affinity. At half maximal 
fluorescence, the Kd is equal to the free Cu
2+ concentration, the concentration of Cu2+ not 
bound to either NTA or A. The Kd can therefore be calculated using equations 2.15 and 
2.16, described in Chapter 2. 
 
 





Samples were run in 50 mM TIP buffer at pH 7.5 at 10 K using a Bruker Elexsys E580 
spectrometer, as described in Chapter 2. 
 
5.4.5. Visible CD 
Samples were run on a Chirascan CD spectrophotometer, as described in Chapter 2, 
between 350 and 700 nm. Samples were run in 160 mM NaCl and 30 mM HEPES at pH 
7.4 at 25 C in a 1 cm pathlength quartz cuvette (Hellma). 
 
5.5. RESULTS 
5.5.1. Cu2+ Affinity Measurements for A(1-42) Monomers and Oligomers 
Affinities of Cu2+ for different alloforms of A were determined from reversal of tyrosine 
(Tyr10) fluorescence quenching caused upon Cu2+ binding, using NTA as a competing 
ligand, which has a 20 pM affinity for Cu2+ at pH 7.4. Figure 5.03 shows the binding 
curves for the NTA competition of the Cu2+ complex for monomeric and oligomeric 
A(1-42). Oligomers were prepared under the same conditions as Matheou et al., who 
have shown that the addition of substoichiometric Cu2+ to A(1-42) almost exclusively 
generates oligomers and protofibrils but not fibres, see Figure 5.01 (Matheou et al. 2014). 
The binding curves are essentially identical with the half maximal fluorescence being 
reached at 1.5 mole equivalents of NTA relative to Cu2+. The corresponding conditional 
Kds at pH 7.4 are therefore also essentially the same at 10 pM, when calculated from both 
equations (equation 2.15 and equation 2.16), as can be seen in Table 5.02. The Kds have 
been calculated using a substoichiometric concentration of Cu2+ as A(1-42) oligomers 
are generated at these substoichiometric molar ratios.  It was also necessary to calculate  






Figure 5.03. The Affinity of Different A(1-42) Oligomerisation States for Cu2+. 
Tyrosine fluorescence binding curves of different A(1-42) oligomerisation states with 
0.4 mole equivalents of Cu2+ using NTA as a competing ligand. a) 10 M A(1-42) 
monomers and b) 10 M A(1-42) oligomers. Titrations were carried out in the presence 















































































Kd = 10 pM
Kd = 10 pM
a)
b)




the Kd in the presence of 30 mM HEPES, and 160 mM NaCl as these were the conditions 
in which the oligomers were formed and characterised. 
 






[Cu2+total] (M) 4 4 
[Cu2+bound] (M) 2 2 
[NTAtotal] (M) 6 6 
[NTAfree] (M) 4 4 
Kd (from eq 2.15) (pM) 10 10 
Kd (from eq 2.16) (pM) 10 10 
 
Values obtained from the binding curves in Figure 5.03 to calculate the Kd at pH 7.4. 
Titrations were carried out in the presence of 160 mM NaCl and 30 mM HEPES at pH 
7.4 at 25 oC. 
 
5.5.2. Cu2+ Affinity Measurements for A(1-16) at Different Stoichiometries, and 
With/Without Buffer 
I wanted to confirm that using substoichiometric (0.4 mole equivalents) and 
stoichiometric (1 mole equivalent) amounts of Cu2+ did not directly influence affinity 
values determined. Furthermore, I want to confirm that competition studies using NTA 
give the same Kd with or without the presence of buffer (30 mM HEPES at pH 7.4 and 
160 mM NaCl). Buffer can compete for metal ions and thus complicate affinity 




measurements, but for this type of competition experiment this may not be a concern. The 
effect of different Cu2+ mole equivalents and presence of buffer on the affinity values 
obtained was studied using the non-native A fragment A(1-16) as this peptide is not 
prone to aggregation or self-assembly but contains the Cu2+ binding ligands. Figure 5.04 
shows the binding curves obtained for 10 M A(1-16) with one mole equivalent of Cu2+ 
(Figure 5.04a), and 0.4 mole equivalents of Cu2+ in the presence and absence of 30 mM 
HEPES and 160 mM NaCl (Figure 5.04b and Figure 5.04c, respectively). The binding 
curves are very similar with half maximal fluorescence being reached at approximately 
one mole equivalent of NTA. Calculating the Kd from each of these binding curves reveals 
A(1-16) has a picomolar affinity, which is summarised in Table 5.03. The variation in 
the values obtained between the three conditions (17-20 pM) is very small (standard error 
= 1 pM) and within the typical experimental variation from fitting the binding curve, 
slight variation in pH or errors in concentration measurements. The Cu2+ affinities 
obtained for the physiologically relevant A(1-42) alloforms, using buffer and 
substoichiometric concentrations of Cu2+ are therefore validated. 
 
The NTA competition experiments suggest that the conditional affinity of Cu2+ for A at 
pH 7.4 is the same, within the associated errors for these experiments, for A(1-16) and 
A(1-42) irrespective of monomeric or oligomeric form for A(1-42). 
 
  





Figure 5.04. The Influence of Buffer and Stoichiometry on the Affinity of A(1-16) 
for Cu2+.  
Tyrosine fluorescence binding curves of 10 M A(1-16) with Cu2+ using NTA as a 
competing ligand. a) A with one mole equivalent Cu2+ in the presence of 160 mM NaCl 
and 30 mM HEPES at pH 7.4. b) A fluorescence in the presence of 0.4 mole equivalents 
Cu2+ in the presence of 160 mM NaCl and 30 mM HEPES at pH 7.4. c) A with 0.4 mole 



























































































































Kd = 20 pM




Table 5.03. The affinity of A(1-16) for Cu2+. 
 
Sample A(1-16) 
1.0 m.e Cu2+ 
Buffer 
A(1-16) 
0.4 m.e Cu2+ 
Buffer 
A(1-16) 
0.4 m.e. Cu2+ 
No Buffer 
[Cu2+total] (M) 10 4 4 
[Cu2+bound] (M) 5 2 2 
[NTAtotal] (M) 11 4 4.4 
[NTAfree] (M) 6 2 2.4 
Kd (from eq 2.15) (pM) 17 20 17 
Kd (from eq 2.16) (pM) 17 20 17 
 
Values obtained from the binding curves in Figure 5.04 to calculate the Kd at pH 7.4 
 
5.5.3. The N-terminal Cu2+-Binding site of Albumin Sequesters Cu2+ from A(1-16) 
Jiang et al. use albumin as a competitor to measure the affinity of Cu2+ for A using EPR 
(Jiang et al. 2012). A similar experiment was therefore performed. The N-terminal 
residues, NH2-Asp-Ala-His-CONH2 (DAH) have previously been identified as a tight 
Cu2+  binding  site  in  albumin  (Patel et al. 1993).  The N-terminal  residues  were  chosen 
rather than full-length albumin to avoid the direct interaction between A and albumin, 
as described in Chapter 3 (Stanyon et al. 2012). EPR is a useful technique for following 
the competition as the coordination geometries of A-Cu2+ and DAH-Cu2+ are very 
different, producing markedly different spectra. The albumin complex is a 4N square-
planar complex while the A complex is 2N2O. The gII and AII values for the two 




complexes are therefore clearly resolved (Peisach et al. 1974). The EPR spectra of Cu2+ 
complexes of other competing ligands investigated, such as NTA and glycine, have 
substantial overlap with the Cu2+-A spectrum and were not appropriate. Figure 5.05 
shows the titration of DAH into Cu2+-A1-16) at a 0.8:1 ratio to ensure there are no free 
Cu2+ ions. It is apparent that the A-Cu2+ spectrum has hyperfine peaks at 2.49 g and 2.34 
g (black dashed lines) that diminish as DAH is titrated in. These hyperfines are replaced 
by those at 2.42 g and 2.26 g, which are a signature of Cu2+ binding to DAH tripeptide. 
The ratio of the intensity between these two sets of hyperfines can be used to create a 
binding curve (Figure 5.05b). The binding of Cu2+ to the DAH tripeptide is tighter than 
A as the EPR spectra give signal for Cu2+-DAH only after just one mole equivalent of 
DAH relative to Cu2+ has been added. 
 
This observation is supported by return of A tyrosine fluorescence as DAH sequesters 
Cu2+ from A(1-16). Maximal fluorescence is achieved at one mole equivalent of DAH 
to Cu2+ (Figure 5.06), indicating Cu2+ binding A(1-16) is weaker than binding DAH. 
 
5.5.4. The Competitive Effects of DAH on Cu2+ Binding to Different A(1-40) and 
A(1-42) Alloforms 
Next the competitive effects of the DAH tripeptide on Cu2+-A(1-42) were investigated. 
Figure 5.07 shows the results of DAH competition with A(1-42) monomers for Cu2+. It 
is evident that the Cu2+-DAH signal rapidly removes all the Cu2+ from A after one mole 
equivalent and that A(1-42) monomers therefore have a weaker affinity for Cu2+ than 
DAH. This is supported by a similar experiment with A intrinsic tyrosine fluorescence 
(Figure 5.08). 
  






Figure 5.05. EPR Shows A(1-16) has a Weaker Affinity for Cu2+ than DAH.  
a) EPR spectra of 62.5 M A(1-16) with 50 M Cu2+ with 0-1.5 mole equivalents of 
DAH tripeptide in relation to Cu2+ in 50 mM TIP buffer at pH 7.5. The black dashed lines 
represent the hyperfines associated with the A-Cu2+ complex and the burgundy dashed 
lines the hyperfines associated with the DAH-Cu2+ complex. b) The binding curve 
obtained from the normalised ratio between the DAH-Cu2+ and A-Cu2+ hyperfines from 































































Figure 5.06. Intrinsic Tyr Fluorescence Shows A(1-16) has a Weaker Affinity for 
Cu2+ than DAH. 
Normalised tyrosine fluorescence at 310 nm from 100 M A(1-16) with 80 M Cu2+ 
with 0-1.5 mole equivalents of DAH tripeptide in relation to Cu2+ in 50 mM TIP buffer 
















































Figure 5.07. EPR Shows A(1-42) Monomers have a Weaker Affinity for Cu2+ than 
DAH. 
a) EPR spectra of 62.5 M A(1-42) monomers with 50 M Cu2+ with 0-2 mole 
equivalents of DAH tripeptide in relation to Cu2+ in 50 mM TIP buffer at pH 7.5. The 
black dashed lines represent the hyperfines associated with the A-Cu2+ complex and the 
burgundy dashed lines the hyperfines associated with the DAH-Cu2+ complex. b) The 
binding curve obtained from the normalised ratio between the DAH-Cu2+ and A-Cu2+ 































































Figure 5.08. Intrinsic Tyr Fluorescence Shows A(1-42) Monomers have a Weaker 
Affinity for Cu2+ than DAH.  
Normalised tyrosine fluorescence at 310 nm from 20 M A(1-42) monomers with 18 
M Cu2+ with 0-5 mole equivalents of DAH tripeptide in relation to Cu2+ in 50 mM TIP 













































The study by Jiang et al. suggests A(1-42) oligomers might produce a different, tighter 
Cu2+ complex to that of A(1-42) monomer. However, here A(1-42) oligomers 
produced the same results as A(1-42) monomers, with DAH sequestering all Cu2+ from 
the A after the addition of only one mole equivalent of DAH (Figure 5.09). This 
demonstrates that DAH also has a tighter affinity for Cu2+ than A(1-42) oligomers. 
 
The relative affinity of A(1-40) monomers and fibres for Cu2+ compared to DAH was 
also tested. Figure 5.10 shows the EPR spectra obtained following the titration of DAH 
into A(1-40) monomers. It is evident that A(1-40) monomers also have all the Cu2+ 
stripped from them by DAH after just one mole equivalent has been added. A(1-40) 
monomers, therefore, have a Kd weaker than 1 pM for Cu
2+ ions. The EPR spectrum of 
A(1-40) fibres bound to Cu2+ is readily replaced by the spectrum of Cu2+ bound to DAH 
as DAH is titrated in (Figure 5.11), reaching complete transfer at one mole equivalent. 
The Kd of DAH for Cu




The ability of albumin to sequester Cu2+ ions from A(1-40) monomers and fibres was 
also tested using visible CD (Vis-CD), using a 1:1:1 stoichiometric ratio of 
A:Cu2+:albumin. Vis-CD does not detect the d-d transitions of the A-Cu2+ complex as 
the Cu2+ ions are not in a chiral environment (Syme et al. 2004), therefore the appearance 
of a signal relates to albumin sequestering and binding the Cu2+ ions. Figure 5.12 shows 
that the Vis-CD spectrum of Cu2+ bound to albumin is the same as albumin added to the 
A-Cu2+ complexes, even in intensity. All Cu2+ has been sequestered from both A(1-
40) monomers and fibres and therefore must have a weaker affinity for Cu2+ than albumin. 
 






Figure 5.09. EPR Shows A(1-42) Oligomers have a Weaker Affinity for Cu2+ than 
DAH.  
a) EPR spectra of 62.5 M A(1-42) oligomers with 50 M Cu2+ with 0-2 mole 
equivalents of DAH tripeptide in relation to Cu2+ in 50 mM TIP buffer at pH 7.5. The 
black dashed lines represent the hyperfines associated with the A-Cu2+ complex and the 
burgundy dashed lines the hyperfines associated with the DAH-Cu2+ complex. b) The 
binding curve obtained from the normalised ratio between the DAH-Cu2+ and A-Cu2+ 































































Figure 5.10. EPR Shows A(1-40) Monomers have a Weaker Affinity for Cu2+ than 
DAH. 
a) EPR spectra of 100 M A(1-40) monomers with 80 M Cu2+ with 0-2 mole 
equivalents of DAH tripeptide in relation to Cu2+ in 50 mM TIP buffer at pH 7.5. The 
black dashed lines represent the hyperfines associated with the A-Cu2+ complex and the 
burgundy dashed lines the hyperfines associated with the DAH-Cu2+ complex. b) The 
binding curve obtained from the normalised ratio between the DAH-Cu2+ and A-Cu2+ 































































Figure 5.11. EPR Shows A(1-40) Fibres have a Weaker Affinity for Cu2+ than DAH. 
a) EPR spectra of 62.5 M A(1-40) fibres with 50 M Cu2+ with 0-2 mole equivalents 
of DAH tripeptide in relation to Cu2+ in 50 mM TIP buffer at pH 7.5. The black dashed 
lines represent the hyperfines associated with the A-Cu2+ complex and the burgundy 
dashed lines the hyperfines associated with the DAH-Cu2+ complex. b) The binding curve 
obtained from the normalised ratio between the DAH-Cu2+ and A-Cu2+ hyperfines from 






























































Figure 5.12 Visible-CD Shows Albumin Sequesters Cu2+ Ions from Monomeric and 
Fibrillar A(1-40).  
Visible CD of 50 M A(1-40) a) monomers and b) fibres pre-complexed with 50 M 
Cu2+ plus one mole equivalent of albumin (red). The Vis-CD spectrum of 50 M HSA 
with 50 M Cu2+ is shown in blue in each panel for comparison. Samples were run at 25 








































All alloforms of A studied have demonstrated a weaker affinity for Cu2+ ions than the 
DAH tripeptide, which has an affinity of 1 pM (Rózga et al. 2007). 
 
5.5.5. ADoes Not Sequester Cu2+ Ions from HSA 
The effect of the reverse titration, adding different A alloforms as a competitor into 
Cu2+-DAH and Cu2+-albumin complexes was also investigated. Figure 5.13a shows that 
at a 1:1 stoichiometry of A to Cu2+ ions, the DAH-Cu2+ complex EPR spectrum is still 
observed for each alloform of A used; A(1-40) monomers, A(1-40) fibres, A(1-42) 
monomers and A(1-42) fibres. The A(1-42) oligomers were not tested as these are only 
stable in the presence of Cu2+. However, it could have been expected that as A(1-42) 
fibres rapidly become oligomers upon binding Cu2+ (Matheou et al. 2014), that the A(1-
42) fibres would sequester Cu2+ from DAH as oligomers would. This indicates that the 
affinity reported here for A of 10-20 pM is not tight enough to sequester Cu2+ ions from 
DAH, when a 1:1 stoichiometric ratio is used. 
 
Similarly, the ability of A to sequester Cu2+ ions from human serum albumin (as well as 
DAH) was also investigated (Figure 5.13b). The EPR spectrum for Cu2+ bound to albumin 
is the same as the Cu2+-DAH spectrum as would be expected because the Cu2+ only 
coordinates with the main chain amides of the first three residues of albumin (Patel et al. 
1993). The spectra obtained at a 1:1 stoichiometry of A to Cu2+ titrated into albumin-
Cu2+ for all four alloforms of A are the same as Cu2+-albumin alone. This demonstrates 
that the affinity of albumin for Cu2+ is considerably tighter, at least an order of magnitude, 
than the affinity of all forms of A studied; monomers, fibres, or oligomers. 
 






Figure 5.13. A Can Not Sequester Cu2+ Ions from DAH nor Full-Length Albumin. 
EPR spectra of 62.5 M DAH (a) and 62.5 M albumin (b) with 50 M Cu2+ following 
addition of 62.5 M of different A alloforms; monomeric A(1-40) (green), fibrillar 
A(1-40) (cyan), monomeric A(1-42) (dark blue), and fibrillar A(1-42) (magenta). 
Black dashed lines represent the centre of the hyperfine peaks observed for the A-Cu2+ 
complex and the red lines those observed for the Cu2+-DAH/albumin complex. All 




















































5.6.1. A has a Picomolar Affinity for Cu2+ Ions Irrespective of A Alloform 
Determining the affinity of Cu2+ for A is, of course, an important parameter. It will 
indicate the likelihood of Cu2+ being bound to A at physiological concentrations. The 
fluorescence quenching studies using NTA as a competitive ligand for Cu2+ binding have 
revealed that regardless of A alloform or fibrillisation state that the Kd of Cu
2+ binding 
to A is in the 10-20 pM range. The affinities are marginally tighter than those reported 
by Sarell et al. but are otherwise in agreement that the A fibrillisation state does not alter 
the binding constant of Cu2+ for A. The elevated affinity reported is closer to that 
described by Jiang et al. for A(1-42) aggregates (~1 pM), however, no difference was 
observed between A(1-42) monomers or A(1-42) oligomers, or for that matter between 
A(1-16), A(1-40) or A(1-42). 
 
5.6.2. The Source of Discrepancy Between Previously Reported Affinities 
There is a small but significant difference between the Kd determined by Sarell et al. in 
the Viles lab (54 ± 5 pM) (Sarell et al. 2009) and this present work (10-20 pM). It is not 
clear where the systematic errors occur. I wondered if the differences were due to how 
the concentration of A was measured as previously the scatter observed in the UV-Vis 
absorption spectrum was accounted for in a different manner. This might have led up to 
a 20 % over-estimation of concentration compared to that obtained from equation 2.06 in 
Chapter 2. Where Sarell et al. obtained a Kd of 50 pM, recalculation of this accounting 
for a 20 % decrease in A concentration gives a Kd of 27 pM. This value is closer to the 
10-20 pM obtained in this work. It highlights the accuracy in measuring affinity and thus 
differences by as much as an order of magnitude can be simply due to small errors in 
measuring concentrations.  




This triggered the question of the effect of systematic discrepancies in the concentrations 
of all solutions used. Table 5.04 shows the different Kd values A(1-42) monomers have 
for Cu2+, Figure 5.02a, when accounting for concentration discrepancies. The individual 
effects of a discrepancy in concentration are not significant but an over-estimation of 
competing ligand (NTA) concentration has the most dramatic effect, with a 20 % over-
estimation increasing the Kd from 10 pM to 14 pM. 
 
The discrepancies between the reported affinities, particularly between those reported by 
Jiang et al., may be attributed to the different conditions in which the complexes were 
formed and the competing ligands used. Rather than using competing ligands with well 
documented affinities for Cu2+, Jiang et al. used an A analogue, A(1-16)(Y10W). The 
affinity of this analogue was calculated to be 135 nM, using direct fluorescence quenching 
in a high concentration of HEPES buffer (500 mM). The buffer effect was then corrected 
to give a Kd of 320 pM. The use of direct fluorescence quenching for determining Cu
2+-
peptide affinity is inherently difficult as the concentration of peptide used must be 
extremely low (<320 pM) to avoid tight binding and will therefore be on the limit of 
accurate fluorescence detection. Using a buffer to compete with the probe for Cu2+ means 
the concentration of A(1-16)(Y10W) used can be higher, however, HEPES is not an 
optimal buffer for this because A concentration must still be in the range of the apparent 
Kd, which is in the nM range in HEPES (Faller et al. 2009). An error in determining the 
affinity of the competing ligand would therefore transfer in calculating the affinity of 
A(1-42) for Cu2+. The difference in affinity between A(1-16)(Y10W) and A(1-42) is 
surprising. The bulky Trp residue close to the Cu2+ binding site His6-His13,14 may reduce 
its affinity for Cu2+ compared to wild type A(1-16) and A(1-42). 
 











































4 4 4 4 4 3.6 3.2 4.4 4.8 
[Cu2+bound] 
(M) 
2 2 2 2 2 1.8 1.6 2.2 2.4 
[NTAtotal] 
(M) 
6 5.4 4.8 6.6 7.2 6 6 6 6 
[NTAfree] 
(M) 




10 12 14 9 8 9 8 11 12 
 
The original values are those tabulated in Table 5.01 column a. An over-estimation of the 
original concentration would mean the concentration would actually be weaker and an 
under-estimation would mean the concentration would be stronger.  




The affinities Jiang et al. calculated using EPR and albumin as a competitor rely on no 
ternary complex being formed between Cu2+, A and albumin. This ternary complex 
formation has previously been proposed by Rozga et al. to be a mechanism for mediating 
Cu2+-related A toxicity (Rozga et al. 2010). This could result in monomeric A, the A 
species thought to bind HSA, being removed from the pool of A free to sequester Cu2+. 
Therefore the concentration of A(1-42) monomer required to sequester Cu2+ from 
albumin would be elevated compared to A(1-42) aggregates that are unable to bind 
HSA. Furthermore, the affinities were calculated from a single EPR spectrum rather than 
a titration of A into the HSA-Cu2+ complex, adding to potential inaccuracies. However, 
the ratio between the hyperfines of the HSA-Cu2+ and A-Cu2+ complexes in the EPR 
spectrum obtained from A(1-42) incubated for 6 hours does appear to be 0.5:0.5, when 
a 5 times excess of A compared to HSA is used. The estimated Kd from this spectrum is 
6 pM (Jiang et al. 2012), which is only slightly tighter than the affinities calculated in this 
work, 10-20 pM. 
 
Finally, the A(1-42) aggregates studied by Jiang et al were formed in the presence of 
one mole equivalent of Cu2+, so are likely to be amorphous aggregates rather than the 
oligomers and protofibrils that are preferentially formed in the presence of 
substoichiometric levels of Cu2+. Amorphous aggregates are not neurotoxic whereas 
oligomers are thought to be the most toxic species of A. The fact that the oligomers have 
the same affinity for Cu2+ as monomeric A(1-42), and indeed A(1-16), demonstrates 








5.6.3. Biological Significance 
Aβ levels are estimated to be greater than 0.5 nM at the synapse (Seubert et al. 1992), 
thus Aβ would be expected to be able to compete with other metal chelators for the 
binding of Cu2+ ions with an affinity of 10-20 pM, especially during depolarisation, when 
Cu2+ can reach concentrations as high as 250 µM within the synaptic cleft (Hartter et al. 
1988, Kardos et al. 1989). 
 
To conclude, the difference between the affinities of A(1-16), A(1-40) and A(1-42) 
in monomeric, fibrillar or oligomeric state for Cu2+ are small and not significant. 
Variations in calculated affinities (see Table 5.04) may actually be down to discrepancies 
in measuring A or competing ligand concentration. Perhaps Kd values between 10 and 
100 pM might be a reasonable conditional dissociation constant for all forms of A at pH 
7.4. 
 











DEVELOPING VISIBLE CD FOR 
STUDYING COPPER BINDING TO 
N-TERMINAL PEPTIDES. 
APPLICATIONS FOR THE PRION 
PROTEIN AND α-SYNUCLEIN; 
AFFINITY MEASUREMENTS AND 
COORDINATION GEOMETRY 
  




Circular Dichroism (CD) spectroscopy in the visible region (Vis-CD) is a powerful 
technique to study metal-protein interactions. In this chapter I develop insight into the 
relationship between the Vis-CD spectrum of Cu2+-peptide complexes and coordination 
geometry and apply this to Cu2+ binding to the prion protein (PrPC) of transmissible 
spongiform encephalopathies and alpha-synuclein (αSyn) of Parkinson’s disease. The 
chapter has been subdivided into 3 distinct parts: 
 
Part A:  Developing Predictive Rules for Coordination Geometry from Visible 
Circular Dichroism of Copper(II) and Nickel(II) Ions in Histidine and Amide Main-Chain 
Complexes. 
Part B:  Copper(II) Sequentially Loads on to the N-terminal Amino Group of the 
Prion Protein (PrPC) Before the Individual Octa-Repeats. 
Part C:  Comparisons of Cu2+ Binding to N-terminal Model Peptides of Alpha-
Synuclein, using Visible Circular Dichroism Spectroscopy: Affinity, Coordination 
Geometry, pH Dependence and Stoichiometry. 
 
In Part A, I compare experimental and computed Vis-CD spectra of Cu2+-loaded model 
peptides in square-planar complexes. I find that the spectra can readily discriminate the 
coordination pattern of Cu2+ bound exclusively to main-chain amides from that also 
involving a side chain (i.e. histidine side chain). Based on the results, I develop a set of 
empirical rules that relates the appearance of particular Vis-CD spectral features to the 
conformation of the complex. These rules can be used to gain insight into coordination 
geometries of other Cu2+ or Ni2+-protein complexes, such as those associated with Prion 
Disease (Part B) and Parkinson’s disease (Part C). 
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The cellular prion protein (PrPC) binds to Cu2+ ions in vivo and a misfolded form of PrPC 
is responsible for a range of transmissible spongiform encephalopathies. Recently, 
disruption of Cu2+ homeostasis in mice has been shown to impart resistance to scrapie 
infection. Using full-length PrPC and model peptide fragments I monitor the sequential 
loading of Cu2+ ions on to PrPC using Vis-CD. I show the N-terminal amino group of 
PrPC is not the principal binding site for Cu2+; however surprisingly, it has a tighter 
affinity for Cu2+ than the individual octa-repeat binding sites present within PrPC. I re-
evaluate what is understood of the sequential Cu2+ loading onto the full-length protein 
and show for the first time that Cu2+ loads on to the N-terminal amino group before the 
single octa-repeat binding sites. 
 
Copper dyshomeostasis has been reported in Parkinson’s disease (PD) and Cu2+ binding 
to alpha-synuclein (αSyn) can accelerate amyloid fibre formation. However, there is still 
some controversy over the coordination geometry and affinity of Cu2+ for αSyn. Here I 
show Vis-CD spectra of Cu2+ loaded model peptides of the N-terminus of αSyn. Using 
Gly as a competitor I determine the affinity of the complexes. It is clear that the Aspartate 
coordination of Cu2+ in αSyn has a stabilising influence on the Cu2+ complex. Affinities 
(at pH 7.4) are much tighter for the αSyn N-terminus tripeptide, MDV, compared to MAV 
with Kds of 0.3 nM and 36 nM. The incorporation of a putative histidine side-chain in the 
N-terminal αSyn complex results in a significant increase in the affinity for Cu2+ to 30 
pM at pH 7.4. These model peptides are related to studies of Cu2+ binding to full-length 
αSyn. 
 
The work presented in Part A and Part B of this chapter forms the basis of work published 
in FEBS Journal 2014 and Biochemistry 2014, respectively (Stanyon et al. 2014a, 
Stanyon et al. 2014b).  






CHAPTER 6: PART A 
 
DEVELOPING PREDICTIVE RULES 
FOR COORDINATION GEOMETRY 
FROM VISIBLE CIRCULAR 
DICHROISM OF COPPER(II) AND 
NICKEL(II) IONS IN HISTIDINE AND 
AMIDE MAIN-CHAIN COMPLEXES 




Circular Dichroism (CD) spectroscopy is a technique that is most commonly utilised in 
the far UV region to study protein secondary structure; however, it can also be used in 
the visible region (Vis-CD) to study transition metal ions in a chiral environment, such as 
metal-protein complexes. Transition metal ions produce Vis-CD spectra that are due to a 
combination of absorption bands arising from d-d electronic transitions. The signal that 
metal ion complexes generate in the visible range of CD can be attributed to three effects: 
the vicinal effect, the conformational effect, and the configurational effect (Martin 1974). 
For Cu2+ or Ni2+ square-planar complexes that typically involve amide main-chain 
coordination within proteins, the vicinal effect dominates, and is modulated by the 
placement of the chiral amino acid side chain above or below the quasi plane of the 
complex (Martin 1974, Tsangaris et al. 1970). 
 
Cu2+ visible absorption bands are derived from three overlapping d-d transitions (Martin 
1974). As CD records the difference in absorption between left and right circularly 
polarised light, individual transitions can produce bands of opposite sign. Thus the 
contribution of each band can be better resolved than with direct absorption spectra. As a 
consequence, CD bands are not always centred on the same wavelength as their 
counterpart band in absorption spectra. The CD spectra produced are unique to the 
coordination geometry of the metal complexed to the protein, although predictive rules 
that correlate Vis-CD spectra with the coordination geometry are not fully developed. 
Comparisons of Vis-CD spectra simulated with quantum chemical methods to 
experimental data can be used to deduce precise coordination geometry of the chiral 
complex (Autschbach 2009, Mori et al. 2011, Pescitelli et al. 2009, Stephens et al. 2010). 
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Natively unstructured proteins, such as those associated with protein misfolding diseases, 
have the ability to coordinate Cu2+ (and Ni2+) ions via main-chain amide nitrogen lone-
pairs (Martin 1974). Cu2+ complexes that involve amide main-chains are typically 
stabilised by favourable side-chain coordination, often a nitrogen in the imidazole ring of 
histidine, and/or the N-terminal amino group. Examples of these types of complexes 
include Cu2+ coordination to prion protein (Klewpatinond et al. 2008, Viles et al. 1999), 
α-synuclein (Binolfi et al. 2012, Rasia et al. 2005), and the N-terminal residues of serum 
albumin (Martin 1974, Milojevic et al. 2014).  
 
6A.2. AIMS 
With an aim to develop a set of empirical rules that correlates the appearance of Vis-CD 
spectra with the coordination geometries of Cu2+ and Ni2+ square-planar complexes, here 
I compare the appearance of the Vis-CD spectra of three sets of Cu2+-loaded model 
peptides and of two sets of Ni2+-loaded complexes. In particular, I study Cu2+-loaded 
peptides including: N-terminally acetylated peptides (Ac-XXH) that have a combination 
of chiral and non-chiral ligands preceding the His residue (where X= Ala or Gly), as well 
as two related sets of peptides that have a free N-terminal amino group with and without 
His residue; NH2-XXH and NH2-XXX respectively. I compare experimental spectra with 
computed spectra based on density functional theory (DFT) (Hasnip et al. 2014) and 
geometry-optimized structures and time-dependent (TD)-DFT calculations 
(Bauernschmitt et al. 1996). I aim to provide a rationale for the observed spectral 
signatures of the complexes as well as the signatures of the linear combinations of 
experimentally derived Vis-CD spectra.  
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6A.3.  EXPERIMENTAL 
6A.3.1. Peptides 
Fmoc chemistry was used to synthesise the various peptides used. All peptides were C-
terminally amidated in order to mimic the continuation of the peptide sequence in the 
larger protein. The peptides were removed from the resin and de-protected before 
purification by reverse-phase HPLC. The samples were characterised using mass 
spectrometry and 1H NMR spectroscopy. 
The following tripeptides studied included:  
Free N-terminus Free N-terminus Acetylated N-terminus 
NH2-AGG NH2-GGH Ac-GGH 
NH2-GAG NH2-GAH Ac-GAH 
NH2-GGA NH2-AGH Ac-AGH 
NH2-AAA NH2-AAH Ac-AAH 
Purchased from Generon Ltd (Maidenhead, UK), A.B.C., Imperial College London and 
China Peptides (Shanghai).  
 
The lyophilised weight of each peptide was used to estimate the concentration, assuming 
20 % moisture content. However, it was the known concentration of metal ions at 
substoichiometric levels to the peptide that was used for the conversion to molar ellipticity 
in CD spectra. The concentration of albumin was determined from UV-visible electronic 
absorption spectra at 280 nm obtained, ε280 = 30,770 M-1 cm-1. 
 
6A.3.2. Circular Dichroism 
CD spectra were obtained as described in Chapter 2. 
 
 




All simulations were carried out by my collaborators; Xiaojing Cong, Giulia Rossetti, 
Jens Dreyer, George Papamokos, and Paolo Carloni. Tripeptide models of GGH and 
AGH in complex with Cu2+ were constructed using Accelrys® Discovery Studio 
Visualizer 3.5 according to the presumed coordination (Klewpatinond et al. 2007a) The 
tripeptides were C-terminally amidated and either N-terminally acetylated (Ac-XGH) in 
order to mimic the His96 and His111 region in PrP or had a free N-terminal amino group 
(NH2-XGH). The geometries of these complexes were optimized in implicit aqueous 
solution using DFT with the Heyd-Scuseria-Ernzerhof (HSE) functional (Heyd et al. 
2006) and the 6-311++G** basis set (Strati et al. 2002). The solvent was treated by 
employing the conductor polarised continuum solvent model (CPCM) (Cossi et al. 2003). 
Frequency calculations on the optimized geometries confirmed that these were true 
minima since no imaginary frequency was found. Free energies were obtained at 298.15 
K and 1 atm. To simulate the electronic CD spectra, TD-DFT calculations were carried 
out on the optimized ground state geometries to explore their electronically excited states. 
This was performed using the same functional, basis set and solvent model as those used 
for geometry optimization. The first 15 states were requested to produce the electronic 
CD spectrum. All calculations were carried out using Gaussian 09 (Frisch et al. 2009). 
The obtained electronic CD data were analysed and the CD spectra were plotted using 
GaussSum 2.2 (O'Boyle et al. 2008). The calculation of the CD spectrum at a given 
wavelength (or energy, E) is done by convoluting the stick spectra with Gaussian band 
shapes for all transitions, using the relation: 
∆ε = 2∆ 2.296 × 10√⁄  × exp−2 − ∆ ⁄  , 
where ∆E is transition energy, and σ is the bandwidth at 1/e peak height (σ = 0.6 eV is 
used empirically here) (Stephens et al. 2010).  
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6A.4. RESULTS AND DISCUSSION 
6A.4.1. His-Cu2+ Complexes Preceded by Amide Coordination Only 
I have directly compared Cu2+-loaded Vis-CD spectra of four possible combinations of 
tripeptides with His at the 3rd position (GAH, GGH, AGH and AAH) for those containing 
a free N-terminal amino group against those with an acetylated N-terminus to mimic Cu2+ 
coordination via residues in the middle of a protein sequence and those centred at the N-
terminal amino group (Figure 1). I chose Ala and Gly for the model peptides as alanine 
is the simplest chiral residue and glycine is non-chiral thus will not directly contribute to 
Vis-CD spectra. In this way the contribution from individual side-chains at different 
coordination positions can be determined.  
 
Comparisons of Vis-CD spectra for the four NH2-XXH model peptides (Figure 6A.01, 
first column) have very similar appearance with positive signal to shorter wavelengths 
and negative signal to longer wavelengths. There is some variation in the relative 
intensities of the spectra, for example, the NH2-AAH spectrum has a greater negative 
signal than the NH2-GGH spectrum. The four peptides are compared to the Vis-CD 
spectra for the related tripeptides with an acetylated N-terminal amino group (Figure 
6A.01, second column). When non-chiral glycine is in the first position, a positive d-d 
transition band to shorter wavelengths and a negative band to longer wavelengths is 
observed in the Vis-CD spectra, which is very similar to the non-acetylated N-terminal 
peptide. In contrast, with alanine in the first position the Vis-CD spectra invert so that the 
signal becomes positive at longer wavelengths and negative to shorter wavelengths. 
 
The same behaviour is observed for peptide fragments from the binding sites within full 
length prion protein, PrP(23-231), centred at His96 and His111. Depending on the presence 
of the chiral or non-chiral (glycine) side chain two residues preceding the His imidazole 
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coordination, the appearance of the Vis-CD is dramatically altered (Berti et al. 2007, Di 
Natale et al. 2009, Gralka et al. 2008, Jackson et al. 2001, Jones et al. 2005, Klewpatinond 
et al. 2007a, Klewpatinond et al. 2007b, Ősz et al. 2007). The spectra of PrP(92-96) and 
PrP(107-111) are shown in Figure 6A.02. This inversion of the spectrum has been 
observed for a number of peptides influenced by the presence or absence of a side chain 
two residues preceding the His side-chain. For example a whole series of penta-peptides, 
eight in all, related to PrP(92-96) and PrP(107-111) (Klewpatinond et al. 2007a). 
Furthermore, the Cu2+ Ac-GGGH and Ac-GGHG visible CD spectra (Orfei et al. 2003) 
have the striking appearance of Ac-GGH, while Cu2+ and Ni2+ square-planar, four nitrogen 
complexes of Ac-ELAKHA (Karavelas et al. 2005) and Ac-TESHAK peptides (Mylonas 
et al. 2002a, Mylonas et al. 2002b), models of the C-terminal tail of histone H2A, have 
the inverted appearance of Ac-AAH, as predicted. 
 
6A.4.2. Simulation Data of Ac-GGH and Ac-AGH Cu2+ Complexes 
Simulations were performed in order to elucidate the reasons for the mirror image relation 
between Vis-CD spectra of Cu2+ loaded Ac-AGH and Ac-GGH. The former contains a 
non-chiral Gly residue in the first position, whereas the latter has a side-chain and is chiral 
at this position. Three possible stereoisomers for Cu(Ac-GGH) were identified. These 
also resemble the three possible stereoisomer conformations for Cu(Ac-AGH) (Figure 
6A.03). Their corresponding simulated Vis-CD spectra are also shown in Figure 6A.03, 
calculated using TD-DFT. The isomers are denoted 1, 2 and 3 for both the Cu(Ac-GGH) 
and Cu(Ac-AGH) complexes. Isomer 1 generates almost the mirror image spectrum of 
isomer 2 and 3. It can be concluded that Cu(Ac-GGH)_1 is the major isomer of Cu(Ac-
GGH) in solution, as its spectrum is the only one resembling the experimental one. This 
agrees well with the free energy of the structures (see Figure 6A.03). Consistently, the 
free energy of  Cu(Ac-GGH)_1 is  significantly lower than that  of the other two isomers 





Figure 6A.01. Comparison of Vis-CD Spectra of Cu2+ Bound to Free and Acetylated 
Model Tripeptides.  
Column I): Cu2+ binding to free N-terminal peptides at pH 7.4, column II): Cu2+ binding 
to acetylated N-terminal peptides at pH 9.5. Row a) = GAH, b) = GGH, c) = AGH, d) = 
AAH. The presence of a chiral residue for the acetylated peptides causes an inversion of 















































































I) NH2-peptide II) Acetyl-peptide




Figure 6A.02. Inverted Vis-CD spectra Within the Prion Protein.  
Vis-CD of one mole equivalent of Cu2+ bound to 100 µM PrP(92–96) and PrP(107–111) 































Figure 6A.03. Calculated Vis-CD Spectra of the Three Possible Stereoisomers of a) 
Cu(Ac-GGH) and of b) Cu(Ac-AGH).  
The isomers 1 and 2 (of each complex) are cis/trans isomers referring to the acetyl O and 
Cu2+ atoms, whilst 1 differs from 2 and 3 in the histidine imidazole that is either below 
or above the plane of the peptide backbone. The calculated free energy of each isomer 
with respect to the lowest-energy one (set as 0 kcal/mol) is also given. Coloured by 
elements: C, gray; N, blue; O, red; H, white and Cu, orange. 
This figure was kindly supplied by my collaborators; Xiaojing Cong, Giulia Rossetti, Jens 
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(about -4 and -1 kcal/mol for Cu(Ac-GGH)_2 and Cu(Ac-GGH)_3, respectively). In 
contrast, Cu(Ac-AGH)_2 and Cu(Ac-AGH)_3 are the major isomers of Cu(Ac-AGH) in 
solution, as their spectra are the only ones resembling the experimental one. In this case, 
however, there are only minor differences (within 1 kcal/mol) in free energy among the 
isomers. These results raise the question why stereoisomer 1 is favourable for Cu(Ac-
GGH), but not Cu(Ac-AGH). A possible explanation is that in Cu(Ac-AGH)_2 the 
Alanine side chain forms hydrophobic interactions with the acetyl group, which may 
compensate the penalty of forming this conformation. Indeed, the energetic contribution 
of such hydrophobic interactions is expected to be a few kcal/mol, corresponding to the 
energy difference between Cu(Ac-GGH)_1 and Cu(Ac-GGH)_2(Pace et al. 2011). The 
same effect is observed in vitro for penta-peptides PrP(92-96) and PrP(105-111) 
(Klewpatinond et al. 2007a) and the same binding in full-length PrPC (Klewpatinond et 
al. 2008). 
 
These results suggest that the absence or presence of a Gly in the first position causes a 
change of the spectrum to its mirror image indirectly. Indeed, the Gly favours the position 
of the His side chain imidazole ring “below” the quasi-plane defined by the Cu2+ and the 
backbone N atoms in these isomers (see the scheme in Figure 6A.04a). On the other hand, 
when Ala is the first residue, it favours instead the “above” position (Figure 6A.04b). 
These positions correlate with the generation of a spectrum or its mirror image: isomer 1 
of each complex differs from the isomers 2 and 3 in the position of the imidazole ring 
with respect to the plane of the backbone N atoms (Figure 6A.03). Hence, the nature of 
the first residue affects the His conformation, which affects the chirality of the complexes. 
This in turn determines the Vis-CD spectral pattern observed experimentally both in the 
peptide models and, for example, in the His96 and His111 sites of PrP (Klewpatinond et al. 
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2007a) and other histidine-containing peptides (Karavelas et al. 2005, Mylonas et al. 
2002a, Mylonas et al. 2002b) 
 
6A.4.3. Simulated NH2-XXH Spectra 
The in vitro Vis-CD spectra of Cu2+ loaded XXH tripeptides with free N-terminal amino 
group (Cu(NH2-XXH)) have been compared to those of the N-terminal acetylated 
tripeptides (Cu(Ac-XXH)) (Figure 6A.01). The presence or absence of a side chain (Ala) 
at the first position does not appear to modulate the spectra greatly as the signatures for 
all four peptides AAH, GGH, AGH, GAH are quite similar. Again DFT and TD-DFT 
calculations have been used on two of the complexes, Cu(NH2-GGH) and Cu(NH2-
AGH), to understand this effect. Geometry optimisation shows that without the N-
terminal acetylation group there is only one stereoisomer for each complex (Figure 
6A.05). The stereoisomer resembles Cu(Ac-GGH)_1 in which the His imidazole ring is 
“below” the quasi-plane of Cu2+ and the peptide backbone. Correspondingly, the Vis-CD 
spectra of Cu(NH2-GGH) and of Cu(NH2-AGH) (Figure 6A.05) also resemble that of 
Cu(Ac-GGH)_1 (Figure 6A.03), consistent with the in vitro spectra (Figure 6A.01). This 
is not unexpected because Cu(Ac-GGH)_1 is the energetically most favoured 
stereoisomer of Cu(Ac-GGH). In the case of Cu(Ac-AGH), stereoisomer 2 is favoured 
likely due to the presence of acetyl (as discussed above), which is absent in Cu(NH2-
AGH) complex.  
 
6A.4.4. Vis-CD Spectra of Ni2+ Complexes are Similar to Cu2+ Complexes 
The ability of metal ions to deprotonate amides and coordinate is unusual but not 
exclusive to Cu2+ ions; Ni2+ ions (Jones et al. 2005) and Pd2+ ions (Garnett et al. 2006) 
also have this property (Martin 1974). Ni2+ binds to albumin with a similar coordination 
  






Figure 6A.04. Schematic Representation of Cu-XXH Stereoisomers.  
Possible stereoisomers of Cu2+ bound to XXH tripeptides, where X is any residue, with 
the histidine imidazole ring a) “below” and b) “above” the quasi plane, defined by the 
backbone N atoms and the Cu2+ ion. 
 
  





Figure 6A.05. The Calculated Configuration and Vis-CD spectra for Cu2+ Binding 
to Free N-Terminal Peptides.  
a) NH2-GGH, b) NH2-AGH. 
This figure was kindly supplied by my collaborators; Xiaojing Cong, Giulia Rossetti, Jens 
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to Cu2+ ions (Sadler et al. 1994). To determine whether the Vis-CD spectra follow the 
same behaviour as Cu2+, I studied the same set of peptides bound to Ni2+ ions. Figure 
6A.06 shows that Ni2+ bound to the histidine-containing tripeptides produces Vis-CD 
spectra similar to those produced by Cu2+ ions. In particular, the CD bands are negative 
to longer wavelengths for NH2-XXH tripeptides with a free N-terminal amino group. 
Similarly, the Ni2+ complexes of Ac-XXH tripeptides, with an acetylated N-terminus, 
exhibit the same behaviour as Cu2+, where with Gly at the first position a positive CD 
band is observed at shorter wavelengths, while with an amino acid with a side-chain (Ala) 
and the associated steric effect, the appearance of the d-d CD bands is inverted. 
 
The CD bands observed for the Ni2+-peptide complexes have all shifted to a shorter 
wavelength in comparison to the corresponding Cu2+-peptide complexes. Cu2+ d-d 
absorption bands for four nitrogen ligands are typically centred at 540 nm, while similar 
Ni2+ complexes absorb at 440 nm. 
 
6A.4.5. Contributions of Residues Around the Chelate Plane are Additive to CD 
Spectra 
Figure 6A.07a shows the series of four Cu2+ loaded NH2-XXH peptides overlaid. The 
variation in the relative intensity of the positive and negative CD bands is quite apparent. 
The GGH spectrum has the most intense positive signal, while AAH has the most intense 
negative signal. Replacement of each glycine with an alanine creates a more negative 
signal, which is particularly apparent when the GGH spectrum is subtracted from the 
individual spectra of AGH, GAH and AAH, Figure 6A07b. These difference spectra 
(Figure 6A.07b) have a very similar appearance to the spectra of Cu2+ loaded NH2-AGG 
NH2-GAG and NH2-AAG, shown in Figure 6A.08a.  
 





Figure 6A.06. Comparison of Free and Acetylated Model Tripeptides Shows the Side 
Chain of Residue 1 Affects Ni2+ Vis-CD spectra.  
Column I) free N-terminal Ni2+ binding at pH 7.4, column II) acetylated N-terminal Ni2+ 















































































I) NH2-peptide II) Acetyl-peptide





Figure 6A.07. Vis-CD spectra of N-terminal Cu2+ coordination involving Histidine 
a) The spectra of AAH, AGH, GAH and GGH bound to Cu2+ at pH 7.4. b) The difference 
spectra from a) with the spectrum of GGH subtracted from each. c) The sum of the visible 
CD spectra to get AAH (AGH+GAH-GGH) overlaid with AAH coordinated to Cu2+. d) 
The spectra of full-length human serum albumin, N-terminal model of human serum 
albumin (DAH), and AAH bound to one mole equivalent of Cu2+. All spectra were 
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Figure 6A.07c shows the comparison of the Cu2+ loaded Vis-CD spectrum for AAH with 
a convoluted spectrum generated by the combination of three Cu2+-loaded spectra; AGH 
plus GAH minus GGH. The generated spectrum is strikingly close to that of AAH. It is 
clear that by replacing the alanines with glycines, the individual contributions of each 
residue can be obtained and summed together to simulate the spectrum of AAH, as 
previously shown for AAA tripeptides by Tsangaris and Martin (Tsangaris et al. 1970). 
This approach is therefore also applicable for coordination that involves side chain 
coordination of this type as well as amide main-chain coordination. 
 
Cu2+ complexed with proteins often involves both N-terminal amino group and His 
imidazole coordination. These complexes have a particularly high affinity for Cu2+ in the 
picomolar range, such as the N-terminal binding domain of serum albumin (Kumar et al. 
2011, Teir et al. 2012). Cu2+ binding to the N-terminus of serum albumin is well 
characterised and is thought to be responsible for transport of exchangeable Cu2+ in blood 
plasma (Patel et al. 1993). Serum albumin is an example of a protein that binds Cu2+ to 
produce a visible CD spectrum that has both negative and positive CD bands with side-
chain coordination as well as main-chain amide coordination, Figure 6A.07d. The Vis-
CD spectrum produced for albumin has the same appearance as the tripeptide DAH, the 
first three N-terminal residues of human serum albumin. Furthermore, the DAH spectrum 
is almost identical to the spectrum of AAH, Figure 6A.07d. 
 
6A.4.6. Cu2+ Square-Planar Complexes in the Absence of Side-Chain Coordination 
More than 40 years ago Tsangaris and Martin indicated that Cu2+ binding to the N-
terminal of peptides via the amide backbone, forming a 4N square-planar complex will 
always generate negative CD bands for the copper d-d electronic transitions (Tsangaris et 
al. 1970). I have confirmed this for peptides containing glycine and alanine residues 
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(Figure 6A.08a). Cu2+ binding to the N-terminal amino group of PrPC shows this type of 
spectrum (Stanyon et al. 2014b), while Cu2+ binding to the N-terminal amino group of α-
synuclein does not because of the additional coordination of an Asp side-chain (Binolfi 
et al. 2012). 
 
Tsangaris and Martin also suggested that contributions from individual residues to the 
Vis-CD spectrum are additive, meaning the individual spectra of three different 
tripeptides containing one chiral residue in each position can be added together to closely 
simulate the spectrum of the tripeptide containing all of those chiral residues (Tsangaris 
et al. 1970). In particular, the Cu2+ bound spectra of the three tripeptides with Alanine at 
each position of the tripeptides (AGG, GAG and GGA) added together has the appearance 
of Cu2+ bound to AAA (tri-alanine). Indeed, the Vis-CD signal for Cu2+ bound tri-glycine 
(GGG) is not detected (Figure 6A.09) because of the lack of main-chain chirality, thus 
there is no vicinal effect (Martin 1974). Figure 6A.08b highlights how closely individual 
residue combinations can predict the appearance of other spectra, with a striking 
similarity between the combined spectrum derived from the addition of three different 
tripeptides and the spectrum of tri-alanine. 
 
6A.5. CONCLUSION 
Vis-CD is a powerful probe (Bal et al. 1997, Binolfi et al. 2008, Karavelas et al. 2005, 
Laitinen et al. 2006, Martin 1974, Milojevic et al. 2014, Mylonas et al. 2002a, Mylonas 
et al. 2002b, Stanyon et al. 2014b, Tsangaris et al. 1970) for determining pH dependence 
of binding (Viles et al. 1999), stoichiometry (Klewpatinond et al. 2008) and affinity of 
transition metal ions (Nadal et al. 2009, Stanyon et al. 2014b). Here I have presented a 
broad set of observations correlating the Vis-CD spectra of Cu2+ or Ni2+ square-planar 
complexes with the coordination geometry:  






Figure 6A.08. Vis-CD Spectra of Square-Planar Cu2+ Coordination at the N-
Terminal of Peptides, Which Lacks Side-Chain Coordination, Always has a 
Negative d-d Band in the CD spectrum 
a) The visible CD spectra of one mole equivalent of Cu2+ bound to 100 µM of the model 
N-terminal tripeptides: AAA, AAG, AGG, GAG, and GGA, at pH 9.5. b) Comparison of 



























































Figure 6A.09. Tri-Glycine Bound to Cu2+ Does Not Produce a Vis-CD signal.  
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i) Entirely negative d-d bands suggest N-terminus and main-chain amide 
coordination but no side-chain coordination. 
ii) N-terminal coordination with His at the second position (such as that found 
for albumin) contains both positive and negative d-d CD bands with the band 
at longer wavelengths being negative. 
iii) Coordination of His residue and preceding amide distant from the N-terminal 
amino group (often observed at higher pH) is modulated by the presence of a 
side-chain and its steric effect at the third position before the His residue. If a 
side-chain is present here the positive and negative bands are inverted 
compared to coordination involving histidine and a free N-terminal amino 
group, three residues apart, with negative signal to shorter wavelengths.  
iv) Spectra can be additive with each chiral residue around the Cu2+ having its 
own individual contribution thus aiding the predictive power of Vis-CD 
spectra in indicating coordination geometry.  
 
In conclusion, I have been able to provide a set of rules, which gives insights into the 
coordination geometry of Cu2+ and Ni2+ binding to proteins and corresponds to the 
appearance of Vis-CD spectra for these biologically relevant transition metal ions. 






CHAPTER 6: PART B 
 
COPPER(II) SEQUENTIALLY LOADS 
ON TO THE N-TERMINAL AMINO 
GROUP OF THE PRION PROTEIN 
(PRPC) BEFORE THE INDIVIDUAL 
OCTA-REPEATS  




There is intense interest in Cu2+ and other metal ions binding to amyloidogenic proteins, 
in particular amyloid-beta peptide (Aβ) in Alzheimer’s Disease, alpha-synuclein (αSyn) 
in Parkinson’s Disease, and the prion protein (PrP) in transmissible spongiform 
encephalopathies (TSEs) (Gaggelli et al. 2006, Viles 2012). Cu2+ ions bind to PrPC in vivo 
(Brown et al. 1997) and induces PrPC endocytosis (Perera et al. 2001), while PrPC 
mediates Zn2+ ion uptake (Watt et al. 2012). Recently it has been shown that transgenic 
mice with a Menkes disease (Atp7a) mutation are resistant to scrapie infection, making a 
strong link between copper homoeostasis and prion disease (Siggs et al. 2012). 
Furthermore, prion related scrapie isolates have been found to contain Cu2+ ions 
(Wadsworth et al. 1999). Moreover, copper chelation has been shown to delay the onset 
of prion disease in mice (Refolo et al. 2001). Interestingly Cu2+ binding to PrPC has also 
been linked to Aβ toxicity in Alzheimer’s Disease (You et al. 2012). It is for these reasons, 
much effort has been directed at characterizing the coordination and affinity of Cu2+ 
binding to PrPC; for reviews see (Millhauser 2004, Viles 2012, Viles et al. 2008). As many 
as six Cu2+ ions have been shown to coordinate to the natively unstructured N-terminal 
domain of PrPC (Klewpatinond et al. 2008), with two binding sites in the amyloidogenic 
region anchored at His111 and His96, and up to four binding sites anchored at the four His 
residues within the octa-repeat region (Figure 6B.01). Vis-CD has proven to be quite a 
powerful approach to study Cu2+ coordination with broadly four different types of Cu2+ 
coordination described, which generate very different Vis-CD spectra (Klewpatinond et 
al. 2008, Morris et al. 2003, Nadal et al. 2009, Ősz et al. 2007, Viles et al. 1999, Viles et 
al. 2008, Wells et al. 2006). 
  






Figure 6B.01. Cu2+ Coordination to the Prion Protein. 
a) The structure of the prion protein with the histidine residues involved in copper 
coordination highlighted. b) The coordination geometry of Cu2+ binding centred around 
His96 and His111. R1 and R2 represent the different amino acid residue side-chains 
preceding each His residue. c) The coordination geometry of  Cu2+ bound to all four 
imidazole side-chains of the His residues in the octa-repeats region, and d) the 
coordination geometry of Cu2+ binding to a single octa-repeat. 
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The locus of binding of Cu2+ to both αSyn and Aβ has been shown to directly involve 
coordination at the N-terminal amino group (Binolfi et al. 2012, Sarell et al. 2009). In 
contrast, Cu2+ binding via the N-terminal amino group of PrPC has not previously been 
highlighted (Klewpatinond et al. 2008, Millhauser 2004).  
 
6B.2. AIMS 
Probe Cu2+ coordination and determine the affinity of Cu2+ binding directly at the N-
terminal amino group of PrPC. Here I use Vis-CD to directly monitor Cu2+ binding affinity 
using glycine as a competitive ligand, and compare Cu2+ binding to model peptides of the 




Fmoc chemistry was used to synthesise the various peptides used. All peptides were C-
terminally amidated in order to mimic the continuation of the peptide sequence in the 
larger protein. Peptides with amidated C-termini and free N-terminal amino groups 
studied included KKR, MKK and AAA. The single octa-repeats peptide and PrP(58-91) 
were acetylated at the N-terminus in addition to amidation at the C-terminus (sequences 
GQPHGGGWGQP and GQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQP, 
respectively). Purchased from Generon Ltd (Maidenhead, UK). 
 
The extinction coefficient at 280 nm was used to determine the concentration of PrPC 
fragments, calculated from the total sum of the extinction coefficients for the number of 
aromatic residues and disulphide bridges in the peptide. Precise concentrations of 
peptides that did not contain aromatic residues were obtained via Cu2+ titrations with 
saturation at 1:1. Typically, lyophilized peptide contained 20 % moisture content. 
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6B.3.2. Circular Dichroism (CD) 
CD spectra were recorded as described in Chapter 2. 
 
6B.3.3. Electron Paramagnetic Resonance (EPR) 
EPR spectra were recorded as described in Chapter 2. Samples were run in 50 mM 
temperature-independent pH buffer composed of 60 % HEPES and 40 % phosphate 
buffer (Sieracki et al. 2008), at either pH 7.5 or pH 10. 
 
6B.3.4. Affinity Measurements 
Affinity measurements were carried out as described in Chapter 2. Glycine was the 
competing Cu2+ chelator used in calculating the affinity of the Cu2+-peptide complexes. 
The values used to calculate the affinities are shown in Table 6B.01. 
 
There is a small discrepancy between the data given in Table 6B.01 and the values 
previously reported (Nadal et al. 2009) due to the total glycine concentration previously 
being used in calculations rather than the [Glyfree]. 
 
The accuracy in the conditional dissociation constants at pH 7.4 reported in Table 6B.01 
is indicated by the number of significant figures the values are reported to (two significant 
figures). An indication of the errors in the Kd values determined can be gained from 
comparison of values for: PrP(23-231); PrP(23-231 ∆octa); mPrP(90-114); and hPrP(91-
115 H96A). Kds are: 34 nM; 26 nM, 32 nM and 45 nM respectively. These values are for 
the same binding site with a mean of 34 +/- 8 nM (sd), the standard deviation indicates 
the significant figures given for Kd values are appropriate. Furthermore, determination of 
the concentration of the competitor glycine at the mid-point of the titration (50% loaded) 
is influenced by the fit of the binding curve, particularly the ∆ε value before a competitor 
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is added and also the baseline signal once all the Cu2+ is bound to the CD silent 
competitor. Determining the mid-point of the titration from more than one CD band 
indicates the precision associated with the fit of the binding curve. 
 
Table 6B.01. Values Used for Calculating the Affinities of Cu2+ for Different Binding 















































105 105 52.5 262.5 162 34 
mPrP(23-
231∆octa)# 
50 50 25 175 127 26 
hPrP(91-115 
H96A)# 
100 100 50 231 136 45 
mPrP(90-
114)# 




50 50 25 172 124 27c 
aDetermined from Vis-CD signal at 540 nm. bDetermined from Vis-CD signal at 310 nm. 
cDetermined using tryptophan fluorescence instead of Vis-CD. #Data obtained from 
(Nadal et al. 2009). 
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6B.4. RESULTS AND DISCUSSION 
Firstly I used Vis-CD to probe Cu2+ binding to a simple tripeptide from the N-terminus 
of human/mouse PrPC, KKR (residues 23-25). The tripeptide MKK was also studied 
because methionine is present in recombinant constructs of full-length PrPC, previously 
used by ourselves and others. In the presence of Cu2+ ions at pH 7.4, the Vis-CD spectra 
of these two different N-terminal sequences are essentially the same with a negative 
ellipticity at 540 nm, associated with the d-d electronic absorption band, and a positive 
band at 318 nm. Cu2+ binds to these N-terminal tripeptides with a 1:1 stoichiometry, see 
Figure 6B.02. EPR spectra of the paramagnetic Cu2+ complex of MKK and KKR indicate 
a square-planar (type II) coordination geometry with AII and gII typical of four nitrogen 
(4N) ligands at pH 10. This suggests the Cu2+ coordination involves the N-terminal amino 
group and the following amide main-chain nitrogens, Figure 6B.03. At physiological pH 
the axial, square-planar, EPR spectrum is retained but there is a clear shift in the A|| and 
g|| values to those more typical of nitrogen and oxygen ligands; a 3N1O or 2N2O complex, 
as highlighted in a Peisach and Blumberg plot (Peisach et al. 1974) in Figure 6B.04. The 
pH dependence of the N-terminal complex is further probed by Vis-CD, shown in Figure 
6B.05. The position of this negative CD band is pH dependent, with higher pH values 
shifting the band to shorter wavelengths. This shift with pH is due to the change in 
coordination geometry, such that a complex consistent with a 4N square-planar geometry 
is favoured at pHs above 8.5 (Bryce et al. 1966). It is notable that the transition between 
a probable 4N to a 3N1O complex and a low pH complex with no amide coordination 
(CD silent) is quite similar for both tripeptides with a pKa of ~6.5 for the transition 
between an optically active complex and one that gives no CD signal. Although, these 
pKas are only approximate due to spectra overlap. 
  





Figure 6B.02. Vis-CD Spectra of Cu2+ Binding the N-Terminal Tripeptide of PrP 
Cu2+ binding at pH 7.4 to a) 200 µM KKR at 318 nm (squares) and 534 nm (diamonds) 
with full spectra inset, and b) 200 µM MKK at 318 nm (squares) and 549 nm (diamonds) 













































































































Figure 6B.03. EPR Spectra of Cu2+ Complexed to the N-Terminal Amino Group of 
PrPC 
a) 200 µM KKR bound to 150 µM Cu2+ at pH 7.5 and pH 10, and b) 200 µM MKK bound 
to 150 µM Cu2+ at pH 7.5 and pH 10. EPR spectra of the paramagnetic Cu2+ complex 
indicate a square-planar (type II) coordination geometry with A|| and g|| typical of 4N 
ligands at pH 10. There is a clear shift in the A|| and g|| values at physiological pH more 



















Figure 6B.04. Peisach-Blumberg Plot Showing the Relationship Between AII and gII 
for the Tripeptides at pH 7.5 and 10 
(Peisach et al. 1974) 
 
  





Figure 6B.05. Comparing the pH Dependence of Cu2+ Binding to the N-Terminal of 
PrPC. 
The normalised peak intensities of bands at 500 and ~570 nm corresponding to Visible 
CD spectra (inset) for 100 µM Cu2+ binding to 100 µM a) KKR, b) MKK, and c) AAA at 
increasing pH. Wavelengths have been chosen to emphasise the approximate pH 
dependence of the 4N complex (~570 nm) and the 3N1O complex (500 nm), although 
there is considerable overlap in peak intensities. 
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The affinity of the N-terminal tripeptides complex at pH 7.4 was determined using glycine 
as a competing ligand, as shown in Figure 6B.06. Non-chiral glycine has a known 
micromolar affinity for Cu2+ (Dawson et al. 1986) and the resulting Cu(Gly)2 complex is 
CD silent. Increasing additions of free glycine to the Cu-peptides causes a reduction in 
the CD bands at 540 nm and 318 nm. The concentration of glycine to cause a 50 % 
reduction in the CD band intensity can be used to determine the apparent dissociation 
constant, Kd, at pH 7.4, (see Chapter 2 and experimental for details). It is clear from the 
binding curves that the affinity for the tripeptides is 250 nM for KKR and similarly 170 
nM for MKK, compared to full-length PrPC that has an affinity of ~30 nM for the first 
mole equivalent of Cu2+ binding to PrPC (Nadal et al. 2009). 
 
Table 6B.02 compares the affinities of Cu2+ binding to recombinant full-length PrPC, and 
smaller recombinant and synthetic peptide fragments of PrPC (previously determined 
(Nadal et al. 2009)) to those of the model N-terminal tripeptides studied here. Previously 
as many as six mole equivalents of Cu2+ have been shown to bind PrPC. The tight binding 
mode is thought to involve all four histidine residues from the octa-repeat region (Kd of 
30 nM or tighter (Walter et al. 2006, Wells et al. 2006)), along with two Cu2+ binding 
sites centered at His110 and His95 (Kd of ~30 nM) with weaker affinity (Kd of ~500 nM) 
for individual octa-repeat binding sites. 
 
It was surprising that copper binding to the individual octa-repeats was weaker than that 
of Cu2+ binding to the N-terminal amino group (Kd of 150-250 nM) as binding of Cu2+ to 
the N-terminal amino group has not previously been identified (Millhauser 2004, Viles et 
al. 2008). To support this observation, I performed a simple competition experiment 
between a single-octa repeat and an N-terminal tripeptide. Figure 6B.07 shows the Vis- 





Figure 6B.06. Visible CD and Affinity of Cu2+ Binding to the N-Terminus of PrPC 
The glycine competition binding curve taken at 540 nm for 200 µM Cu2+ bound to a) 200 
µM KKR, and b) 200 µM MKK at pH 7.4. Full spectra are inset for 0-20 mole equivalents 
glycine; red trace is no glycine and the purple trace is 20 mole equivalents. Kd calculated 
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Table 6B.02. Comparison of Cu2+ Binding Affinities for Different Sites on PrPC at 
pH 7.4. 
PrP Fragment Kd (nM) PrP Fragment Kd (nM) 
NH3(KKR)a 240, 260 PrP(23-231 ∆octa)b 26 
NH3(MKK)a 190, 120 hPrP(91-115 H96A)b 45 
mPrP(23-231)b 34 mPrP(90-114)b 32 
mPrP(57-67)b (single-octa) 800, 200c mPrP(57-90)b (multiple octas) 27c 
aDetermined from Vis-CD bands at 540 nm and 318 nm, respectively. bAdapted from 
(Nadal et al. 2009). cDetermined using tryptophan fluorescence instead of Vis-CD. 
 
CD spectrum of an equimolar mixture of MKK and a single octa-repeat (PrP(58-68)) with 
increasing amounts of Cu2+. It is clear that the Cu2+ ions load sequentially on to the MKK 
tripeptides first as indicated by the initial appearance of a negative Vis-CD band at 540 
nm. At one mole equivalent of Cu2+ ions a new set of Vis-CD bands appear, typical for 
the very different Vis-CD signals observed for Cu2+ binding to a single octa-repeat. This 
sequential loading is highlighted by difference spectra shown in Figure 6B.07c and 
6B.07d. This data strongly supports the affinity measurements (Figure 6B.06 and Table 
6B.02) indicating that for these model peptide fragments, Cu2+ preferentially binds to the 
N-terminal amino group before the single octa-repeats. 
 
Next I performed a similar competition experiment with the intact four octa-repeats 
peptide, PrP(58-91), shown in Figure 6B.08. The spectra are dominated by the more 
intense CD bands for the individual octa-repeats (Figure 6B.08a). However, it is clear 
from the plot of the normalized intensity of the CD signal, Figure 6B.08b, that the Cu2+ 




Figure 6B.07. Visible CD Competition of Cu2+ for MKK and an Individual Octa-
Repeat 
a) 100 µM MKK and 100 µM single octa-repeat plus Cu2+ in 30 µM steps at pH 7.4 (red 
through to purple). b) Normalised intensity of the bands at 620 nm and 500 nm with 
increasing Cu2+. c) The data presented in a) for 0-1 mole equivalent of Cu2+ (red through 
to yellow) and 1 mole equivalent of Cu2+ bound to MKK (black). d) The data presented 
in a) for the following two equivalents with the spectrum from the first equivalent 
subtracted (light green through to purple) and 1 mole equivalent of Cu2+ bound to a single 
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Figure 6B.08. Visible CD Competition of Cu2+ for MKK and PrP(58-91) 
a) 100 µM MKK and 100 µM PrP(58-91) plus Cu2+ in 50 µM steps at pH 7.4 (red through 
to purple). b) Normalised intensity of the bands at 480, 580 and 670 nm with increasing 
Cu2+. c) The data presented in a) for 0-1.5 mole equivalents of Cu2+ (red to orange), 
highlighting the MKK contribution. d) Difference spectra of the data presented in a) for 
2.5-8 mole equivalents of Cu2+ (light green to purple), with the spectrum from the second 
equivalent subtracted from the subsequent spectra. The signal from MKK is not observed 
in the difference spectra. 
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loads onto MKK (480 nm signal) before the individual octa-repeats (CD bands at 580 and 
670 nm). The MKK band saturates at ~ 2 mole equivalents due to Cu2+ ions also forming 
the tighter affinity tetra-histidine complex, which is Vis-CD silent. The bands at 580 nm 
and 670 nm, typical of Cu2+ ions binding to a single octa-repeat, saturate at ~5 mole 
equivalents as one Cu2+ ion binds each of the four octa-repeats. 
 
The wavelength of the Vis-CD signal for the N-terminal amino group binding in these 
competition experiments does not precisely match the CD spectra for the MKK tri-peptide 
alone with a negative peak centred at 540 nm. This is because the single octa-repeats have 
positive CD signal at wavelengths above 540 nm, which has the effect of cancelling out 
the negative N-terminal CD signal to the longer wavelengths and so shifts the negative  
CD band to shorter wavelengths (~480 nm). This effect is apparent in Figures 6B.07a, 
6B.08a and 6B.09b, and also the simulated data in Figure 6B.09d. 
 
Finally, I wanted to determine if there was evidence for Cu2+ binding to the N-terminal 
amino group preferentially over the individual octa-repeats within full-length PrPC(23-
231). Figure 6B.09 shows Vis-CD spectra of Cu2+ binding full-length mouse PrPC(23-
231) adapted from data previously published (Klewpatinond et al. 2008). The general 
appearance of the series of spectra is rather complicated due to the multiple binding 
modes of Cu2+, as shown in Figure 6B.10. However, when the spectrum of the first two 
equivalents of Cu2+ addition (Figure 6B.09a) are subtracted from subsequent spectra 
(Figure 6B.09b) a clearer picture of Cu2+ binding sites sequentially loading on to PrPC is 
apparent. In previous studies the significance of the relatively weak negative CD band 
centered at ~470 nm was overlooked. Re-visiting this data, it is clear that this Vis-CD 
band is due to Cu2+ binding at the N-terminal amino group. Figures 6B.09c and 6B.09d 
show how binding of Cu2+  to individual sites using small peptide fragments contributes 





Figure 6B.09. Visible CD of Cu2+ Bound to Full-Length PrPC(23-231) 
a) Cu2+ titration into PrP(23-231) in 0.3 mole equivalents up to two mole equivalents. b) 
2-9 mole equivalents of Cu2+ bound to PrP(23-231) with the first 2 mole equivalents 
subtracted. c) Simulated Vis-CD spectra of the titration of the first two mole equivalents 
of Cu2+ into PrP(23-231) from individual spectra of PrP(107-111) and PrP(92-96) (inset). 
d) Simulated Vis-CD spectra of the subsequent titration of Cu2+ into PrP(23-231) after 
the first two mole equivalents from individual spectra of MKK plus four single octa-
repeats (inset). The arrow indicates the signal assigned to binding at the N-terminal amino 
group; there is a shift from 540 nm for MKK signal to 480 nm due to overlap with the 
octa-repeat signal. Panel a) and b) are taken from data previously published 
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Figure 6B.10. Visible CD of Cu2+ Titration of PrP(23-231) 
Addition of 0 -9 mole equivalents of Cu2+ to 100 µM mouse PrPC(23-231). This data is 
shown in Figure 6B.08b with the spectrum of the first two equivalents of Cu2+ subtracted 
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 almost precisely to the appearance of the Vis-CD for the full-length protein. With Cu2+ 
binding centered at His95 and His110 (Figure 6B.09a,c) followed by binding at the N-
terminal amino group and individual octa- repeats (Figure 6B.09b,d). Note that the tighter 
binding for the multiple octa-repeats (Kd of 27 nM) is not observed in Vis-CD as it does 
not give a signal because there is no coordination to the chiral main-chain. The sequential 
loading agrees with the affinities calculated, shown in Table 6B.02. In full-length 
PrPC(23-231) it is clear that binding at the N- terminal amino group has a similar or tighter 
affinity to binding at the individual octa-repeats. 
 
6B.5. BIOLOGICAL SIGNIFICANCE 
PrPC is responsible for generating a range of TSEs in humans, cattle and sheep and is 
linked with Cu2+ ion imbalance (Siggs et al. 2012). The presence of Cu2+ is associated 
with scrapie prion isolates and strains of prion disease (Wadsworth et al. 1999) and Cu2+ 
destabilizes the native fold of PrPC (Younan et al. 2011). Furthermore, Cu2+ binds to PrPC 
in vivo at the synapse (Brown et al. 1997) and can trigger PrPC endocytosis (Perera et al. 
2001). The concentration of Cu2+ can reach as high as 15-250 µM at the synapse after 
neuronal depolarization (Brown et al. 1997, Kardos et al. 1989); consequently nanomolar 
affinity is tight enough for binding to occur in vivo. The binding modes of Cu2+ to PrPC 
via multiple histidines, rather than individual histidines within the octa-repeats (Walter et 
al. 2006, Wells et al. 2006), or within the amyloidogenic region (His95 and His110) have 
a considerably tighter affinity than the N-terminal amino group. The binding of Cu2+ at 
the N-terminal amino group of PrPC is not a novel coordination mode as most proteins 
could bind Cu2+ in this way with similar ~ 200 nM affinities. The principle Cu2+ binding 
site of Aβ and αSyn involve the N-terminal amino group but with a thousand times tighter 
affinity, with a Kd of 50 pM (Sarell et al. 2009) and 200 pM (Hong et al. 2009), 
respectively. These tighter affinities are due to the additional involvement of side-chain 
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coordination. This raises the question, whether in vivo, loading of Cu2+ to the relatively 
weak individual octa-repeat binding sites is physiologically significant. However, PrPC is 
marked by its well conserved natively unstructured domain of ~100 residues that is 
capable of binding multiple Cu2+ ions. Transient high occupancy of these binding sites 










CHAPTER 6: PART C 
 
COMPARISONS OF Cu2+ BINDING TO N-
TERMINAL MODEL PEPTIDES OF 
ALPHA-SYNUCLEIN, USING VISIBLE 
CIRCULAR DICHROISM SPECTROSCOPY: 
AFFINITY, COORDINATION GEOMETRY, 
pH DEPENDENCE AND STOICHIOMETRY 
  




Parkinson’s disease (PD) is a neurodegenerative disease marked by the presence of Lewy 
bodies in the substantia nigra. These Lewy bodies are comprised of amyloid fibres of the 
protein alpha-synuclein (αSyn). In solution, monomeric αSyn is natively unstructured but 
it has the propensity to form alpha helices when bound to lipids, the crystal structure of 
which is shown in Figure 6C.01 (Ulmer et al. 2005). The sequence of αSyn can be split 
into three sections; the N-terminal domain, the central non-amyloid β component (NAC) 
domain, and the C-terminal domain. The NAC domain is a hydrophobic region spanning 
residues 61 to 95 that is involved in amyloid formation. 
 
In PD increased Cu2+ concentrations in the cerebrospinal fluid are reported (Pall et al. 
1987) and those with chronic exposure to copper in industry have an increased rate of PD 
(Gorell et al. 1998). Metals have been proposed as triggers for misfolding and assembly 
of αSyn in Parkinson’s disease (PD). More than a decade ago the acceleration of the 
kinetics of fibrillisation of αSyn by metal ions was described (Paik et al. 1999, Uversky 
et al. 2001, Yamin et al. 2003). However, these early studies used concentrations of metal 
ions higher than those normally found physiologically. Significantly, subsequent studies 
using much lower concentrations of Cu2+ ions also accelerated fibre formation (Rasia et 
al. 2005). They showed that a 1:1 binding of Cu2+ with 100 µM of αSyn will significantly 
reduce the lag-time of fibrillisation. Cu2+ has also been shown to exacerbate toxicity of 
αSyn in cell cultures (Wright et al. 2009). αSyn is largely found intracellularly at 
presynaptic terminals in the reducing environment of the cytosol where copper ions are 
predominantly Cu+. There have been some studies of Cu+ coordination to αSyn (Binolfi 
et al. 2010a). However, a proportion of αSyn is secreted by neuronal cells extracellularly 
(Borghi et al. 2000, Lee 2008) and so Cu2+ binding is also relevant. It is for these reasons  
 





Figure 6C.01. The Crystal Structure of Alpha-Synuclein. 
The structure of micelle-bound αSyn highlighting the 3 separate domains of the sequence; 
the N-terminal region, the non-amyloid β component (NAC) region, and the C-terminal 
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that much effort has been directed at characterising the coordination and affinity of Cu2+ 
binding to αSyn. For reviews see (Binolfi et al. 2012, Hasegawa et al. 2002, Viles 2012).  
 
The coordination of Cu2+ and other metal ions can affect the misfolding protein in a 
number of possible ways. The change in charge may affect the self-association, or the 
morphologies (strain) of the amyloids concerned (Uversky et al. 2001, Wright et al. 
2009). Furthermore, the redox activity of Cu2+ can lead to hydroxyl radical and other 
reactive oxygen species production, a hallmark of protein misfolding diseases (Davies et 
al. 2010, Meloni et al. 2011, Wang et al. 2010). The coordination geometry and affinity 
of the complex is therefore clearly important in understanding these processes. 
 
The locus of binding of Cu2+ to αSyn has been shown to involve the N-terminal amino 
group (Binolfi et al. 2012, Drew et al. 2008, Kowalik-Jankowska et al. 2005, Rasia et al. 
2005). Various values have been suggested for the affinity of Cu2+ for αSyn (Binolfi et 
al. 2010b, Davies et al. 2010, Dudzik et al. 2011, Hong et al. 2009) and for assorted 
model peptides (Binolfi et al. 2010b, Jackson et al. 2009), with Kds ranging between ~200 
nM (Jackson et al. 2009) and 100 pM (Dudzik et al. 2011). Here I use Vis-CD to directly 
monitor Cu2+ binding affinity using glycine as a competitive ligand, and compare Cu2+ 
binding to model peptides of the N-terminus to the full-length αSyn.  
 
It has been suggested that αSyn binds Cu2+ ions through two different modes; solely at 
the N-terminal residues MDV (Figure 6C.02a) (Binolfi et al. 2008, Binolfi et al. 2010b, 
Kowalik-Jankowska et al. 2005) or alternatively, via the N-terminal residues together 
with imidazole of histidine at position 50 (Figure 6C.02b) (Bortolus et al. 2010, Drew et 
al.  2008,  Dudzik  et  al.  2011,  Kowalik-Jankowska  et  al.  2005).  To  investigate  the  






Figure 6C.02. The Square-Planar Cu2+ Coordination Geometries of a Variety of 
Peptides 
The coordination geometries of a) mode 1 of Cu2+ binding to αSyn via MDV, b) mode 2 
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influence of His50 on Cu2+ coordination, I have designed a peptide that has the sequence 
of residues 1-7 and 46-52 of αSyn (MDVFMKGEGVVHGV). These complexes are 
compared with Cu2+ complexes found in other misfolding proteins.  
 
6C.2. AIMS 
Cu2+ binding to αSyn has been studied a good deal with Vis-CD (Binolfi et al. 2008, 
Binolfi et al. 2010b, Kowalik-Jankowska et al. 2005, Rasia et al. 2005) and I aim to build 
upon these studies. I aim to understand the influence side-chain coordination of Cu2+ by 
Asp2 and His50 have on the affinity, pH dependence and appearance of the Vis-CD spectra 
for the N-terminal αSyn Cu2+ complex and resolve some of the conflicting observations 




Fmoc chemistry was used to synthesise the various peptides used. All peptides were C-
terminally amidated in order to mimic the continuation of the peptide sequence in the 
larger protein. The peptides were removed from the resin and de-protected before 
purification by reverse-phase HPLC. The samples were characterised using mass 
spectrometry. 
 
Peptides with amidated C-termini and free N-terminal amino groups studied included 
MDV, MAV, AAA and MDVFMKGEGVVHGV, a designed sequence based on alpha 
synuclein residues 1-7 and 46-52, all purchased from Generon Ltd (Maidenhead, 
UK).The peptides did not contain aromatic residues thus concentrations were obtained 
via Cu2+ titrations with saturation at 1:1. Typically, lyophilised peptide contained 20 % 
moisture content. 
Chapter 6: Developing CD for Studying Cu2+ Binding to N-terminal Peptides 
248 
 
6C.3.2. Circular Dichroism (CD) 
CD spectra were recorded as described in Chapter 2. 
 
6C.3.3. Absorbance 
Visible absorption spectra were obtained with a Hitachi U-3010 double beam 
spectrophotometer between 400 and 800 nm, sampling points every 2 nm, using a 1 cm 
pathlength quartz cuvette. Typically 3 scans were recorded and the baseline spectrum 
subtracted from each scan. 
 
Small aliquots of fresh aqueous solutions were used to add metal ions (Cu2+ as 
CuCl2.2H2O). Titrations were carried out in the presence of 20 mM ethylmorpholine 
buffer at pH 7.4. The pH was measured before and after acquiring each spectrum. 
 
6C.3.4. Affinity Measurements 
Affinity measurements were carried out as described in Chapter 2. Glycine was the 
competing Cu2+ chelator used in calculating the affinity of the Cu2+-peptide complexes. 
 
6C.4. RESULTS AND DISCUSSION 
6C.4.1. Cu2+ Affinity of αSyn 
To investigate the influence of side chain-coordination upon Cu2+ binding at the N-
terminal amino group of αSyn, three peptides have been generated; MDV, MAV and 
αSyn(1-7,46-52) (MDVFMKGEGVVHGV), which include side chains thought to be 
involved in Cu2+ coordination in αSyn (Asp2 and His50). The Cu2+ affinity of these three 
αSyn-related peptides at pH 7.4 have been calculated using glycine competition 
experiments (Figure 6C.03, Table 6C.01). The difference in affinity for the 3 peptides is 
quite marked. In particular, only 1.2 mole equivalents of glycine are required to remove 
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half of the Cu2+ from MAV, whereas considerably more glycine, 8.5 mole equivalents, is 
required to remove Cu2+ from MDV, while as much as 34 mole equivalents are required 
to compete off half of the Cu2+ from the αSyn model tetradecamer peptide containing a 
histidine. This equates to a conditional dissociation constant (Kd), at pH 7.4 of 270 nM, 
320 pM and, and 30 pM respectively. The Cu2+ complex that involves a histidine is tighter 
than the N-terminal tripeptide complex in the absence of histidine side-chain 
coordination. The aspartate in MDV makes binding more than two orders of magnitude 
tighter than MAV. MAV has an affinity more similar to that of the N-terminus of PrP at 
pH 7.4 (Stanyon et al. 2014b), see Table 6C.02. The affinity of Cu2+ for MDV calculated 
here is very similar to that reported for full-length αSyn, described by a number of groups 
using a range of techniques, these studies give similar results with Kds in the 10-7 M range 
at pH 7.4 (Table 6C.01) (Davies et al. 2010, Dudzik et al. 2011, Hong et al. 2009). Others 
have reported affinities weaker than the 100 pM (Binolfi et al. 2010b, Jackson et al. 2009) 
but none have suggested an affinity as tight as our designed peptide containing a His 
residue twelve residues from the N-terminus. 
 
Table 6C.01. Comparison of Cu2+ Binding Affinities for αSyn 
Protein/peptide Kd pH Author Method 
MDV 0.32 nM 7.4 This work Vis-CD 
MAV 270 nM 7.4 This work Vis-CD 
αSyn(1-7,46-52) 28 pM 7.4 This work Vis-CD 
αSyn 0.2 nM 7.4 (Hong et al. 2009) ITC 
αSyn 0.1 nM 7.4 (Dudzik et al. 2011) EPR 
αSyn 0.4 nM 7.0 (Davies et al. 2010) ITC 
 





Figure 6C.03. The Affinity of Cu2+ Binding to Alpha-Synuclein 
The glycine competition binding curves for one mole equivalent of Cu2+ bound to a) 500 
µM MDV, b) 300 µM αSyn(1-7.46-52), and c) 500 µM MAV at pH 7.4. Full spectra are 
inset for 0-20 mole equivalents glycine; red trace is no glycine and the purple trace is 20 
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6C.4.2. Vis-CD of Cu2+ Coordination at the N-Terminal Residues of αSyn 
It is well established that Cu2+ can bind to the N-terminal amino group of proteins with 
additional main-chain amide nitrogen coordination (Martin 1974, Stanyon et al. 2014a, 
Stanyon et al. 2014b)(Parts A and B of this chapter). These Cu2+ complexes with no side- 
chain coordination produce Vis-CD spectra with only negative signal for the d-d 
absorption bands. Comparison of these spectra with the Vis-CD spectrum of the tripeptide 
MDV, known to be the Cu2+ binding site for αSyn at the N-terminus (Drew et al. 2008, 
Dudzik et al. 2011, Rasia et al. 2005), shows a very different spectrum, producing a 
positive band for the d-d-transition bands (Figure 6C.04a). However, strikingly, replacing 
the aspartate  with alanine (to give MAV)  produces a very different spectrum,  which is 
much closer in appearance to the AAA tripeptides (Figure 6C.04a). The switch in the 
appearance of the MDV spectrum is due to the aspartate side chain being involved in 
coordination (Binolfi et al. 2010b, Drew et al. 2008, Dudzik et al. 2011). It is clear that 
for complexes that involve side-chain coordination, in addition to amide main-chain 
coordination, very different Vis-CD spectra can be observed. 
 
The spectrum of αSyn(1-7,46-52) is shown in Figure 6C.04b. The Vis-CD spectrum has 
similarities to MDV but the positive d-d transition band is shifted to a shorter wavelength, 
with a Vis-CD maximum at 570 nm for αSyn(1-7,46-52) while MDV has a Vis-CD 
maximum at 610 nm. This is thought to be due to a shift from a 2N2O coordination 
complex (two nitrogen and two oxygen square-planar coordination geometry) (Figure 
6C.02a)  to  a  3N1O  complex  as  a  nitrogen  from  the  histidine  replaces  a  coordinating 
oxygen from water (Figure 6C.02b). This shift to a shorter wavelength for αSyn(1-7,46-
52) is also evident in the visible absorption spectra (Figure 6C.04c), with a maximum at 
630 nm for MDV and 605 nm for the tetradecamer containing histidine. The wavelength 
maximum  shifts to a  shorter wavelength  with each  increase in  the number  of peptide 






Figure 6C.04. Model Peptides of αSyn Give Very Different Spectra Due to Aspartate 
Side-Chain Coordination 
Visible CD spectra of Cu2+ bound at pH 7.4 to a) MDV (light blue), MAV (light purple) 
and AAA (dark red), and b) αSyn(1-7,46-52) (dark blue) and MDV (light blue). Inset 
highlights the shift in the d-d transition band from 610 nm to 570 nm. c) The visible 


































































































Chapter 6: Developing CD for Studying Cu2+ Binding to N-terminal Peptides 
253 
 
nitrogens involved in forming the complex. Generally, 4N complexes have an absorbance 
band centred at 540 nm, 3N1O are at 625 nm, and 1N3O are at 765 nm (Bryce et al. 
1966). 
 
6C.4.3. Stoichiometry of Cu2+ Coordination 
Titration of Cu2+ on to MDV and MAV shows a clear 1:1 stoichiometry with fixed CD 
bands at 612 and 555 nm, respectively, that increase in intensity until saturation at 1 mole 
equivalent (Figure 6C.05). In contrast, the stoichiometry of αSyn(1-7,46-52) is different 
with a CD band at 580 nm that increases in intensity up to one mole equivalent and then 
reduces to be replaced by a band at 540 nm (Figure 6C.05c). This is indicative of a second 
binding mode, the spectrum of which has been obtained by subtracting the MDV at one 
mole equivalent spectrum from the αSyn(1-7,46-52) spectrum at two mole equivalents 
(Figure 6C.06). This spectrum is similar to that of Cu2+ coordinated to the peptide acetyl-
GAH-amide, suggesting the second binding site is centred around the His residue 
(Chapter 6A) (Klewpatinond et al. 2007a). 
 
6C.4.4. Comparison with Full-Length αSyn 
It is notable that studies for full-length αSyn report Vis-CD spectra much closer to our 
MDV spectrum than the spectrum of αSyn(1-7,46-52) (Binolfi et al. 2008, Binolfi et al. 
2010b, Rasia et al. 2005). Both Vis-CD and EPR data strongly support the dominant Cu2+ 
complex as not containing His50 in αSyn (Binolfi et al. 2010b). The considerable 
reduction in the number of residues between the N-terminus and the His in the model 
peptide used here of αSyn(1-7,46-52) (twelve residues) promotes His coordination in the 
N-terminal complex. In the case of full-length αSyn, it remains to be established if His50 
can  participate in  coordination  under certain  conditions,  for example  fibre or oligomer 





Figure 6C.05. The N-Terminal of αSyn Binds Cu2+ with a 1:1 Stoichiometry 
Stoichiometry of copper binding at pH 7.4 to a) 500 µM MDV – inset normalised ∆ε from 
bands at 300 nm (squares) and 612 nm (diamonds) , b) 300 µM MAV – inset normalised 
∆ε from bands at 312 nm (squares) and 555 nm (diamonds), and c) 600 µM αSyn(1-7,46-


























































































































































Figure 6C.06. Difference Spectrum of αSyn(1-7,46-52) and MDV 
The spectrum of MDV (red) subtracted from αSyn(1-7,46-52) (blue) gives the 
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formation at lower pH or in the presence of cryoprotectants, such as glycerol, used in low 
temperature EPR measurements. It is notable that Bortolus et al. described His50 
involvement at pH 6.5 (Bortolus et al. 2010). While Drew points to a mixture of both 
coordination geometries, their relative proportions are likely to be pH sensitive (Drew et 
al. 2008). 
 
6C.4.5. pH Dependence of Cu2+ Binding 
The pH dependence of Cu2+ binding to the 3 different αSyn model peptides (Figure 
6C.07a-c) shows that αSyn(1-7,46-52) coordination with a 3N1O geometry remains 
dominant from basic conditions to as low as pH 5 (Figure 6C.07a). Similarly, the 2N2O 
complex of MDV remains very stable over a range of pHs, with no indication of a shift 
to other coordination geometries with an increase in pH (Figure 6C.07b). The mid-point 
of Cu2+ complex formation occurs at a relatively low pH of 4.6 for MDV (Fig 6C.07b). 
The pH dependence of the MDV complex agrees closely with studies by Binolfi et al. on 
the first six residues of αSyn (MDVFMK) that also showed a pKa of 4.6 (Binolfi et al. 
2010b). It is clear that the Asp has a significantly stabilising influence in the complex 
even at a relatively low pH. In contrast, for MAV, the Vis-CD suggests complete loss of 
amide Cu2+ coordination complex below pH 7, with a mid-point at pH 7.5, compared to 
pH 4.6 for MDV (Figure 6C.07c). This type of pH dependence for MAV is similar to the 
tripeptide AAA, shown in Figure 6C.07d. 
 
6C.5. COMPARISONS OF Cu2+ BINDING α−SYNUCLEIN WITH OTHER 
AMYLOIDOGENIC PROTEINS 
A common feature of the amyloid forming proteins Αβ, αSyn and PrPC is that they are 
natively unfolded, either partially or in their entirety. This facilitates Cu2+ coordination 
via the main-chain. The ability of αSyn, Aβ (Sarell et al. 2009) and to a lesser extent PrPC 





Figure 6C.07. Comparison of the pH Dependence of Cu2+ Binding αSyn(1-7,46-52), 
MDV, MAV, and AAA 
The normalised peak intensities of bands corresponding to Visible CD spectra (inset) for 
one mole equivalent of Cu2+ binding to 100 µM a) αSyn(1-7,46-52), b) MDV, c) MAV, 





























































































































































4 5 6 7 8 9
pH
Chapter 6: Developing CD for Studying Cu2+ Binding to N-terminal Peptides 
258 
 
 (Stanyon et al. 2014b) to bind Cu2+ at the N-terminus is a common feature among the 
three amyloidogenic proteins. However, the affinity of Cu2+ for these proteins is quite 
different (Sarell et al. 2009, Stanyon et al. 2014b). The N-terminal of PrPC has an affinity 
much weaker than αSyn and Aβ (See Table 6C.02) yet is comparable to the affinity of 
Cu2+ for MAV. The coordination of Cu2+ binding to these sites occurs solely through 
main-chain amides. αSyn and Aβ have appreciably greater affinities for Cu2+ binding 
directly at the N-terminus, at neutral pH, due to the involvement of additional side-chain 
coordination; Asp2 in the case of αSyn (Binolfi et al. 2012) and His6,13,14 as well as 
carboxylates in the case of Aβ (Drew et al. 2009, Sarell et al. 2009). The affinity of Cu2+ 
for αSyn is approximately an order of magnitude weaker compared to Aβ yet as the 
concentration of Cu2+ can reach as high as 15-250 µM at the synapse after neuronal 
depolarisation, this affinity is still strong enough for binding to occur in vivo (Brown et 
al. 1997, Kardos et al. 1989). The tight affinity of Cu2+ for the designed peptide is very 
similar to that of Cu2+ binding to Aβ, which also coordinates via Asp and His and the N- 
terminus. The question remains as to whether under certain conditions, such as 
fibrillisation, oligomerisation or low pH, a larger macro-chelate is favoured in αSyn 
similar to that described here using the designed peptide. 
 
Table 6C.02. Comparison of Cu2+ Binding Affinities of Amyloid Proteins that 
Involve the N-Terminal Amino Group 
αSyn Model Peptide Kd at pH 7.4 
(This Work) 
Protein Kd at 
pH 7.4 
Author 
αSyn(1-7,46-52) 28 pM Aβ 50 pM (Sarell et al. 2009) 
MDV 0.32 nM αSyn 0.2 nM (Hong et al. 2009) 
MAV 270 nM PrPC 250 nM Chapter 6B 
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Amyloid beta (Aβ) is the main constituent of extracellular plaques in the brain of 
Alzheimer’s disease (AD) patients. The fibrillisation of Aβ is central to the development 
of AD. It is known that the majority of Aβ found in blood plasma is bound to human 
serum albumin (Biere et al. 1996, Kuo et al. 2000). The high levels of albumin found in 
blood plasma are thought to be the explanation for why amyloid plaques do not occur in 
the peripheral tissue despite Aβ levels in blood being similar to the levels in the brain 
interstitium. The main risk factor for developing AD is age and it is also known that 
albumin concentrations decrease with age (Klonoff-Cohen et al. 1992). The key aim of 
this thesis was to understand the role albumin plays in Aβ fibrillisation at physiological 
concentrations and in the presence of other extracellular components. 
 
I have shown in this thesis that HSA can inhibit Aβ fibrillisation at concentrations as low 
as those found in the cerebrospinal fluid (3 µM). The extent of inhibition closely 
correlates with the percentage of Aβ monomer that can bind to albumin based on the 
published modest Kd of 5 µM (Rózga et al. 2007a). This work raises the possibility that 
albumin may be protective against the development of AD and in vivo studies to test this 
in the future are important. Albumin is less able to inhibit Aβ fibrillisation in the presence 
of other molecules that bind the hydrophobic pockets of albumin. In this thesis, I have 
demonstrated this for cholesterol and palmitic acid. Interestingly, both elevated levels of 
serum cholesterol and a high fat diet increase the risk of developing AD (Kalmijn et al. 
1997, Kivipelto et al. 2002, Kivipelto et al. 2001, Laitinen et al. 2006, Morris et al. 2003, 
Whitmer et al. 2005). This raises the possibility that this elevated risk may therefore be 
due to the interaction with albumin, preventing Aβ from binding to albumin and inhibiting 
fibrillisation. The fact that albumin replacement is showing promise as a treatment for 
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AD (Boada et al. 2009) may be through clearance of fatty acid or cholesterol loaded 
albumin in addition to clearance of the Aβ-albumin complex. 
 
Albumin levels are known to decrease with age but there has been no connection reported 
between albumin levels and the susceptibility of developing AD. With the current 
development of big data science, the association may become apparent in the near future 
as vast patient databases can be analysed. It may also be possible to establish whether the 
use of certain pharmaceuticals in the treatment of other disease also increase the risk of 
developing AD, such as prolonged use of the anti-coagulant warfarin, a drug that binds a 
hydrophobic pocket of albumin. 
 
Albumin is not just a transport protein for hydrophobic molecules but also binds Cu2+ 
ions at its N-terminus with a one picomolar affinity (Rózga et al. 2007b). Disruption of 
Cu2+ homeostasis has been linked to the development of AD in several animal models 
(Sanokawa-Akakura et al. 2010, Sparks et al. 2003). Cu2+ binding to Aβ in vitro has been 
shown to influence the fibrillisation of Aβ (Matheou et al. 2014, Sarell et al. 2010). The 
determination of the affinity of Cu2+ for Aβ is therefore important in ascertaining whether 
this interaction is physiologically relevant and whether albumin can sequester Cu2+ from 
Aβ. 
 
In this thesis, I have shown that the affinity of Aβ for Cu2+ is in the 10-20 pM range. The 
affinity is not influenced by peptide length nor fibrillisation state; oligomeric Aβ(1-42) 
has an affinity in the same range as monomeric Aβ(1-42) and Aβ(1-40). This is a very 
tight affinity, making an interaction between Aβ and Cu2+ in vivo extremely likely. This 
is especially true when considering at the synapse, the major release site of Aβ, the 
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concentration of Cu2+ can reach 15-250 µM after depolarisation (Hartter et al. 1988, 
Kardos et al. 1989). However, the affinity of the Aβ-Cu2+ complex is weaker than the 
affinity of Cu2+ for albumin and I have demonstrated that albumin can sequester Cu2+ 
from all Aβ alloforms and fibrillisation states. This ability gives albumin a second 
potential protective mechanism against Aβ toxicity. 
 
Cu2+ dyshomeostasis is linked to several other neurodegenerative diseases in addition to 
AD, including Parkinson’s disease and prion diseases, such as Creutzfeld-Jacob disease 
(Gorell et al. 1998, Siggs et al. 2012). In this thesis I have determined the affinity of Cu2+ 
for the amyloids associated with these diseases, alpha-synuclein (αSyn) and the cellular 
prion protein (PrPC), respectively. The affinities are weaker than the Aβ-Cu2+ complex 
but are still physiologically relevant. αSyn binds a single Cu2+ ion at its N-terminal with 
a Kd in the 10
-10 M range whereas PrPC can bind up to seven Cu2+ ions with affinities in 
the nanomolar range. This raises the possibility that albumin could be protective against 
other neurodegenerative diseases as well by sequestering Cu2+ from all amyloid proteins 
involved. 
 
This thesis highlights the importance of overlapping interactions with endogenous 
proteins and molecules in the development of neurodegenerative disease. I focus on the 
interaction of Aβ with common, abundant extracellular components, specifically albumin 
and Cu2+ ions. Future in vitro studies of neurodegenerative disease must take into account 
the complex nature of interactions that occur in vivo to be physiologically relevant. The 
synapse has a multitude of molecules that can interact as visualised in Figure 6.01. Not 
only can Aβ interact with albumin and Cu2+ but also PrPC. Indeed the toxicity of Aβ is 
dependent on interactions with Cu2+, PrPC and N-methyl-D aspartate receptors, 
demonstrating a link between neurodegenerative diseases. 
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